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ABSTRACT 
Poly (butyl 2-cyanoacrylate) nanoparticles have been prepared 
with a range of particle sizes by varying the nature and 
concentration of stabiliser added to the polymerisation medium. 
Particle size analysis was performed by photon correlation 
spectroscopy. The range of diameters produced using dextran 
stabilisers was found to be approximately 100 to 800nm. This could 
be extended to 3ym using j3 
-cyclodextrin and to 20nm using 
polysorbate 20. The results infer that the nanoparticles are 
sterically stabilised. 
The molecular weight of the cyanoacrylate polymer formed during 
nanoparticle production was found to be dependent on the type of 
stabiliser used together with the polymerisation pH and monomer 
concentration. The bulk of the polymer had a relatively low 
molecular weight (<2000) which indicates that nanoparticles are 
formed by an aggregative mechanism. 
Dextran was found to copolymerise with the monomer to give an 
interfacial layer of the polysaccharide attached by covalent 
linkages. By using dextrans bearing charged functional groups it was 
possible to alter the electrophoretic behaviour of the resulting 
nanoparticles. 
Partial oxidation of the surface dextran introduced aldehyde 
groups which were capable of covalently binding a simple amine, 
aniline, thereby enhancing the uptake and decreasing the release 
rate of this compound. This technique may be applicable to the 
covalent coupling of antibodies or cytotoxic agents to the 
nanoparticle surface. 
Nanoparticles were radiolabelled with a technetium-99m-dextran 
complex and the biodistribution of this colloid determined in 
rabbits by gamma scintigraphy following intravenous injection. Most 
of the nanoparticle suspension (approximately 50%) was cleared by 
the liver and spleen. Coating the nanoparticles with non-ionic 
surfactants (poloxamer 338 or Tetronic 908) failed to alter 
significantly this distribution pattern. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
1.1. CONCEPT OF DRUG TARGETING 
The ability to target pharmaceutically active molecules to 
specific sites in the body has been actively pursued ever since 
Ehrlich (1906) first envisaged the use of "magic bullets" for the 
eradication of disease. Interest in this concept has increased 
significantly in recent years with the advent of new technology and 
a greater understanding of the processes involved in drug delivery 
both at a cellular and sub-cellular level. Despite these advances 
and the vast literature which has been generated (e. g. Gregoriadis 
et al, 1982 and 1985; Goldberg, 1983; Juliano, 1980) site specific 
drug targeting remains an elusive goal. 
The aim of this introduction will be to present a balanced view 
of the potential of drug targeting through an understanding of the 
problems involved, and the possibilities for resolving them. 
Particular emphasis will be placed on the use of carrier systems. 
Other approaches such as prodrug design have been reviewed elsewhere 
(Stella et al, 1980). 
1.2. PROBLEMS WITH CONVENTIONAL DRUG DELIVERY 
Following the administration of a drug, either by the oral 
route or by injection, the drug substance will distribute throughout 
the body as a function of the intrinsic properties of its molecular 
-2- 
structure. The final amount of drug reaching its target site may 
only be a small fraction of the administered dose, as represented 
diagrämatically in figure I. I. Accumulation at non-target sites may 
n 
lead to adverse reactions and unwanted side effects. 
One way of circumventing this problem is to apply the drug in a 
region local to its intended site of action. The range of 
conventional formulations for local administration, such as sprays, 
inhalers, creams, eye drops, etc., have been augmented in recent 
years by several more sophisticated systems. These have included the 
Ocusert system for pilocarpine delivery to the eye (Armaly and Rao, 
1973) and the Progestasert intrauterine device for contraceptive use 
(Tatum, 1977). Further examples are still under investigation such 
as colloidal carriers for intra-articular injection in arthritis 
(Ratcliffe et al, 1984). However, this approach of 'targeting' via a 
locally applied controlled release device is of limited use in 
treating disseminated disease states or when the target tissue is 
inaccessible. In such cases systemic drug administration is 
necessary. 
One such example of the need for systemic drug targeting is in 
cancer chemotherapy where the severe adverse reactions due to 
cytotoxic agents are a major limiting factor. The lack of anti- 
tumour specificity displayed by cytotoxic agents results from the 
low level of biochemical differentiation between host and tumour 
cells which, together with the heterogeneous nature of tumour cell 
populations, limits the effectiveness of current therapeutic 
approaches (Poste, 1985). Although progress has been made in 
reducing the severity of cytotoxic induced side effects by multiple 
a 
U 
. - 
>( 
0 
4J 
U 
CD 
9- 
9- 
C) 
Q) 
'C7 
C/) 
v 
a) 
4J 
4J 
N 
D) 
L 
v 
+J 
c 0 
z 
C 
. - 
C 
"rr 
.o 
C 
N 
4J 
O 
a- 
I 
1J 
ZD 
O 
CL) L 
U 
X 
W 
F- 
W 
.-Q 0-4 
P--4 F- Cn 
"-0 ®! we__ 
v 
E 
ö 
.o 
a) 
110.0- 
---- 
I 
W 
CJ) 
f- 
W 
CD 
CD 
J 
a 
r-1 d) 
10 
10 
N 
.0 O 
14 
14 
a) 
-3- 
administration schedules and kinetic dosage regimens (Price et al, 
1981), there is a limit to their effectiveness. Selective drug 
targeting to tumour sites not only would lead to a reduction in 
adverse reactions but also open the possibilities of using highly 
potent toxins (Jansen et al, 1982). 
The systems available for achieving site specific delivery 
range from direct chemical modification of the drug molecule, 
prodrug design, to the use of carriers such as colloids and macro- 
molecules (Juliano, 1980). These carrier systems will be discussed 
in later sections (1.6 and 1.7) after first examining the general 
aspects of targeting in relation to physiological factors. 
1.3. FACTORS AFFECTING DRUG CARRIER BIODISTRIBUTION 
The physico-chemical properties of an injected carrier system 
will effect its in vivo distribution and ultimately influence its 
ability to reach the target site. The role of these properties is 
particularly well illustrated in the case of particulate systems 
(Davis, 1981; Ilium and Davis, 1982a). Particle size, shape and 
number, together with surface charge and surface characteristics all 
influence the biofate of colloids upon injection. These properties 
are particularly important in relation to particle sequestration by 
the reticulo-endothelial system (RES) (Frier, 1981). The RES is a 
collective name for a group of highly phagocytic mononuclear cells 
derived from the bone marrow (Bradfield, 1984). These cells are 
found throughout the body, either at fixed sites or free in the 
circulation. The RES is alternatively known as the mononuclear 
phagocyte system (MPS). Large concentrations of reticulo-endothelial 
-4- 
(RE) cells are found in the liver (fixed macrophages called Kupffer 
cells), spleen and bone marrow. RES mediated clearance is a major 
factor in determining the biodistribution of colloidal systems. 
1.3.1. Effect of Particle Size and Shape 
s 
The fate of an intravenously (i. v. ) injected colloid can be 
related to various physiological processes as a function of particle 
size (Poste, 1985; Tomlinson, 1983). This is shown diagramatically in 
figure 1.2. Particles with a mean diameter greater than 
approximately 7, um become entrapped in the capillary bed of the lungs 
due to mechanical filtration (Ilium and Davis, 1982a and b; Kanke et 
al, 1980). However, the situation is complicated by the influence of 
particle shape which can result in lung entrapment of small fibres 
(Ilium et al, 1982) and the gradual clearance and relocation 
elsewhere of spherical particles 7-12}ßm in diameter (Slack et al, 
1981). In addition, for particles less than 7pm which are 
aggregated, positively charged or very hydrophilic, lung deposition 
can still be significant (Wilkins and Myers, 1966). 
Normally, smaller particles (<7pm), following i. v. injection, 
are deposited in the liver, spleen and bone marrow by RES mediated 
uptake (Ilium and Davis, 1982a; Singer et al, 1969). The 
partitioning between these three sites depends on their relative 
blood flow, capacity and kinetics of uptake. This results in a 
normally predominant hepatic clearance by Kupffer cells. 
Although most particles in the size range 0.0025-10ýpm 
accumulate in the RES, particle size does have an effect on 
clearance rate (Juliano and Stamp, 1975; Senior et al, 1985) and 
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distribution within the RES (Frier, 1981). Large particles, in 
general, are rapidly removed by the liver and spleen whereas small 
particles are cleared more slowly and show a greater tendency to 
concentrate in bone marrow. This has been shown, for example, by 
Frier (1981) with antimony sulphide colloid of sizes 200-400nm 
(rapid hepatic clearance) and <10nm (slower bone marrow 
accumulation). 
Reducing particle size below approximately 100nm introduces the 
possibility of vascular escape via fenestrations, or openings, in 
the lining of blood vessels. There are three major classifications 
of blood capillaries; continuous capillaries; fenestrated 
capillaries; and discontinuous or sinusoidal capillaries (Weiss and 
Creep, 1977). Extravasation of particles via continuous capillaries 
is highly unlikely since these have endothelial cells joined by 
tight junctions and an uninterrupted subendothelial basement 
membrane. Escape via fenestrated capillaries is theoretically 
possible via the fenestrae in the endothelial cells. These 
fenestrae, however, are spanned by a thin membranous diaphragm 
which, together with the continuous subendothelial membrane of these 
capillaries, makes particle penetration seem unlikely. In contrast, 
sinusoidal capillaries of the liver have no basement membrane and 
those of the spleen and bone marrow only have an interrupted 
membrane. The fenestrae of these capillaries are particularly large 
(approximately 100nm). Extravasation of colloids via this route is 
feasible and probably accounts for the observed accumulation of 
small liposomes in liver parenchymal cells (Poste, 1983). 
-6- 
The possibilities of targeting sites outside the vascular 
system appear to be severely limited except for areas possessing 
sinusoidal capillaries. The microvascular structure of certain 
tumours, however, is known to be defective (Peterson, 1979) and it 
has been proposed (Grislain et al, 1983) that it may be possible to 
target 'leaky' tumours in this way. In contrast, Poste (1983) has 
raised doubts about such an approach since the proportion of tumour 
capillaries allowing extravasation may well be low and not all 
tumours possess a defective microvasculature. 
1.3.2. Effects of Surface Characteristics (llydrophobicity/ 
Hydrophilicity) 
Immediately upon injection into the blood stream colloidal 
particles become coated with various blood components (opsonisation). 
The nature of this adsorbed layer can have marked effects on the 
distribution of colloids, particularly in connection with RES 
mediated clearance. Antibodies act directly as opsonins for 
macrophages by specifically coating a wide range of particles (Boxer 
and Stossel, 1974) and also activating the complement pathway (Gigli 
and Nelson, 1968). RES macrophages possess membrane receptors for 
the Fc region of immunoglobulins and for the C3 component of the 
complement sequence (Bradfield, 1984). Macrophages can recognise 
also particulate material through the nature of the particle surface 
(Frier, 1981). 
The uptake of blood components onto bacteria has been studied 
by Van Oss (1978), who suggested that surface hydrophobicity is a 
critical determinant in the opsonisation process. Particles with 
-7- 
hydrophilic surfaces are rendered more hydrophobic by adsorption of 
immunoglobulin G (IgG). In contrast, hydrophobic particles are taken 
up by macrophages without the necessity of opsonisation. 
Alteration of particle surface characteristics which affect 
opsonisation and/or particle hydrophobicity/hydrophilicity would be 
expected to bring about changes in RES uptake. This has been shown 
in rabbits by Ilium and Davis (1984a and b) with 131i labelled 
polystyrene particles coated with various polymers. Following i. v. 
injection the liver and spleen uptake of the latex was reduced from 
90% to 46% by adsorption of poloxamer 338 (figure 1.3). Liver and 
spleen accumulation were reduced as well using poloxamer 188, but 
this surfactant was less effective. The kinetics of uptake, however, 
were relatively unaffected except for IgM coated particles (table 
1.1). Of the various coating materials used only poloxamer 338 
produced any prolonged (8 days) alteration in distribution (table 
1.1). Similar studies in rats by Leu et al (1984) with poloxamer 188 
coated poly methyl methacrylate particles resulted in a reduction of 
liver uptake from 85% to 38%, 30 minutes after injection. This was 
accompanied, however, by an increase in spleen uptake (4% uncoated, 
21% coated) so that total RES clearance was still high. In addition, 
liver uptake gradually increased over a period of 24 hours for the 
coated particles indicating possible displacement of the surfactant 
and particle opsonisation. Reductions in macrophage uptake have been 
reported also for emulsion systems prepared with poloxamer 338 
(Davis and Hansrani, 1985), and poloxamers 338,188, and polysorbate 
20 (Stossel et al, 1972). 
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Figure 1.3. Effects of coating with poloxamers 
on the distribution of polystyrene latex in 
rabbits. Activity-time profiles for different 
body regions after administration of uncoated, 
poloxamer 188 coated and poloxamer 338 coated 
latex particles. Uncoated: liver/spleen (a); 
lung/heart (. ). Poloxamer 188 coated: liver/ 
spleen (o); lung/heart ('). Poloxamer 338 
coated: liver/spleen (v); lung/heart 
(n=3, mean- standard error). 
Ilium and Davis, 1984b. 
TABLE 1.1. The kinetics of uptake and organ distribution of uncoated 
and coated polystyrene latex particles (Ilium and Davis, 1984b). 
System Rate of Extent of Tissue distribution 
uptake in uptake in after 8 days 
the liver the liver 
(T50%) after 20 mina Liver Lung 
Uncoated latex 50.3 sec 90% 59.5% 0.2% 
Latex coated 
with lecithin 50.3 sec 76% 55.7% 2.3% 
Latex coated 
with IgA 66.1 sec 88% 61.7% 0.2% 
Latex coated 
with 
poloxamer 388 55.0 sec 46% 30.0% 0.5% 
Latex coated 
with 
poloxamer 188 65.6 sec 70% 60.8% 1.6% 
significant difference from latex. 
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The mechanisms involved in reducing RES sequestration are 
obviously complex. Surface coatings alter not only particle hydro- 
phobicity but also affect surface charge (Ottewill, 1967). In 
addition, the increase in particle steric stabilisation imparted by 
the surface polymer probably decreases particle-cell (macrophage) 
adhesion together with the uptake of opsonic factors (Davis et al, 
1985). 
1.3.3. Effect of Surface Charge 
Particle surface charge can have marked effects on the 
clearance and deposition of colloids. Wilkins and Meyers (1966) 
altered the electrophoretic mobility (EP'M) of 1.305pm polystyrene 
latex with coatings of either gum arabic (GA) to provide a negative 
charge, or polylysyl gelatin (PLG) to give a positive charge; 
mixtures of CA and PLG gave intermediate charges. Following 
injection of these various colloids into rats, the mobility was seen 
to affect both the rate of clearance and site of deposition. 
Negatively charged particles were taken up by the liver and this 
distribution maintained, while positively charged colloids showed an 
initial (15 minutes) appreciable accumulation in the lungs and 
subsequent (72 hours) relocation to the liver and spleen. Although 
these particles displayed various EPM's in buffer, in rat serum the 
mobilities for all particles were essentially identical. The 
differences in organ distribution, therefore, cannot be attributed 
to surface charge alone. 
Surface charge also affects the phagocytosis of paraffin oil 
emulsions by polymorphonuclear leukocytes (Stossel et al, 1972). 
-9- 
Emulsions prepared with emulsifiers giving a strong net negative 
charge (e. g. acetylated albumin) or a strong net positive charge 
(e. g. diethylaminoethyl-dextran) showed a higher rate of ingestion 
compared with weakly negative emulsifiers (e. g. gelatin). In 
contrast, Davis and Hansrani (1985) found no clear correlation 
between zeta potential and in vitro macrophage phagocytosis for 
soybean oil emulsion systems prepared with a range of phosphatide 
emulsifiers. 
Similar work with liposomes has shown that increasing the 
negative surface potential by altering phosphatide content has a 
strong suppressive effect on ingestion of liposomes by mouse 
peritoneal macrophages when the liposomes are opsonised by 
complement (Roerdink et al, 1983). It was concluded that 
opsonisation and strong negative surface charge can be opposing 
forces that work actively against each other. These findings 
correlate with those of Hnatowich and Clancy (1980) who determined 
the distribution of liposomes two hours after injection in mice. 
Increasing the negative liposome charge by replacing lecithin with 
cardiolipin decreased liver and spleen accumulation by 5- and 
20-fold respectively. However, there was an increase in bone 
accumulation (presumably RES mediated) such that most of the 
liposomes were found in RES tissues. In contrast, other workers have 
found that negative liposomes, in comparison with neutral or 
positive liposomes, show a faster rate of clearance (Juliano and 
Stamp, 1975; Senior et al, 1985) and higher liver and spleen uptake 
(Richardson et al, 1978). 
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Clearly the connection between phagocytosis, RES uptake and 
surface potential is far from simple and concomitant changes in 
other surface properties may override any effects produced by 
variations in surface charge. 
1.3.4. Effect of Particle Number 
Initial clearance rate by the RES can be affected by the 
presence of large numbers of particles occupying available RES 
receptors or exhausting opsonising factors (Saba, 1970). Although 
clearance rate may be affected by large doses of colloidal material, 
the distribution within the RES does not seem to be altered 
(Benacereff et al, 1975). It is possible, however, to overload the 
RES either by single large doses or repeated administration. 
Subsequent injections remain in the circulation and this is 
discussed as a means of affecting distribution patterns in section 
1.4.3.1. 
1.4. MODES OF DRUG TARGETING 
Site specific drug delivery systems can be classified according 
to the methods employed for achieving target site localisation. 
These are termed either passive, physical (external) or active 
targeting (Poste and Kirsh, 1983). 
1.4.1. Passive Targeting 
Passive targeting refers to the natural distribution pattern of 
the carrier in vivo. The fate of particulate systems will be 
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determined largely by the factors discussed in section 1.3. 
Therefore it is possible to target passively the lungs and RES with 
relative ease. 
1.4.1.1. Passive lung targeting 
Entrapment of large particles (>7ym) in the capillary bed of 
the lungs has been exploited in radiodiagnostic imaging as well as 
for the delivery of anticancer agents to the lungs (Yoshioka et al, 
1981). Illum and Davis (1982b) have shown the potential of attaining 
sustained release of acidic drugs in lung capillaries using 
diethylaminoethyl-cellulose microspheres. However, this material is 
not biodegradable and therefore is unsuitable as such for potential 
clinical use. 
1.4.1.2. Passive RES targeting 
RES mediated clearance of drug targeting systems is normally a 
major disadvantage. Sequestration by RE cells not only decreases 
targeting effiency, but can also result in damage to the RES, 
particularly if the carrier payload is a highly cytotoxic agent 
(Poste, 1983). This can have serious consequences in cancer patients 
since mononuclear phagocytes are active in preventing the spread of 
metestases (Poste, 1983; Fidler, 1977). Despite these drawbacks RES 
clearance can be exploited to gain benefit (Alving, 1983). 
Macrophages form an important part of the host defence 
mechanism against tumour cells. When activated, these cells are 
capable of killing tumour cells via an immunologically non-specific 
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mechanism that is unaffected by tumour cell cycle phase or anti- 
tumour drug resistance (Poste et al, 1982). Macrophages may be 
activated by lymphokines, such as macrophage activating factor (MAF) 
or synthetic compounds such as muramyl dipeptide (MDP). These have 
been incorporated into liposomes and used to activate alveolar 
macrophages in mice, thereby augmenting host defences and resulting 
in a significant reduction in the metastatic burden of tumour 
bearing animals (Fidler et al, 1981 and 1982). However, it has been 
emphasised (Poste et al, 1982) that macrophage mediated destruction 
of large tumour burdens may not be feasible and this approach is 
limited to the erradication of micro-metastases and residual tumour 
cells remaining after surgery or chemotherapy. 
Liposomes have been used to target infections of the RES such 
as leishmaniasis (Alving et al, 1978; Alving, 1983), crypto- 
coccosis (Graybill et al, 1982), candidiasis (Lopez-Berestein et al, 
1983) and histoplasmosis (Taylor et al, 1982). In all cases 
liposomal entrapment of the anti-parasitic drugs increased their 
therapeutic index. Such approaches may be of benefit for the control 
of disseminated fungal infections which are a major problem 
associated with the use of cytotoxic agents (Poste, 1985). 
Soluble carriers are also taken up by the RES and this too has 
been investigated. Conjugates of rabbit serum albumin with two DNA 
synthesis inhibitors, 5-fluorodeoxyuridine and cytosine arabinoside, 
are ingested mainly by Kupffer cells. This has been used 
successfully to treat mice infected with Ectromelia virus which 
replicates initially in Kupffer cells (Fiume et al, 1982). 
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1.4.1.3. Passive intra-arterial targeting 
Intra-arterial injection of large particles results in 
filtration by the first capillary bed encountered. Injection into 
arteries supplying tumour sites would result, therefore, in 
significant accumulation in the locality of the malignancy before 
RES clearance could take effect. This technique has been 
investigated with various microspheres composed of ethylcellulose 
(Kato et al, 1980), albumin (Tomlinson et al, 1984) and starch 
(Lindberg et al, 1984). With this latter system the microspheres 
(40pm diameter) are co-injected with cytotoxic agents. The resultant 
blockage of the tumour arterioles induces localised hypoxia and high 
concentrations of drug. Although now undergoing clinical trial 
(Russell, 1983) this type of approach is only useful for well 
defined malignancies, being of little value in treating disseminated 
tumours or metastases. 
1.4.2. Physical Targeting 
In physical targeting some characteristic of the environment is 
used either to direct the carrier to a specific location or to cause 
selective release of its contents there. This is normally achieved 
through some external targeting mechanism such as induced local 
hyperthermia or a localised magnetic field. 
1.4.2.1. Localised drug release through induced hyperthermia 
In the presence of certain serum proteins, principally lipo- 
proteins, unilamellar liposomes can be designed to release their 
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payload rapidly at their liquid crystalline phase transition 
temperature (Weinstein and Leseruran, 1984). Liposomes with phase 
transition temperatures of about 420C can be made to release their 
drug preferentially in a capillary bed subjected to moderate local 
hyperthermia. In this way increased tumour uptake of methotrexate 
has been achieved resulting in moderate effects on tumour growth 
(Weinstein et al, 1980). Nevertheless, liver accumulation is still 
significant and this approach does not address the problem of 
metastatic lesions (Yatvin et al, 1984). 
1.4.2.2. Localised drug release through pH sensitive carriers 
In an attempt to exploit pH differences between normal and 
tumour tissues, Yatvin et al (1980) proposed the use of p1! sensitive 
liposomes. The in vitro release of the model drug carboxyfluoroscein 
can be enhanced 5-fold at pH 6, compared with pH 7.4, by 
incorporating the pH sensitive lipid N-palmitoyl L-homo- cysteine 
into liposomes (Yatvin et al, 1984). It is unlikely, however, that 
pH differences will be so marked in vivo and hepatic clearance again 
will be limiting. 
1.4.2.3. Localised targeting by an applied magnetic field 
Widder et al (1978) first reported the use of magnetically 
responsive microspheres for localised site specific drug delivery. 
Albumin microspheres (approximately fpm diameter) were prepared 
containing small particles of magnetite (Fe304) and following 
intra-arterial injection in rats made to localise in the tail at the 
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site of an applied magnetic field. In this way more than 50% of the 
carrier was targeted to the magnetised tail segment. Subsequent 
studies investigated the anti-tumour activity of doxorubicin 
containing magnetic microspheres against a tail implanted Yoshida 
rat sarcoma (Widder et al, 1981). With a single magnetically 
localised doxorubicin dose of 0.5 mg/kg, 90-100% regression was 
obtained compared to 0% regression for a 10-fold higher dose of 
non-targeted drug. Localisation of the carrier in this way results 
in high levels of drug in the immediate tumour environment. In 
addition, after localisation, albumin microspheres are able to 
migrate out of the vasculature (Widder et al, 1983) probably as a 
result of an endocytic response secondary to mechanical pushing 
against endothelial cells (Widder and Senyei, 1983). Studies with 
magnetically targeted biological response modifiers, poly IC (an 
interferon inducer) and protein A (an interferon inducer and T- and 
B-cell mitogen), also have yielded promising results (Widder and 
Senyei, 1983). 
Other magnetically responsive carriers such as nanoparticles 
(Ibrahim et al, 1983), erythrocytes (Zimmerman, 1983) and emulsions 
(Akimoto and Morimoto, 1983) have been prepared. 
Although the results with magnetically responsive albumin 
microspheres seem promising, they are obtained using the highly 
favourable model of tail implanted tumours, i. e. the tumour site is 
readily accessible to the applied magnetic field. For deep seated 
tumours, microsphere localisation would be more difficult to attain. 
Encouraging results from targeting to the kidneys (Ibrahim et al, 
1983; Kato et al, 1979) and lungs (Morimoto et al, 1981), although 
-16- 
offering a greater challenge, do not address this problem entirely. 
In addition, this method would not be applicable in treating 
metastases. 
1.4.3. Active Targeting 
Active targeting refers to a deliberate modification of the 
carrier in order to alter its natural disposition pattern, directing 
it to specific organs, tissues or cells. Several of these 
modifications, such as coating with surfactants to suppress macro- 
phage capture, and alteration of particle size and charge, have been 
discussed in section 1.3. Other approaches include blockade of liver 
Kupffer cells or attachment of cell specific ligands and monoclonal 
antibodies. 
1.4.3.1. Reticulo-endothelial system blockade 
One approach in preventing the capture of drug carriers by 
cells of the RES is to pre-block the RES with placebo colloid. 
Subsequent injections of drug carrier in treated animals are not 
subjected to RES clearance. Blockade can be achieved with substances 
such as carbon, methyl palmitate, latex particles, dextran sulphate, 
heat aggregated albumin and liposomes (Bradfield, 1984). By using 
liposomes to block the RES of mice bearing EMT6 tumours, Profitt et 
al (1983) were able to increase by 50% the tumour targeting ability 
of 
i11In loaded liposomes. Ilium and Davis (1984b) have used latex 
particles and dextran sulphate to block the RES of rabbits. 
Subsequent injections of radiolabelled polystyrene particles 
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resulted in only 30% of the injected dose accumulating in the liver 
and spleen compared with 90% for unblocked animals. In both studies 
clearance from the circulation was greatly reduced. 
The clinical potential of this technique is doubtful since 
impairment of RES function can have serious consequences, 
particularly in cancer patients (Poste, 1983; Poste and Kirsh, 
1983). Indeed, any drug targeting system accumulating in the RES 
would need to be readily degradable so that RES overload does not 
occur with repeated dosing. 
1.4.3.2. The use of cell specific ligands 
The binding by cell-surface receptors of certain molecules, 
such as sugars, lectins, peptide hormones and small haptens, can be 
utilised to target carrier systems to specific cell types. 
Removal of sialic acid from glycoproteins exposes galactosyl 
residues which can bind specifically to receptors on the surface of 
hepatocytes. Desialyted fetuin has been used to transport a variety 
of DNA synthesis inhibitors to mouse hepatocytes infected with 
Ectromelia virus (Fiume et al, 1982). Results indicated a higher 
incorporation of drug into hepatocytes resulting in increased 
efficacy. It was proposed that this system may be applicable to 
treating hepatitis infections. Asialofetuin has also been used 
successfully as a carrier of primaquine in treating Plasmodium 
berghei infected mice (Trouet et al, 1982). Alternatively, carrier 
molecules can be galactosylated and used to deliver cytotoxics to 
hepatoma cells (Schneider et al, 1985). 
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Similar approaches may be applied to target a number of other 
sites (Gregoriadis et al, 1985). Examples of the use of glyco- 
lipids or glycoproteins with liposomes are given by Weinstein and 
Leseruran (1984) and Widder et al (1982). In contrast to monoclonal 
antibodies, many of these substances are readily available and 
complications with target recognition are less likely to occur in 
vivo. However, they lack the breadth of target choice of 
immunoglobulins as a group and will be limited to a small number of 
tumour types (Gregoriadis, 1977). 
1.4.3.3. The use of nonoclonal antibodies 
Ever since Kohler and Milstein (1975) first reported the 
production and isolation of antibodies displaying specificity for 
single antigenic determinants, the concept of a monoclonal antibody 
(MCA) targeted cytotoxic modality has been rigorously explored. 
Several approaches have been investigated concerning the design 
of such a system (Sikora et al, 1984). Direct covalent attachment of 
cytotoxic molecules to MCA's is not very efficient, resulting in 
only approximately 10 drug moleclues per antibody and diminishing 
the antigen binding capacity (Kulkarni et al, 1981). Conjugation via 
intermediate carrier molecules such as poly L-glutamic acid (Rowland 
et al, 1975) or dextran (Pimm et al, 1982) substantially increases 
the drug-antibody ratio and retains a higher degree of antibody 
activity. Also, this approach is more versatile chemically in terms 
of conjugation and drug release (Trouet et al, 1981). 
MCA's have been used to target high energy beta-emitters such 
as 
1311 
and 
32P, 
although with disappointing results (Schneinberg 
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and Strand, 1982). However, radiolabelling with gamma-emitters has 
been used successfully in tumour localisation and diagnosis (Midoux 
et al, 1984). 
Much interest has been shown in the use of MCA's for the tumour 
targeting of powerful toxins such as diphtheria toxin, ricin and 
abrin. These toxins consist of two polypeptide chains, A and B, 
which are linked via a disulphide bond. The B chain, which acts as 
the cell recognition and binding moiety, can be cleaved from the A 
chain, which is highly cytotoxic. Coupling of the isolated A chain 
to MCA then produces, in theory, a highly cytotoxic agent or immuno- 
toxin (Jansen et al, 1982). Although extremely potent in vitro, 
these immunotoxins have proved disappointing in vivo. Other powerful 
toxic molecules such as venom phospholipases and bacterial 
cytolysins could be coupled to MCA's in a similar way (Sikora et al, 
1984). 
MCA mediated targeting of particulate carriers offers a 
distinct advantage in terms of payload capacity compared with MCA- 
carrier-drug conjugates (Couvreur, 1984). MCA can be linked to 
liposomes either by adsorption or covalent coupling (Weinstein and 
Leserman, 1984). The targeting capability of these liposomes in 
certain circumstances is very efficient; for example, liposomes 
conjugated with antibody to L929 murine fibroblasts, associated with 
these cells in 6- to 20-fold greater amounts compared with non- 
specific liposomes (Heath et al, 1983). Also, the ability of 
methotrexate-gamma-aspartate to inhibit L929 growth was increased 
nearly 7-fold. Although no studies have been published using MCA to 
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target microspheres loaded with drug, the coupling of antibodies to 
microspheres has been reviewed by Ilium and Jones (1985). 
In addition to problems encountered with the use of drug 
carriers alone, as already discussed, there are inherent drawbacks 
associated with the application of MCA mediated targeting. These 
have been considered by Poste and Kirsh (1983) and are outlined 
below. 
a) Antigen specificity. Apart from antigen idiotypes on B-cell 
tumours, totally tumour specific antigens still have to be isolated. 
The binding of anti-tumour MCA to non-target cells displaying tumour 
related antigens is a potentially serious problem for targeted 
immunotoxins. 
b) Tumour cell heterogeneity. Differences in tumour cell antigen 
phenotype occur between cells of the same primary tumour, between 
primary and metastatic cells, and between metastatic cells from the 
same primary tumour. A mixture of MCA's which recognise different 
antigenic determinants would be needed to target the entire neo- 
plastic cell population and different mixtures would be required to 
treat the same tumour type in different patients. 
c) Anti-idiotypic antibodies. Most MCA's currently used are murine 
immunoglobulins, which can elicit production of anti-idiotypic 
antibodies. This blocks MCA activity and can cause hypersensitivity 
reactions. The administration in low doses of immunosuppresive 
agents, such as cyclophosphamide, could alleviate this problem, or 
antibody immunogenicity could be reduced by removal of the Fc 
portion to leave F(ab')2 fragments. Alternatively, human MCA could 
be used (provided production difficulties can be overcome). 
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d) Release of free antigen. Natural shedding of tumour antigen or 
large scale release induced by tumour cell destruction could block 
effectively antibody mediated targeting. Consequent RES uptake of 
antigen blocked antibody complexes could be hazardous, especially 
with immunotoxins. RES uptake, however, may be utilised for removal 
of free antigen by pre-treatment with non-therapeutic MCA coated 
liposomes. 
e) Antigenic modulation. Loss of tumour cell antigenicity or 
immunoselection of antigen negative tumour cells following initial 
treatment will negate the effectiveness of subsequent treatment 
cycles. Employing two MCA's recognising the same antigen, but 
different epitopes, or recognising different antigens, are possible 
solutions. 
Far from solving the difficulties of site specific targeting, 
the problems introduced by the use of MCA are daunting. This 
approach, however, still holds potential, particularly for targeting 
neoplastic lymphoid subsets (Poste and Kirsh, 1983) and in ex vivo 
treatment of leukaemic bone marrow (Muirhead et al, 1983). 
1.5. TARGET SITE SPECIFICITY 
The degree of specificity achieved by drug targeting can be 
classified according to the level of selectivity of the delivery 
system (Poste and Kirsh, 1983: Widder et al, 1979). First order 
delivery is described as targeting to individual organs or tissues 
(organ targeting); second order refers to targeting to a specific 
cell type(s) within a tissue (cellular targeting); and third order 
targeting involves delivery to selected intracellular compartments 
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in target cells (sub-cellular targeting). Although it is possible to 
attain each level of targeting with various delivery systems, no 
single system exists which can achieve all three levels. 
The order of targeting may be of particular importance in 
cancer chemotherapy since solid malignancies usually consist of a 
heterogeneous collection of tumour cells which vary in their 
response to anti-neoplastic agents. This is probably the factor most 
responsible for the current lack of success in cancer chemotherapy 
and necessitates the use of multiple-drug regimens (Poste and Kirsh, 
1983). Therefore, not only would any potential drug targeting system 
be required to deliver its payload to a range of tumour cell 
sub-populations, but also be capable of accommodating an array of 
drugs. Furthermore, because cytotoxic agents act at a variety of 
sub-cellular sites, a degree of third order targeting may be 
necessary to ensure maximum therapeutic efficiency if the survival 
of drug resistant tumour cells is not to remain a major cause of 
treatment failure. 
1.6. SYNTHETIC DRUG CARRIER SYSTEMS 
From the vast array of drug carriers studied in recent years no 
single device has emerged as being clearly superior or fulfilling 
all the requirements of an ideal system. This may be understood in 
considering the criteria of an ideal carrier (Widder and Senyei, 
1983; Tomlinson, 1984) which, briefly, require that it should; 
1) be easy to prepare in a sterile form, 
2) be easy to store and to administer, 
3) be non-toxic and non-allergenic, 
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4) have a high capacity for a range of drugs, 
5) not release its payload prematurely, 
6) protect the payload from degradation, 
7) accumulate and remain at the desired site of action, 
8) release the drug(s) in an active form at a suitable rate and in 
therapeutic amounts to the target cell(s), 
9) be biodegradable with minimal toxicity. 
In attempting to meet these requirements two main types of 
carrier systems have been developed; soluble macromolecular drug 
carriers and particulate carriers. 
1.6.1. Soluble Macromolecular Drug Carriers 
The concept of a target specific macromolecular drug carrier is 
shown by figure 1.4 (Ringsdorf, 1975). In this representation the 
polymer backbone is modified by three functional moieties. One area 
is used to fix the 'pharmacon' or therapeutic agent. This is done 
via covalent bonds which may be permanent or temporary depending on 
whether the therapeutic agent can exert its effect whilst bound to 
the carrier. Target specificity is achieved by the attachment of a 
'homing device' such as an antibody, lectin or hormone. The third 
part of the conjugate can be used for controlling physico-chemical 
properties such as molecular weight, solubility, electrical charge 
and hydrophilic/lipophilic balance. 
Several polymeric materials have been utilised as carrier 
molecules. The choice of polymer is important in determining the 
biodistribution of injected carrier systems. In particular, RES 
uptake and glomerular filtration are highly dependant upon molecular 
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weight. Albumin has been used extensively, being readily available, 
well defined and chemically versatile due to large numbers of free 
carboxyl and amino groups. Dextrans too have attracted much 
attention due to their high water solubility, range of well defined 
molecular weights, low toxicity and ability to conjugate a wide 
range of drugs. Other molecules such as polylysine, polyglutamic 
acid and pyran also have been proposed as carriers and examples of 
the use of all these polymers are given by Sezaki and Hashida 
(1985). Results, however, in treating neoplastic cells in vivo are 
disappointing due to a lack of target specificity. 
For selective targeting of tumour cells a homing device needs 
to be attached to the cytotoxic agent, either by direct conjugation 
or through a carrier molecule. The use of MCA's in this respect has 
been dealt with already (section 1.4.3.3. ) and further examples are 
given elsewhere (Sezaki and Hashida, 1985). Apart from MCA's, 
lectins such as concanavalin A (Kitao and Hattori, 1977) and 
hormones (Cikes, 1978) have been proposed as targeting agents. 
Although in theory soluble drug carriers have a greater 
potential for extravasation and accumulation at target sites than 
particulate carriers, their overall effective dimensions are still 
sufficiently large, in many cases, to limit vascular escape (Pouton, 
1985). Decreasing molecular size, however, introduces the problem of 
rapid glomerular filtration. Also, the chemical modifications 
involved in preparing these carriers predispose them to clearance by 
the RES (Poste and Kirsh, 1983). Together with their low payload 
capacity these problems combine to offer little or no advantage over 
particulate carriers. 
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1.6.2. Particulate Drug Carriers 
The term 'particulate carrier' is used to describe systems 
which, by definition, are thermodynamically unstable and 
irreversible, as distinct from true solutions of macromolecular 
carriers (Shaw, 1910). Both types of systems are colloidal by nature 
and separation on grounds of molecular dimensions is not possible. 
Thus, particulate carriers can range in size from a few nanometres, 
such as small liposomes, to several micrometres as with ethyl- 
cellulose microspheres. Comprehensive reviews on a range of systems 
are available elsewhere (Davis, 1981; Oppenheim, 1981; Tomlinson, 
1983) while this section will be limited to discussing biodegradable 
carriers suitable for systemic administration. 
1.6.2.1. Liposomes 
Liposomes are composed of one or more concentric lipid bilayers 
enclosing an equal number of aqueous spaces. Three major types of 
liposomes can be formed depending on the preparative technique 
(Weinstein and Leserman, 1984). Multilamellar vesicles (MLV) are 
easy to prepare and relatively stable but are highly polydisperse 
(80nm to lOpm). Small unilamellar vesicles (SUV) are much less 
polydisperse but suffer from poor stability and low payload 
capacity. The third type of liposome, large unilamellar vesicles 
(LUV), are the most efficient with respect to drug encapsulation but 
they are difficult to prepare. 
Phosphatidylcholines (such as lecithin) are usually the major 
liposome constituents (40-70%) together with cholesterol and a 
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negatively charged lipid such as phosphatidylserine. Positively 
charged liposomes are normally formed by incorporating stearylamine. 
Drug loading is achieved by incorporating water soluble drugs into 
the internal aqueous compartment(s). The preparation and handling of 
liposomes has been discussed by Szoka and Papahadjopoulos (1980). 
The particulate nature of liposomes largely determines their 
biofate according to the factors already discussed. In addition, the 
composition of the lipid bilayer also seems to influence their 
distribution pattern (Senior and Cregoriadis, 1982). This is 
probably due to the fluid nature of these vesicles allowing exchange 
between liposome lipids and circulating lipoproteins (Scherphof et 
al, 1978). This, eventually, can lead to the disruption of liposome 
integrity and release of encapsulated drug. Attempts at stabilising 
the lipid membrane by incorporation of cholesterol, although 
successful in this respect, may increase liver uptake due to 
enhanced association of apoprotein E with the liposome surface 
(Widder et al, 1982). 
Several of the versatile properties of liposomes have been 
highlighted already (e. g. temperature and pH sensitivity). In 
addition to these, particle size can be controlled over the range 
25nm to 10pm, site specific ligands are readily incorporated and 
liposomal charge may be easily altered (Cregoriadis and Allison, 
1980). Doubts, however, have been raised concerning size hetero- 
geneity, stability, drug incorporation and production difficulties 
(Poste and Kirsh, 1983). Thus, the great attention paid to liposomes 
may be disproportionate to their potential in comparison with other 
drug targeting systems for use in cancer chemotherapy. 
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1.6.2.2. Polymeric nano- and aicrospheres 
The preparation, properties and uses of polymeric microspheres 
have been reviewed in a series of articles by Kreuter (1983a, b and 
c) and by Davis et al (1984). The materials used to form the 
particle matrix may be classified broadlly into two groups; 
synthetic polymers and natural macromolecules. Within this latter 
group serum albumin has been studied extensively. First suggested as 
drug carriers by Kramer (1974), albumin microspheres have been used 
in combination with many therapeutic classes of drugs (Tomlinson, 
1983; Yapel, 1979). Albumin microspheres can be prepared in a number 
of ways (Yapel, 1979), allowing control of particle size over a wide 
range (Tomlinson, 1983). One method involves heating a water-in-oil 
emulsion of the protein plus drug to give aggregates of drug loaded 
albumin. The microspheres are isolated by evaporating the water and 
removing the oil by washing with solvents. This method, however, is 
limited by degradation of heat-labile drugs and partitioning of 
lipophilic drugs into the oil phase. Alternatively, a chemical cross 
linking agent such as formaldehyde, glutaraldehyde or 2,3-butadione 
can be used without the need for heating (Kreuter, 1983a). Cross 
linking agents may be used also to harden particles produced by the 
desolvation of albumin solutions (Oppenheim, 1981). These reagents, 
however, can react with amino groups of drug molecules thereby 
interfering with their incorporation. Normally drug loading is very 
efficient for water soluble compounds and up to 35% by weight of the 
carrier can be drug (Tomlinson, 1984). 
Gelatin too has been examined extensively for use in the 
preparation of particulate carriers. Yoshioka et al (1981) were able 
-28- 
to form nano- or micro-spheres of gelatin depending on the 
preparative technique. Small nanospheres (280nm diameter) were 
formed by cross linking a sonicated gelatin emulsion, whereas larger 
microspheres (14.9ym) were formed with a vigorously shaken emulsion. 
The same authors could then target mitomycin C either to the liver 
(280nm particles) or lung (14.9ym particles). 
Usually, microspheres composed of synthetic molecules are 
prepared from acrylate polymers composed of either methyl meth- 
acrylate, acrylamide, N, N'-bis acrylamide, alkyl 2-cyanoacrylate 
(ACA) or copolymers of 2-hydroxyethyl methacrylate, methacrylic acid 
and acrylamide (Kreuter, 1983a). Other materials may be used such as 
4-vinyl pyridine and glutaraldehyde. Most particles formed from 
these monomers are not biodegradable and, therefore, are not 
suitable for drug targeting. However, particles composed of poly 
(alkyl 2-cyanoacrylate) (Couvreur et al, 1979a) and co-polymers of 
acrylamide and dextran, termed polyacryldextran microspheres, (Edman 
et al, 1980) are biodegradable. 
Poly (alkyl 2-cyanoacrylate) (p(ACA)) nanoparticles have 
attracted much attention for use in cancer chemotherapy. The next 
section will deal with this system in greater detail and will serve 
as an example of the considerations needed in the design of a 
suitable drug carrier. 
1.7. POLY (ALKYL 2-CYANOACRYLATE) NANOPARTICLES 
Initial attempts at producing a novel particulate lysosomo- 
tropic carrier (Couvreur et al, 1977) identified the need for a 
biodegradable system that would avoid prolonged overloading of 
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lysosomes. This work with polyacrylamide nanocapsules led to the 
development of p(ACA) nanoparticles, first reported by Couvreur et 
al (1979a). By varying the size of the alkyl ester group (generally 
methyl to hexyl) a range of nanoparticles with different properties 
can be produced. 
1.7.1. Preparation 
In the general method of preparation, the monomer is added to a 
rapidly stirred aqueous solution (pli 2-4) of a stabiliser such as a 
dextran or non-ionic surfactant (Couvreur et al, 1982a; Maincent, 
1982), although the formation of nanoparticles without the addition 
of polymeric stabilisers has been reported (Ibrahim et al, 1982; Van 
Snick et al, 1985). Anionic polymerisation of the monomer gives the 
corresponding p(ACA) which forms the nanoparticle matrix. Once 
polymerisation is complete the suspension is filtered to remove 
large particles and neutralised ready for use or lyophilisation. 
1.7.2. Physico-chemical Properties 
1.7.2.1. Morphology 
Nanoparticle morphology has been studied by both scanning and 
transmission electron microscopy (SEM and TEM) and shows these 
systems to consist of discrete spheres bearing a smooth surface 
(Kreuter, 1983d; E1-Samaligy and Rohdewald, 1982; Couvreur et al, 
1982a). Analysis of freeze-fracture replicas of nanoparticles by 
Kante et al (1980) also showed the presence of irregular profiles 
which where approximate ellipses with a maximum axial ratio of 1.5. 
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TEM studies have indicated these particles consist of a highly 
porous interior (Kreuter, 1983d) producing a large surface area for 
drug sorption. Although no continuous limiting envelope surrounding 
poly (methyl 2-cyanoecrylate) (p(MeCA)) nanoparticles could be 
identified by Couvreur et al (1979a), the same workers later 
proposed poly (butyl 2-cyanoacrylate) (p(BCA)) nanoparticles to 
possess a more homogeneous outer ring (Kante et al, 1980). This was 
not observed for all particles, however, and may be an artifact 
produced by the preparation technique. 
1.7.2.2. Particle size 
From the reports of various workers (Kreuter, 1983d; Couvreur 
et al, 1982a) the particle size of these systems appears to be in 
the range of approximately 30-S00nm, although no detailed study on 
the control of nanoparticle size was available prior to commencing 
this project. Detailed discussions concerning nanoparticle size are 
given in chapter 2. 
1.7.2.3. Polymer molecular weight 
Molecular weight analysis by gel permeation chromatography 
indicates nanoparticles are composed mostly of short polymer chains 
with a polystyrene equivalent number average molecular weight of the 
order 2000 (El-Egakey et al, 1983). The molecular weight was found 
to increase slightly with ester chain length, polymerisation ph, and 
stabiliser (polysorbate 20) concentration. Marked differences have 
been found, however, between nanoparticles produced with or without 
-31- 
poloxamer 188 stabiliser (Couvreur et all 1984; Van Snick et all 
1985). Nanoparticles produced in the presence of this surfactant 
possessed a high molecular weight component not seen in polysorbate 
20 systems. In addition, the polymer molecular weight was found to 
be affected by the polymerisation p11, ester size, and the addition 
of certain drugs to the polymerisation medium (Van Snick et all 
1985). These effects, due to the stabiliser and incorporated drug, 
may be of importance when considering drug release from the carrier. 
Further aspects of nanoparticle molecular weight and composition are 
discussed in chapter 3. 
1.7.2.4. Electrophoretic mobility and surface charge 
The electrophoretic mobility of aggregated nanoparticles has 
been determined by Kreuter (1983d). The particles were found to have 
a negative surface charge which was substantially reduced in the 
presence of human serum indicating a significant interaction of 
serum components with the nanoparticles. The electrophoretic 
mobilities in water of nanoparticles composed of the methyl, ethyl 
and butyl esters were found to be -2.33, -2.18 and -2.01 
)Im. cm. s-1. V 1 respectively. These values correspondingly decreased 
to 
-0.23, -0.23, and -0.19 pm. cm. s-V after the samples were 
incubated in serum overnight. 
1.7.2.5. Surface Hydrophobicity 
This property has been investigated by compressing nano- 
particles composed of different cyanoacrylate esters into tablets 
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and determining their water contact angles, giving an order of 
decreasing hydrophobicity of butyl> ethyl> methyl (Kreuter, 1983d). 
The surface hydrophobicity was reduced greatly by incubating the 
nanoparticles with human serum indicating, again, a strong inter- 
action with plasma proteins. Such an interaction could lead to 
particle opsonisation and rapid uptake by the RES. 
1.7.3. Nanoparticle Degradation 
The in vitro degradation mechanism of p(ACA) was identified 
first by Leonard et al (1966) who proposed a reverse Knoevenagel 
reaction resulting in polymer chain hydrolysis and formation of an 
alkyl 2-cyanoacetate and formaldehyde. The degradation rate was 
found to be a function of the ester chain length and pit, such that 
the rate decreased as the homologous series was ascended and as the 
pH decreased. This was confirmed by Vezin and Florence (1980) who, 
in addition, found the rates of degradation to vary with particle 
specific surface, particle size, polymer molecular weight and 
molecular weight distribution. A modified reaction mechanism was 
proposed in which degradation occurs only at chain ends. Leneerts et 
al (1984a), however, dispute these findings when examining the 
degradation of poly (isobutyl 2-cyanoacrylate) (p(iBCA)) nano- 
particles. These workers found that at pll 7 only 5% of the polymer 
degraded via the formaldehyde pathway after 24 hours, and at p1l 12 
the value reached only 7%. Conversely, after 24 hours at pH 12, 
between 85 and 94% of the polymer was found to have degraded via an 
alternative mechanism involving isobutanol production due to ester 
hydrolysis. 
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Wade and Leonard (1972) first postulated that ester hydrolysis 
may be involved in the degradation of these polymers in vivo. 
Although it has been stated that polymer degradation is independent 
of any added esterase (Vezin and Florence, 1978) other studies have 
shown nanoparticles to undergo enzymatic ester hydrolysis yielding a 
primary alcohol and water soluble poly (2-cyanoacrylic acid) 
(Lenaerts et al, 1982; Crislain et al, 1983). This enzymatic pathway 
would augment the chemical ester hydrolysis which is unlikely to be 
significant at pit 7.4 or below. 
The degradation of nanoparticles in vivo, therefore, will be 
highly complex involving at least two pathways dependent upon such 
parameters as the ester group, pH, molecular weight, particle size, 
enzyme activity, etc.. The choice of monomer does offer, however, 
some degree of control over nanoparticle degradation (Couvreur et 
al, 1979b). 
1.7.4. Drug Loading 
Drug uptake may be achieved either by incorporation during the 
polymerisation stage or by adsorption once the nanoparticles are 
isolated. Addition of drug to the reaction medium, however, can 
interfere with nanoparticle formation (Maincent, 1982). In addition, 
drugs possessing the weakly nucleophilic moieties hydroxyl, amino or 
carboxylate, may copolymerise with the monomer (Leonard et all 1966; 
Sehmeissner, 1970). This may reduce the payload of free active drug, 
although at the low pH of nanoparticle formation protonation of 
amino and carboxylate functions should render such compounds 
unreactive. Whilst nanoparticle formation does not require an 
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initiating energy input, such as chemical, thermal or electro- 
magnetic, which could have detrimental effects on drug payload as 
experienced with other systems (Oppenheim, 1981), the high 
reactivity of the monomer can pose problems if drug uptake is 
achieved by incorporation. Most of the payload, however, appears to 
be adsorbed at the particle surface as indicated by the similarities 
in uptake of triamcinolone diacetate achieved either by 
incorporation or adsorption (El-Samaligy and Rohdewald, 1982). There 
would appear to be little advantage, therefore, in adding the drug 
to the polymerisation medium. 
A wide range of drugs have been loaded into nanoparticles as 
shown by the examples in table 1.2. This table gives the drug uptake 
in terms of the amount of drug per unit weight of carrier, which is 
much more important when considering the payload of the system than 
quoting percentage uptake alone (Oppenheim, 1981). Generally, the 
uptake is greatest for hydrophobic unionised molecules and is 
enhanced by nanoparticles composed of longer chain esters. Therefore 
fluorescein, which is strongly sorbed at low pH's in its non-ionised 
form, rapidly desorbs as the pit is raised due to anion formation, 
and shows a higher loading with nanoparticles composed of poly 
(ethyl 2-cyanoacrylate) (p(ECA)) compared with the p(MeCA) (Couvreur 
et al, 1979a). The sorptive behaviour of p(BCA) nanoparticles has 
been studied in detail using the model drug verapamil which 
displayed Langmuir type adsorption (El-Egakey and Speiser, 1982a). 
As expected, temperature rise, surfactants, and dispersing agents 
decreased adsorption, while increase in electrolyte concentration 
and pH increased adsorption. 
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1.7.5. Drug Release 
The rate of drug release from p(ACA) nanoparticles closely 
follows the rate of nanoparticle degradation (Couvreur et al, 1979b; 
Lenaerts et al, 1984a). By the choice of monomer it is possible to 
control drug release rates (figure 1.5) although the influence of 
other factors affecting nanoparticle degradation need to be 
considered. These results imply that the drug is dispersed 
throughout the nanoparticle matrix. This is in contrast to the 
findings of El-Samaligy and Rohdewald (1982) who proposed that drug 
release is mainly an estimation of drug desorption which is only 
partially augmented by polymer degradation. As long as a polymer 
surface exists an adsorption/desorption equilibrium is still 
present, so that drug release is complete only after final 
nanoparticle degradation. Diffusion of the drug through the p(ACA) 
matrix can also occur (El-Egakey and Speiser, 1982b), thereby 
complicating the release characteristics further. In vivo, the 
situation is probably much more complex with protein surface 
interactions and macrophage uptake possibly leading to a much faster 
release. 
1.7.6. Toxicity of the Carrier 
Much of the data concerning p(ACA) toxicity are derived from 
their use as surgical tissue adhesives. The decrease in 
histotoxicity of these compounds as the homologous series is 
ascended (Leonard et al, 1967) is related to the degradation rate of 
the polymer. The more toxic faster degrading esters (e. g. methyl) 
Figure 1.5. Evolution of actinomycin D from nanoparticles 
composed of various cyanoacrylate esters. 
(V) p(MeCA) 
(") p(MeCA) and p(ECA) mixture (2: 1) 
(o) p(MeCA) and p(ECA) mixture (1 : 1) 
(A) p (MeCA) and p (ECA) mixture (1: 2) 
(0) p(ECA) 
Couvreur et al, 1979b. 
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lead to a rapid local accumulation of toxic metabolites believed to 
be formaldehyde and alkyl 2-cyanoacetates (Leonard et al. 1966). 
Mori et al (1967), however, found little difference between the 
ethyl, propyl and butyl esters. The route of administration and site 
of deposition also appear to be important since p(BCA) implanted 
subcutaneously was found to display little histotoxicity (Houston et 
al, 1970) whereas intra-articular injection of the same compound 
produced severe tissue inflammation (Ratcliffe et al, 1984). 
Nanoparticle toxicity has been investigated both in vitro and 
in vivo by Kante et al (1982). The LD50 values for p(iBCA) and 
p(BCA) nanoparticles were found to be 196 and 230 mg/kg 
respectively, following intravenous injection of 9.2 mg/ml 
suspensions in mice, although the injection medium alone was not 
free of toxicity (LD50 = 33.4 ml/kg). Incubation of p(MeCA) 
nanoparticles with mouse peritoneal macrophages in vitro produced 
marked histotoxicity whereas p(iBCA) nanoparticles at the same 
concentration showed no signs of toxicity. Also, nanoparticles of 
the butyl ester only produced cellular damage of hepatocytes at high 
concentrations (2x104 particles per cell). Neither intact 
nanoparticles nor their degradation products were found to be 
mutagenic by the Ames test. In addition, no carcinogenic action has 
been associated with the use of these polymers in surgery (Collins 
et al, 1969). 
These results indicate that nanoparticles composed of the 
higher esters of the series have a low toxicity although the 
production of formaldehyde in the degradation pathway will have to 
be carefully considered.. One possibility of reducing toxicity 
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involves the formation of nanoparticles using alkyl 2-phosphonyl- 
acrylates currently under development (Hastings, 1984). In these 
compounds the cyano group has been replaced by a phosphonate moiety 
which should be less toxic. 
1.7.7. Considerations for Targeting With Nanoparticles 
1.7.7.1. Fate of the carrier following injection 
Intravenous injection of 14C-labelled p(iBCA) nanoparticles in 
mice resulted in 78% of the injected dose being localised in the 
liver after only 5 minutes (Grislain et al, 1983). This behaviour is 
indicative of uptake by liver Kupffer cells which was shown by 
determining the intra-liver distribution of nanoparticles in rats 
(Lenaerts et al, 1982 and 1984b). After rapid uptake the Kupffer 
cell concentration was found to decrease with time, while in 
contrast liver endothelial cell nanoparticle concentration reached a 
maximum after 30 minutes indicating a slower capture mechanism. 
Particle size was found to have no effect on the liver distribution 
of nanoparticles. 
Studies in mice bearing a subcutaneous grafted Lewis Lung 
Carcinoma showed a different nanoparticle distribution compared with 
healthy mice (Grislain et al, 1983). Significant levels of 
radioactivity were found in the tumour and in the metastatic lungs 
of cancerous animals, with no lung accumulation in healthy animals. 
This was attributed to passage of the carrier through the vascular 
endothelium and uptake by endocytic tumour cells. However, no 
histological studies were performed so it is not possible to 
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determine whether intact nanoparticles localised in the tumour or if 
the increase in radioactivity was due to the uptake of nanoparticle 
degradation products formed elsewhere. Alternatively, the localised 
radioactivity could be attributed to blood pooling since the Lewis 
Lung Carcinoma is a haemorrhagic tumour. In contrast Ilium et al 
(1984) did not observe any tumour localisation of nanoparticles in 
mice bearing an osteogenic sarcoma. 
Subcutaneous or intramuscular injection of 14C-labelled nano- 
particles produced a slow release of radioactivity which 
concentrated in the gut wall with no activity detectable in the 
liver (Grislain et al, 1983). This would imply that lymphatic 
transport of the carrier did not occur or that the nanoparticles 
degraded at the injection site slowly releasing soluble radioactive 
degradation products. 
1.7.7.2. Effects of nanoparticles on drug distribution, toxicity 
and anti-tumour activity 
When considering the fate of p(ACA) nanoparticles in vivo it is 
not surprising that drugs administered with these carriers tend to 
localise in tissues rich in RE cells. Rats injected with actinomyin 
D incorporated into p(BCA) nanoparticles showed, after 24 hours, 
concentrations 64- and 44-fold higher for the liver and spleen 
respectively compared with the free drug (Kante et al, 1980). In 
addition, higher levels were observed in the muscle tissues and 
lungs. Similar findings have been obtained with vinblastine 
(Couvreur et al, 1980a). In comparison, enhanced liver and spleen 
uptake were not so pronounced with actinomycin D incorporated into 
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p(MeCA) or p(ECA) nanoparticles although levels of this drug in the 
lungs and small intestine were significantly higher in nanoparticle 
injected animals (Kante et al, 1980). The distribution of 
actinomycin D, therefore, appears to be affected by the nature of 
the carrier. This may be altered further by administering the drug 
with magnetically responsive p(iBCA) nanoparticles (Ibrahim et al, 
1983). Ten minutes after injection of these particles loaded with 
3H-actinomycin D, an approximately three times higher radioactive 
concentration was found in the kidneys of mice bearing a magnet 
compared with a control. Also, the liver uptake in these animals was 
reduced by one third. Other drugs such as 5-fluorouracil (Kreuter 
and Hartmann, 1983), doxorubicin (Couvreur et al, 1982b) and 
75Se-norcholestenol (Kreuter et al, 1983) also display an altered 
biodistribution when administered in nanoparticle form. 
These effects on drug biodistribution may be expected to alter 
the toxicity profiles of cytotoxics when administered with 
nanoparticles. The adsorption of doxorubicin onto p(iBCA) 
nanoparticles produced a significant reduction in mortality and 
weight loss in mice under various dosage and administration 
schedules compared with free drug (Couvreur et al, 1982b). In 
addition, lower levels of the drug were found in the myocardium of 
animals given the nanoparticle preparation, which may be of 
importance considering the high cardiotoxicity of doxorubicin. 
Kreuter and Hartmann (1983), however, found the toxicity of 
5-fluorouracil in mice, as measured by leukopenia, weight loss and 
premature death, to be enhanced when given with p(BCA) 
nanoparticles. This was proposed to result from increased 
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accumulation in the bone marrow since this organ belongs to the RES 
and myelosuppression is the dose limiting factor for 5-fluorouracil. 
Similarly, actinomycin D adsorbed onto p(MeCA) nanoparticles was 
found to have a higher mortality compared with free drug when 
injected into rats bearing a soft tissue sarcoma (Brasseur et al, 
1980). 
Initial studies indicate that the antitumour effect of 
cytotoxics may be enhanced by administration with nanoparticles. An 
enhanced reduction in the growth of mouse Crocker Sarkoma S180 was 
seen with 5-fluorouracil bound to p(BCA) nanoparticles compared with 
free drug, although this was also associated with increased toxicity 
(Kreuter and Hartmann, 1983). Similarly, Brasseur et al (1980) 
reported a considerable decrease in the growth of a rat soft tissue 
sarcoma (S250) with actinomycin D adsorbed onto p(MeCA) nano- 
particles (figure 1.6). The carrier alone did not demonstrate any 
significant antitumour activity. Clinical trials in humans are now 
in progress although no conclusive data are yet available (Couvreur 
et al, 1985). 
1.7.7.3. Nanoparticle targeting mediated via monoclonal antibodies 
Monoclonal antibodies may be attached to nanoparticles either 
via a protein spacer (Couvreur, 1984) or directly by adsorption 
(Ilium et al, 1983). In the latter case each poly (hexyl 
2-cyanoacrylate) (p(HCA)) nanoparticle was found to take up on 
average 2000 antibodies (791T/36 antitumour osteogenic sarcoma). 
These particles interacted specifically with antigenic tumour cells 
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Figure 1.6. Tumour size of S250 sarcoma in mice 
treated with free actinomycin D Cu) or with 
actinomycin D adsorbed onto p(MeCA) nanoparticles (A). 
Dosage: two i. v. injections (arrows) of 111yg 
actinomycin D (free or sorbed) per kg. Controls (. ). 
Brasseur et al, 1980. 
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in vitro with the antibody retaining its immunospecificity for at 
least four days at 4°C. 
When this system was tested in mice bearing 788T osteogenic 
sarcoma no specific tumour uptake was detected and the nanoparticles 
localised mainly in the liver and spleen (Ilium et al, 1984). 
Obviously, in vivo the situation is much more complex and many 
problems such as antibody displacement, particle opsonisation and 
removal by the RES must be overcome before nanoparticle tumour 
specific targeting can be achieved using monoclonal antibodies. 
1.7.8. Other Applications of Nanoparticles 
The rapid uptake of nanoparticles by Kupffer cells of the liver 
and the high accumulation of nanoparticle associated drugs in this 
organ could be utilised for the treatment of hepatic diseases. Avila 
(1983) assessed the activity of two nanoparticle adsorbed drugs, 
formycin B (FoB) and 4-aminopyrazolo (3,4-d) pyrimidine (APP) in 
Trypanosoma cruzi infected mice. A significant increase in anti- 
trypanosomal activity was observed when FoB and APP were fixed to 
p(iBCA) nanoparticles, corresponding to a diminution in mortality 
and parasitaemia. 
The release rate of subcutaneously injected insulin in mice may 
be controlled by incorporation of insulin into nanoparticles 
composed of different esters, with the slower degrading 
nanoparticles provoking a longer hypoglycaemic response (Couvreur et 
al, 1980b). Attempts at delivering insulin orally in nanoparticle 
form failed to produce any hypoglycaemic action. Either the 
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nanoparticles did not protect the insulin against proteolytic 
degradation or they were not absorbed. 
1.8. SUMMARY AND AIMS 
It has been shown that site specific drug delivery is a highly 
complex area. Before any further progress can be made a greater 
understanding of the basic physiological and biochemical parameters 
is required. The same can be argued for a more detailed analysis of 
drug carrier systems in terms of physico-chemical properties. Of the 
systems available p(ACA) nanoparticles represent a highly versatile 
drug delivery system being easy to prepare, biodegradable and having 
low toxicity. The choice of monomer determines the rate of 
nanoparticle degradation and affects surface hydrophobicity and drug 
loading. These particles are capable of sorbing and modifying the 
tissue distribution of a wide range of drugs and can enhance the 
activity of cytotoxic agents against experimental tumours in 
animals. There is evidence to suggest that nanoparticles may 
localise in certain tumours and nanoparticles coated with monoclonal 
antibody specifically target tumour cells in vitro, although this 
could not be demonstrated in vivo. Despite this, there is little 
detailed knowledge of nanoparticle formation, composition, physico- 
chemical properties and fate in vivo. The aim of this project will 
be to answer some of these questions via a systematic study of 
nanoparticle preparation and in vivo behaviour. Particular emphasis 
will be placed on the control of particle size, surface charge, 
molecular weight, and surface interactions, all of which have been 
shown to affect the behaviour of colloidal drug targeting systems. 
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CHAPTER TWO 
CONTROL OP NANOPARTICLE SIZE 
2.1 INTRODUCTION 
The importance of particle size in determining the fate of an 
injected colloidal drug carrier has already been illustrated 
(section 1.3.1). Varying the size of p(ACA) nanoparticles would 
allow, therefore, some degree of control over the biodistribution of 
the carrier and its payload. In particular, the formation of small 
monodisperse nanoparticles may be important when regarding possible 
extravasation of the carrier (Poste, 1985). The control of 
nanoparticle size would not only increase the versatility of the 
system as a drug carrier but also yield valuable information 
concerning the mechanism of particle formation. 
Parallel studies with other polymer colloids such as 
polystyrene (Fitch, 1971 and 1980; Hearn et al, 1981), have resulted 
in a thorough understanding of particle formation and in the control 
of latex particle size over a wide size range. Goodwin et al (1978) 
were able to regulate accurately the particle size of polystyrene 
particles by varying the reaction conditions during an emulsifier 
free polymerisation process. From these results it was possible to 
derive an equation to predict particle size given as 
log D-0.238 log I [M 1.723 + 4929 
-0.827 [2.1) 
IN T 
where the final particle diameter, D(jpm), in the size range 0.1 to 
fpm is dependent on the absolute temperature, T, the ionic strength 
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of the aqueous phase, I, the initiator concentration, P, and monomer 
concentration, M. 
These results may be related to the mechanism of particle 
formation (Goodwin et al, 1973). Polystyrene particles are 
stabilised by electrostatic forces which are affected by changes in 
the surface charge density and electrical double layer. The free 
radical polymerisation mechanism results in the charged initiator 
being incorporated in the polystyrene polymer as an end group. 
Increasing initiator concentration, or increasing temperature which 
increases the rate of initiator formation, leads to an increase in 
the number of charged end groups and a higher surface charge. This 
enhances particle stability and is reflected in a decrease in size. 
Adding more monomer to the system is equivalent to decreasing the 
initiator concentration, thereby resulting in an increase in 
particle size. If the ionic strength of the aqueous phase is 
increased, the electrical double layer is compressed, resulting in a 
decrease in the effective surface charge, or zeta potential, as seen 
by an increase in particle size. 
The findings of these workers will serve as a suitable basis 
for the investigation of the control of p(ACA) nanoparticle size. In 
addition, the requirement of a stabilising agent for the preparation 
of a stable colloidal system offers an alternative means of 
controlling nanoparticle size. The choice of stabilisers for 
nanoparticle preparation will be influenced by the requirement of 
low toxicity. Although this problem can be overcome to some degree 
by removal of any free toxic material in the polymerisation medium, 
the methods available for purifying colloidal dispersions are often 
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time consuming and not totally effective (Hearn et al, 1981). Also, 
removal of the stabilising polymer may result in particle 
flocculation (Kreuter, 1983a). Consequently dextrans, non-ionic 
surface active agents (poloxamers and polysorbates) and 
(3 
-cyclodextrin have been employed. 
2.2. EXPERIMENTAL METHODS AND MATERIALS 
2.2.1 Nanoparticle Preparation 
A standard polymerisation formulation was used throughout and 
altered as necessary to study the effect of each variable on p(BCA) 
nanoparticle size. All chemicals were of standard laboratory grade 
unless otherwise stated. Glassware was thoroughly cleaned and rinsed 
with filtered (0.2ym membrane filter, Whatman, UK) distilled water. 
Standard preparation. To 24.75m1 of a filtered (0.2pm membrane 
filter) stirred aqueous solution of 0.5% w/v dextran 70 (molecular 
weight 70300; Sigma, UK) in approximately 0. O1N hydrochloric acid 
(pH 2.25) was added 0.25ml of butyl 2-cyanoacrylate (BCA) (Sichel 
Werke, FRG). Stirring was achieved by means of a glass-covered 
magnetic stirrer bar and the stirring rate adjusted to disperse 
fully the monomer (approximately 1000 rpm). Reactions were carried 
out in a stoppered 25m1 Ouickfit conical flask at ambient 
temperature (20°C). After polymerisation was complete (normally 
2hours ) the suspension was filtered through a sintered glass funnel 
(grade 4, pore size 11-16)lm) to remove any large particle 
agglomerates. The polymerisation end point was determined by adding 
0.5m1 acetone to a 1. Oml sample of the reaction mixture, followed by 
-46- 
2 drops of a freshly prepared solution of potassium permanganate 
(0.1% w/v) at the same p11 as the polymerisation medium; rapid 
discharge (within 5 seconds) of the pink colour indicated the 
presence of monomer and stirring was continued until all monomer was 
consumed. Each preparation was carried out in duplicate to ensure 
the results were reproducible. A formulation was only regarded as 
acceptable if the bulk of the monomer formed discrete particles. 
Effect of stirring speed and ultrasonication. The effect of stirring 
rate on particle size was determined by stirring the reaction medium 
mechanically with a glass paddle. Stirring rate was measured with an 
optical digital tachometer (Compact Dot-1, Compact Instruments, UK). 
The minimum and maximum stirring rates were restricted by the need 
to fully disperse the monomer in the aqueous phase and by the upper 
speed limit of the stirrer, respectively. 
To determine whether ultrasonication could be used as an 
alternative method for monomer dispersion the reaction vessel was 
either placed in an ultrasonic bath (Decon FS100, Decon Ultrasonics, 
UK) or an ultrasonic probe (Dawe Soniprobe 7532B, Dawe Instruments, 
UK), at power setting 4, was immersed in the reaction medium. 
Effect of monomer concentration. The monomer concentration was 
varied over the range 0.25 to 7% v/v by adding various volumes of 
monomer to the polymerisation medium such that the final reaction 
volume was always 25ml. Suspensions above 7% v/v were not free 
flowing and therefore not examined. 
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Effect of acidifying agent. Dextran 70 solutions (0.5% w/v) were 
prepared at pH 2.25 using the following acids: acetic, ascorbic, 
citric, hydrochloric, nitric, phosphoric and sulphuric. 
Effect of pH. The pHi of the polymerisation medium was adjusted over 
the range 1.0 to 3.5, as determined by a calibrated pN meter, by 
varying the hydrochloric acid concentration. 
Effect of temperature. The reaction temperature was varied over the 
range 4 to 80°C by either cooling the reaction flask with ice or 
immersing it in a thermostatically controlled water bath (' 1°C). 
Effect of ionic strength. Sodium chloride or calcium chloride over 
the concentration range 0.01 to 0.25 mole dm 
3 
were added to the 
polymerisation medium prior to monomer addition. With calcium 
chloride, the dextran 70 solution was prepared in distilled water 
and the final pH adjusted to 2.25 with hydrochloric acid after 
addition of the electrolyte. 
Effect of dextran concentration and molecular weight. The dextran 70 
concentration was varied over the range 0.05 to 2.5% w/v. This was 
repeated with dextran 40 (molecular weight 40000; Sigma) and dextran 
10 (molecular weight 10300; Sigma). 
Effect of/3-cyclodextrin concentration. Dextran 70 in the standard 
formulation was replaced with t3-cyclodextrin (Chinoin Pharma- 
ceuticals, Hungary) and the concentration varied over the range 0.75 
to 1.75% w/v. This range was limited by the production of grossly 
flocculated systems at a concentration less than 0.75% w/v and the 
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low water solubility of /3-cyclodextrin (maximum 1.87% w/v at 25°C) 
(Szejtli, 1982). 
Effect of poloxamer type and concentration. Dextran 70 in the 
standard formulation was replaced with poloxamer 188 (Pechiney Ugine 
Kuhlmann, UK) and the concentration of this surfactant varied over 
the range 0.1 to 2.5% w/v. Poloxamers 184,237,238 and 338 
(Pechiney Ugine Kuhlmann) were examined at a concentration of 
0.5% w/v. 
Effect of polysorbate type and concentration. Dextran 70 in the 
standard formulation was replaced with polysorbate (Tween) 20 
(Koch-Light Laboratories, UK) and the concentration of this 
surfactant varied over the range 0.3 to 2.5% w/v. Polysorbates 40 
and 60 (Koch-Light Laboratories) were examined at a concentration of 
0.5% w/v. 
Effect of Brij 96. Brij 96 (Honeywell-Atlas, UK) was used to replace 
dextran 70 in the standard preparation at a concentration of 0.5% 
W/V. 
Other stabilisers. In addition to the polysaccharides and 
surfactants listed above various other stabilisers were used in 
place of dextran 70. These were polyethylene glycols (PEG'S) 400, 
600,1000,1500 and 6000 (BDH, UK) at concentrations up to 5.0% w/v, 
polyvinyl- pyrrolidone (BDH) at concentrations up to 5.0% w/v, and 
glucose (BDH) at 5.0% w/v. With these stabilisers, however, most of 
the monomer formed an amorphous polymer mass with little or no 
discrete nanoparticle formation. 
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The use of the poly-ionic stabilisers dextran sulphate and 
diethylaminoethyl-dextran is discussed in chapter 4. 
2.2.2. Particle Size Analysis 
The majority of the nanoparticle samples were analysed by photon 
correlation spectroscopy (PCS) which offers many advantages over 
more classical particle sizing techniques such as electron 
microscopy (McConnell, 1981). The rapid analysis time, minimal 
sample preparation, and wide applicable size range (5 to 2000nm) are 
particularly important considering the large number and range of 
samples under investigation. Examples of the use of PCS in 
pharmaceutical analysis are available in the literature 
(Fairbrother, 1979; Roe and Barry, 1983). 
Electron microscopy (SEM) was used to validate PCS measurements 
and to obtain a particle size distribution (PSD). For particles 
prepared using /S -cyclodextrin as the stabiliser, size analysis was 
performed using a Coulter Counter. 
Polystyrene latex standards of diameter 166 and 450nm were 
obtained from Polysciences (USA) and a standard of diameter 390nm 
was kindly donated by Dr. J. Hearn (Trent Polytechnic). These were 
all sonicated for 20 minutes prior to use. 
2.2.2.1. Photon correlation spectroscopy 
The instrument used was based on a commercially available 
Malvern system (Malvern Instruments, UK) and is represented 
diagrammatically in figure 2.1. This consisted of a 14mal, 441.6nm, 
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helium-cadmium laser (Liconex, USA) irradiating the scattering cell 
held in a thermostatted water bath at 25: 0.05°C. The resulting 
scattered light was detected at 900 by a variable angle photon 
detection system which transmitted the signal to a Malvern K7025, 
64-channel, multibit correlator (Malvern Instruments). This was 
interfaced with a Commodore PET 2001-32N microprocessor (Commodore 
Business Machines, USA) and the correlation data were analysed by a 
Malvern Applications Program (7025 Spect. I. VI; Malvern Instruments). 
Details concerning the adjustment and maintenance of this instrument 
have been given by Pearce (1984). 
Samples were diluted before measurement with distilled water 
freshly filtered through a 0.2ym membrane filter (Whatman). The 
optimum correlation sample time was determined for each nanoparticle 
suspension since both the calculated diameter and polydispersity 
index vary according to the sample time employed (Derderian and 
MacRury, 1981) and this in turn depends upon the size and PSD of 
each suspension. This is shown for a polystyrene latex sample in 
figure 2.2. Each sample was then analysed a total of 15 times to 
give an average value for the particle diameter and polydispersity 
index. The coefficient of variation for the diameter measurements 
was less than 3.0% and the measurement standard deviation of the 
polydispersity index typically 0.02. 
2.2.2.2. Scanning electron microscopy 
The nanoparticle suspensions were applied to a hydrophilic 
copper plate and freeze-dried before coating with a platinum/carbon 
film. Samples were examined in a Hitachi S-700 FE-SEM (Hitachi 
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Electronics, Japan), fitted with a field emission electron source, 
at an excitation energy of 20kV and magnifications of either 20000, 
45000 or 90000. Photographic prints of the electron micrographs were 
then examined with a particle size analyser (Model TCZ3, Carl Zeiss, 
FRG). A minimum of 300 individual particles were analysed for each 
sample. 
2.2.2.3. Coulter Counter 
For nanoparticle systems with an average diameter larger than 
2ym the particle size analysis was performed using a Coulter Counter 
(Model TA, Coulter Electronics, UK). The apparatus was fitted with a 
30ym-orifice tube previously calibrated with polystyrene latices or 
pollens of known diameter. Samples were diluted with a suitable 
electrolyte (Isoton II, Coulter Electronics). 
2.3. RESULTS AND DISCUSSION 
2.3.1. PCS Theory and Interpretation of Results 
Measurement of particle size by PCS is based on the theory that 
the observed time dependence of the fluctuations in intensity of 
scattered light from a colloidal dispersion, is a function of the 
size of the scattering particles (Chu, 1974). When a colloidal 
system is illuminated by a laser light source the relative phases of 
the scattered light waves from different particles vary as the 
particles undergo Brownian motion, causing the intensity of 
scattered light at the detector to fluctuate with time. Although 
fluctuations for individual particles occur randomly there is a well 
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defined lifetime for the build up and decay of scattered light 
intensity as shown in figure 2.3 (Posey et al, 1974). 
The particle size of the system is found through the technique 
of photocount autocorrelation (Pusey et al, 1974). To understand 
this process consider the intensity curve of figure 2.3 as being 
divided into time intervals of length T, which in practice is the 
correlator sample time. During any sample time the scattering 
intensity is proportional to the number of detected photons which 
for a typical PCS experiment gives approximately one million 
individual sample intervals, i, each containing a photocount, n. The 
number of photons detected in sampling interval i, centred on time 
ti, is then defined as n(ti). The autocorrelator then constructs the 
sum of products 
iý (N-M) 
n(ti). n(ti+m) (2.2] 
iR1 
for a range of delay times, mT (also given as Y ), where m 
1,2,3,.., M, and M is the number of channels built into the 
autocorrelator. N is the number of sampling intervals of length T in 
the experimental run. As the experiment proceeds the second order 
autocorrelation function, G2(''), accumulates in the correlator 
channels until time NT. The resulting G2(-r) is normalised by 
dividing by the square of the mean scattering intensity to give the 
normalised second order autocorrelation function, g2(y). 
Through the Siegert relation (Goodall et al, 1980) g2(or) may be 
given in terms of the normalised first order autocorrelation 
function, lgl('r)l, by 
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Figure 2.3. Typical trace of fluctuating scattered light 
intensity from a colloidal dispersion and the 
corresponding distribution of photocounts (Pusey et al, 
1974). 
Assigning the the photocount (n) in the first time 
interval (t1) as ntI and the total number of intervals 
as N, then the channel contents for a 64 channel auto- 
correlator would contain the following sums of products: 
Channel 1_ (nt1. nt2) + (nt2. nt3) + (nt3. nt4) +. """"""""" 
........... 
(ntN-64. ntN-63). 
Channel 2 w(nt1. nt3) + (nt2. nt4) + (nt3. nt5) +"""""""""" 
........... 
(ntN-64. ntN-62). 
Channel 64=(ntl. nt65) + (nt2. nt66) + (nt3. nt67) +""""""" 
........... 
(ntN-640ntN)" 
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g2() -1+ Ig1(Y)1z (2.31 
The translational diffusion coefficient, D, of the particles 
can now be obtained since 
1g, (-r) I- exp(-r r) (2.4) 
where r, the decay constant, is related to the scattering vector, 
K, and D by 
r- DK2 [2.5) 
and 
K4 TI n sine/2) [2.6) 
in which n is the index of refraction of the scattering medium, 8 is 
the scattering angle and a the incident laser light wavelength. 
Combining equations [2.3] and [2.4] gives 
82(Y) -1+ exp(-2r-r) [2.7] 
or 
ln[ 82(7)-1 l- 
-2r^r [2.8) 
A plot of ln[ g2('r)-l j vs ^r 
, 
therefore, gives a straight line 
of slope 
-2I'. D is then calculated from equation [2.5] and used to 
obtain the equivalent spherical hydrodynamic diameter, dh, by 
recourse to the Stokes-Einstein equation 
dhýkT 
3'ITr1D 
[2.9) 
where k is Boltzmann's constant, T is the absolute temperature and r 
the solvent viscosity. 
The above treatment only applies strictly for a monodisperse 
system of non-interacting particles that are small compared with the 
incident light wavelength. However, for a polydisperse system 
-54- 
consists of a sum of exponentials (Pusey et al, 1974) given 
as 
ao 
c(r) exp(-r-r) dr (2.10] 
0 
where G(P ) is the normalised distribution of decay rates. 
The complete solution to equation [2.10] can be obtained by 
Laplace inversion. This is impossible, however, given the precision 
of the experimental data and an alternative method has to be used. 
One approach is Koppel's (1972) method of cumulants which involves 
expanding exp(-r i') about exp(-r r ), where I' is the mean decay 
rate, giving the expression (Brown et al, 1975) 
ln[ 00.5.181('Y)I ]- ln(C0.5) 
-1 -r +12 1P2 (f ) 
21 I` 2 
-1 
1h (I', 
-)3 + 
...., 
[2.11J 
31 I' 3 
where yr is the rth moment about the mean of G(r) and the parameter 
C is a constant depending on the optical design (Brown et al, 1975). 
Although this equation is only exact when all terms are 
considered, the data can usually be adequately described by the 
first few terms. Data analysis then involves a curve fitting 
procedure to the first two terms of equation [2.11], giving the mean 
and variance of G(r ). The z-average diffusion coefficient and the 
equivalent z-average particle diameter, dz, (Green et al, 1976) may 
be calculated from I' and the z-average variance of the distribution 
is given by 
o_ß, 2/r2 [2.12] 
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where Q is known as the quality parameter or polydispersity index 
(Pusey et al, 1974). For a monodisperse system 0 should be zero 
theoretically although this is difficult to achieve in practice (for 
example, we found for a monodisperse latex Q=0.03). Values of Q< 
0.02 suggest approximate monodispersity whereas values of 0<0.2 
suggest relatively narrow distributions (Pearce, 1984). If 0 is 
larger than 0.2 it can only be considered as a qualitative guide to 
polydispersity because the mathematical approach to calculating 0 
becomes invalid at these distribution bandwidths (Pearce, 1984). 
PCS data can alternatively be analysed by a number of other 
mathematical techniques (Chu et al, 1979) to yield a PSD, although 
these treatments are highly involved and require very precise data 
which are susceptible to experimental error. Provided the PSD is 
log-normal, however, it is possible to derive a relationship 
describing the distribution of sizes (Pearce, 1984) by utilising the 
second moment about the mean of the size distribution (Hearden, 
1960) and relating this to the polydispersity index as given by 
C(d) 
- 
[2 TI ln(1 + Q)]-0.5 
x exp -{ Ind - In[ dz/(1 + Q) 
2.5 J)2 [2.13] 
21n 1+Q 
where G(d) is the relative number population of particle size d. 
By solving this equation over the appropriate size range the 
PSD may be obtained in terms of particle number. A computer program 
has been written to do this and details are given in appendix I. 
Equation (2.13] is based on the equation for a log-normal PSD which 
may be accurately defined in terms of its geometric mean diameter, 
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dg, and geometric standard deviation, O 'g (Ilcarden, 1960). These two 
terms can be obtained by reference to equation (2.13) as 
dg 
- 
dz/(1 + 0) 2.5 (2.14) 
and 
d 'g ' exp(Iln(1 + 0))0.5} [2.15] 
Using dg and 6g it is possible to calculate any of the 
classical average particle diameters (Hatch and Choate, 1929; Hatch, 
1933). For example, the number average diameter, dn, is given by 
do 
- exp(ln dg + 0.5 1n2 6g) (2.16) 
Calculation of do is particularly important since this can be 
compared directly with do obtained by electron microscopy. 
Although this theory is relatively simple and easy to apply, it 
is subject to several constraints; mainly that the PSD must be 
log-normal and unimodal, and for highly polydisperse samples the 
mean size should be small compared with the wavelength of the laser. 
Sample contamination with dust must be avoided since this would 
adversely increase values of dz and Q. 
This theory was tested by comparing PCS and SEM measurements of 
colloidal dispersions, as shown in table 2.1. In each case although 
the diameter calculated from SEM is less than the corresponding PCS- 
diameter, as observed by other workers (Munro and Randle, 1976), the 
values of do calculated from dz and Q, according to equation [2.16], 
are in good agreement with those obtained by SEM. Figure 2.4 gives a 
typical particle size histogram from scanning electron micrograghs 
of p(BCA) nanoparticles and shows the system to be log-normally 
distributed (r 
- 
0.9977 for the corresponding log-probability plot) 
and unimodal as required by the constraints to equation [2.13]. 
TABLE 2.1 Comparison of do calculated from dz and 0 values 
obtained by PCS with do obtained from electron microscopy (EM). 
Sample dz (nm) Q do from dz do determined 
and 0 (nm) by EM (nm) 
Nanoparticle 203 0.079 174 165 
Nanoparticle 160 0.103 131 122 
Nanoparticle 159 0.150 120 130 
Latex 180 0.037 168 166 
Latex 417 0.044 383 390 
Latex 469 0.033 440 450 
Polystyrene latex EM size was determined by the supplier. 
Nanoparticles composed of p(BCA). 
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Figure 2.5 compares the theoretical PSD'e calculated from PCS data 
and the log-probability plot of the histogram and shows a reasonable 
agreement between the two. Thus, while recognising the limitations 
to the use of this theory, it does provide a useful means of 
estimating the theoretical nanoparticle PSD and obtaining a range of 
average particle diameters. 
2.3.2 Influence of Physico-chemical Factors on Nanoparticle Size 
2.3.2.1 Influence of stirring rate and ultrasonication 
The variation of nanoparticle diameter and polydispersity index 
with stirring rate is shown in table 
increase approximately linearly with 
accompanied by a general increase in 
significant change in do with speed. 
diameter of the system remains const, 
distribution increases with stirring 
investigated, stirring rate does not 
size of the resulting nanoparticles. 
2.2. Although dz was found to 
stirring rate this was 
0, thereby resulting in no 
It appears that the mean 
ant but the width of the 
rate. Therefore, over the range 
significantly affect the mean 
As an alternative method for dispersing the monomer throughout 
the polymerisation medium, ultrasonication was investigated by 
employing either an ultrasonic bath or probe. The ultrasonic bath 
was found to be unsuitable due to incomplete dispersion of the 
monomer in the aqueous phase. The use of an ultrasonic probe 
resulted in formation of nanoparticles with a dz of 409nm and an 
unacceptably high polydispersity index of 0.22. Ultrasonication is 
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TABLE 2.2 Influence of stirring rate on the average particle 
diameter and polydisperaity index of p(BCA) nanoparticles. 
Stirrer speed dz (nm) p do (nm) 
(rpm) 
600 126 0.070 110 
750 131 0.087 111 
1000 136 0.099 113 
1500 137 0.071 119 
2000 142 0.140 109 
2500 148 0.121 118 
3000 161 0.149 122 
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therefore considered an unsuitable method for nanoparticle 
production. 
2.3.2.2. Influence of nonooer concentration 
The variation in particle diameter and polydispersity index for 
p(BCA) nanoparticles as a function of the initial monomer 
concentration is given in figure 2.6. Although it was possible to 
change the nanoparticle size by varying the initial monomer 
concentration, the pattern is complex and limited by the importance 
of a low polydispersity index and the maximum monomer concentration 
of 72 v/v for a free flowing suspension. At low monomer 
concentrations, below 1% v/v, 0 was found to be high, but decreased 
rapidly with increasing monomer concentration. Both dz and do show 
increases for monomer concentrations up to 1% v/v, a subsequent fall 
over the range of 1 to 2.5% v/v, and a final increase at higher 
concentrations. This complex pattern is unexpected. A monotonic 
increase in size with monomer concentration would have been expected 
from the results of other workers (Goodwin et al, 1978; Rembaum et 
al, 1979) who found the particle size of various latex systems to 
increase with monomer concentration as shown, for example, by 
equation [2.1). 
2.3.2.3. Influence of acidifying agent 
The results obtained with the various acids investigated are 
shown in table 2.3. Hydrochloric, sulphuric, nitric and citric acids 
were all found to be suitable agents for nanoparticle production 
Figure 2.6. The influence of monomer concentration 
on the particle size and polydispersity index of 
p(BCA) nanoparticles. 
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TABLE 2.3 Influence of acidifying agent at p1! 2.25 on the particle 
size and polydispersity index of p(BCA) nanoparticles. 
Acid dz (nm) Q do (nm) 
Hydrochloric 148 0.062 131 
Citric 131 0.066 115 
Sulphuric 176 0.048 160 
Nitric 158 0.081 135 
Acetic 811 0.201 562 
Ascorbic 
failed to yield discrete particles. 
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with little difference in the resultant nanoparticle diameter or 
polydispersity index. The phosphoric acid system, however, produced 
particles with a wide PSD as indicated by the high value of Q. 
Acetic acid is not suitable since high concentrations were required 
to give the correct pH for polymerisation and the resultant 
nanoparticles had a high polydispersity index. The large average 
particle size obtained with acetic acid is probably due to swelling 
of the nanoparticles caused by incorporation of the acid within the 
polymer matrix of the particles. Attempts at nanoparticle formation 
employing ascorbic acid as the acidifying agent failed to yield any 
discrete particles. No advantage, therefore, is to be gained by 
using an acid other than dilute hydrochloric acid as the acidifying 
agent. 
2.3.2.4. Influence of pH 
The effects of pH on dz, dn, and 0 are given in figure 2.7. The 
particle size shows a minimum at pH 2 for dz and, due to the 
changing value of Q, a slightly lower minimum for dn. The 
polydispersity index falls with increasing pH and reaches a plateau 
at pH 2.5. At pH greater than 3.5 polymerisation was too rapid to 
allow discrete particle formation and at pH less than 1 too slow to 
be applicable in practice; at pH 0.5 the polymerisation process was 
incomplete after 2 days at room temperature. 
These results may be explained by reference to the 
polymerisation mechanism outlined in scheme 2.1. Polymerisation 
occurs via an anionic mechanism (Coover and McIntire, 1979) 
involving initial nucleophilic attack on the t3-carbon of BCA. The 
Figure 2.7. The influence of polymerisation pH on 
particle diameter and polydispersity index for 
p(BCA) nanoparticles. 
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resulting carbanion reacts with further monomer to give oligomeric 
chains which nucleate leading to the formation of nanoparticles. The 
major initiating nucleophile under aqueous conditions is 0}i , the 
concentration of which will vary with pH. At high pH and hence high 
hydroxyl ion concentration, the polymerisation rate is too rapid to 
allow particle formation and leads to the direct polymerisation of 
monomer droplets producing an amorphous polymer mass. As p1i 
decreases the decrease in reaction rate allows discrete nanoparticle 
formation to occur. If the pH is too low, however, the 
polymerisation period is greatly extended and nanoparticles in this 
system become swollen with monomer. Coagulation of these semi-fluid 
particles is not reversible and produces a polydisperse system of 
larger particles. Hence, a minimum size is observed in the pH 
profile when polymerisation is slow enough to give discrete 
nanoparticles but not too slow to allow excessive particle 
coagulation. 
Control of nanoparticle size by varying the polymerisation pH 
may be achieved to a small degree within the range pH 2 to 3.5. The 
use of pH values below 2 is precluded by slow rates of reaction and 
the formation of systems with a broad particle size distribution. 
2.3.2.5. Influence of temperature 
Although altering the reaction temperature would be expected to 
change the rate of polymerisation its effect is obviously not as 
critical as the influence of p11 on reaction rate and consequent 
particle size, as shown by the results in table 2.4. The slight 
increase in dz and 0 with temperature is probably due to an increase 
TABLE 2.4 Influence of polymerisation temperature on the particle 
size and polydispersity index of p(BCA) nanoparticles. 
Temperature (°C) dz (nm) Q do (nm) 
4 152 0.062 135 
20 148 0.062 131 
35 156 0.070 136 
50 157 0.072 137 
65 163 0.073 142 
80 171 0.097 142 
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in particle coagulation caused by the rise in kinetic energy of the 
system producing a broader particle size distribution; dn, however, 
remains fairly constant indicating that the mean particle size is 
unaffected. 
Temperature, therefore, does not constitute a suitable variable 
for the control of nanoparticle size and there is no advantage to be 
gained by working at other than ambient temperature. 
2.3.2.6. Influence of added electrolytes 
Table 2.5 shows the addition of sodium chloride or calcium 
chloride to the polymerisation medium, over the concentration range 
0.01 to 0.25 mole dm 
3, had no effect on nanoparticle size or PSD. 
These results imply that the surface charge of p(BCA) nanoparticles 
is not important with respect to particle size or maintenance of 
colloidal stability and indicates that the system is sterically 
stabilised. If particle surface charge was responsible for 
maintaining stability, the final nanoparticle size would be highly 
dependent upon the ionic strength of the polymerisation medium as 
found by Goodwin et al (1978) (see section 2.1). 
2.3.3. Influence of Stabilisers on Nanoparticle Size 
2.3.3.1 Influence of concentration and molecular weight of dextran 
Dextrans are a homologous series of polysaccharides composed of 
D-glucopyranose units with predominantly o4-(1-6) linkages. They are 
available in a wide range of molecular weights, produced by the 
controlled degradation of high molecular weight dextrans to yield 
TABLE 2.5 Influence of added electrolyte concentration and valency 
on the particle size and polydispersity index of p(BCA) 
nanoparticles. 
Concentration Sodium chloride Calcium chloride 
(mole dm 3) dz (nm) 0 do (nm) dz (nm) 0 do (nm) 
0.01 147 0.069 129 146 0.072 127 
0.02 152 0.072 132 151 0.052 136 
0.05 149 0.062 132 145 0.054 131 
0.10 144 0.058 129 144 0.061 128 
0.15 150 0.064 133 147 0.073 128 
0.25 146 0.068 128 145 0.057 130 
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smaller dextrans with essentially the same structure but of 
considerably lower molecular weight. 
The influence of concentration and molecular weight of dextran 
on nanoparticle size and polydispersity index is given in table 2.6. 
It was found that at concentrations less than 0.5% w/v an increase 
in dextran concentration resulted in a marked decrease in particle 
size with all three molecular weights of dextran; the lowest 
(dextran 10) showing the largest variation with concentration. This 
concentration effect, however, was much less pronounced over the 
concentration range 0.5 to 2.5% w/v. The variation in polydispersity 
index showed a general increase with stabiliser concentration for 
dextrans 40 and 70 concentration but a decrease with dextran 10. 
Similar findings concerning the variation of particle size with 
stabiliser concentration have been reported for the formation of 
poly (methyl methacrylate) particles in the presence of graft 
copolymer dispersants (Walbridge, 1975). 
A simple linear relationship between nanoparticle size and 
dextran concentration can be found for the concentration range 
investigated according to 
m 
log c 
(2.71 
where D is the particle diameter (dz or dn), c is the corresponding 
dextran concentration, and m and i are constants specific to the 
dextran molecular weight and average diameter utilised. This 
relationship is shown graphically in figure 2.8. 
The effect of dextran concentration on nanoparticle size can be 
explained by reference to the theory of particle formation in 
TABLE 2.6 Variation of dz, do and 0 with dextran concentration and 
molecular weight. 
Conc. Dextran 70 Dextran 40 Dextran 10 
(X w/v) dz 0 do dz Q do dz Q do 
(nm) (nm) (nm) (nm) (nm) (nm) 
0.05 212 0.049 193 243 0.027 230 770 0.147 585 
0.10 181 0.060 161 
0.25 156 0.051 141 
0.50 148 0.062 131 
1.00 138 0.056 123 
196 0.036 182 
158 0.039 146 
145 0.050 132 
134 0.086 114 
575 0.108 469 
247 0.079 212 
168 0.056 150 
139 0.051 126 
2.50 126 0.094 105 131 0.116 105 109 0.058 97 
Figure 2.8. Graphical representation of the linear 
relationship between dz and the reciprocal log 
concentration of dextran as defined by equation 2.17 
over the concentration range 0.05 to 2.50% w/v. 
Linear regression analysis of the data gives 
the following results where m is the slope of the 
line, i is the intercept an dr is the correlation 
coefficient. 
(0) dextran 10 (m = 707, i = -213, r=0.9845) 
(0) dextran 40 (m = 115,1 = 79, r=0.9979) 
(o) dextran 70 (m = 82, i= 96, r=0.9957) 
Similar results can be obtained for dn. 
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dispersion polymerisation (Barrett and Thomas, 1975). Nanoparticle 
formation is believed to occur via a nucleation mechanism in an 
analogous manner to other polymer colloids (Fitch, 1971 and 1973). 
Initiation of 
-polymerisation in the aqueous phase results in the 
formation of oligomeric chains which grow in solution until they 
reach a critical molecular weight which is dependent upon the 
solubility of the oligomer in the reaction medium. The chains then 
either collapse upon themselves producing particle nuclei 
(self-nucleation) or several growing oligomeric chains may associate 
with each other to form an aggregate which, above a certain critical 
size, precipitates forming a new stable nucleus (aggregative 
nucleation). In either case the nuclei can grow by capture of 
further oligomers from solution or by absorption of monomer which 
subsequently polymerises within the particle matrix. The stability 
of the resultant colloidal system is achieved by uptake of polymeric 
stabilisers, i. e. dextrans, from solution. 
The initial high number of particle nuclei and their small 
particle size results in a very large total surface area. At low 
dextran concentrations the amount of stabiliser is insufficient to 
cover the available surface effectively, resulting in an unstable 
colloidal system. These small particles therefore agglomerate until 
the total particle surface area has decreased to a point such that 
the amount of dextran available is sufficient to produce a stable 
suspension. Normally this process leads to a grossly flocculated 
system with a wide particle size distribution. However, as seen in 
this study (table 2.6), controlled agglomeration and the growth of a 
narrowly disperse particle population is possible. This effect is 
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indicative of a process whereby the stabilising polymer is 
irreversibly attached to the particle surface, as has been reported 
(Barrett and Thomas, 1975) for poly (methyl methacrylate) particles 
produced using a dispersant which anchors irreversibly to the 
particle surface through copolymerisable groups. 
At increased dextran concentrations it is possible to stabilise 
effectively a larger total particle surface area, resulting in the 
formation of stable nanoparticles of a lower size. Above a certain 
dextran concentration, however, nanoparticle size was found to 
remain fairly constant in each system. This constancy indicates the 
presence of an additional limiting mechanism at high dextran 
concentrations, which determines a final particle size. 
The differences in particle size between nanoparticle systems 
prepared with the same concentration of the three molecular weights 
of dextran over the range 0.05 to 0.5% w/v, as seen in table 2.6, 
can be explained by considering the theoretical aspects of steric 
stabilisation. Although a full treatment of this complex subject is 
not presented here, comprehensive reviews are available (Vincent, 
1974; Sato and Ruch, 1980). 
The total interactive energy, Vt, produced by the approach of 
two polymer coated particles is given by 
Vt 
- 
Va + VrE + VrS [2.18) 
where V. is the van der Waals' attractive potential energy, VrE is 
the electrical repulsive energy and VrS is the steric repulsive 
energy of the polymer overlap interaction. If Vt is negative upon 
close approach of the two particles, flocculation or coagulation 
will occur, whereas if it is positive, colloidal stability will be 
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maintained. In the case of particles with low surface charge, i. e. 
small VrE, the sign of Vt will be determined largely by the 
magnitude of VrS in a sterically stabilised system. Vrs, which is 
equivalent to AG 
a, 
the Gibbs free energy change of the steric 
interaction, can be expressed in terms of the enthalpy change, A1189 
and entropy change, As 6, of the 
interaction by 
AG 
- 
AH 
-T AS 
s88 
[2.191 
Initial attempts at calculating the repulsive potential energy 
in steric stabilisation by Mackor (1951) considered only the 
entropic term, AS. By a statistical method analysing the approach 
of two flat plates, one bearing an adsorbed molecule of length 1, 
the repulsive energy, AG 
e, 
due to the entropy change at a given 
distance, H, was found to be dependent on 1 and the number of 
adsorbed molecules in a unit surface area at the interface. This 
derived relationship was used by Sato (1971) to develop an equation 
describing the stability of iron oxide dispersions in cyclohexane 
stabilised by fatty polyamides. This was given as 
AG (6 
- 
d) 2 (2r +S+ d) (2.20) 
S 
where GOO is the surface coverage when H -w 
, 
Ns is the number of 
segments extending to the outside of the adsorbed layer, k is 
Boltzmanns' constant, r is the particle radius, 
S is the adsorbed 
layer thickness and d is the distance from the particle surface to 
the adsorbed film contact point. Mackor's model has been extended by 
several other workers such as Clayfield and Lumb (1966), Bagchi and 
Vold (1970), and Meier (1967). 
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The enthalpy contribution to A(; 13 was first considered by 
Fischer (1958) who proposed the excess chemical potential produced 
by the overlap of adsorbed polymer layers would give rise to a 
repulsive osmotic force given as AG 
m. 
the free energy of mixing 
repulsion, as 
AG 
- 
4'IIRTBC2 ic-H m3 2j 
where R is the gas constant, C is 
concentration and B is the second 
in solution. Similar relationship 
ý3r + 26' +Nf2.211 
2 
the adsorbed layer polymer 
virial coefficient of the polymer 
s were obtained by Ottewill and 
Walker (1968) and Napper (1968). The total interactive repulsive 
energy due to steric stabilisation, AG 6, may 
be estimated by 
summing the contributions of AG 
e 
and I Gm, although this is far 
from satisfactory considering the different models upon which each 
theory is based and single modelled calculations are to be preferred 
(Vincent, 1974). However, by reference to equations such as [2.20] 
and [2.21) it can be seen that both the osmotic and entropic 
repulsion models predict that an increase in the adsorption layer 
thickness, 6, should enhance the stability of a dispersion. Since 
is dependent upon the molecular weight of the polymer (Sato and 
Ruch, 1980), stability should increase with increasing molecular 
weight which is reflected in a decrease in particle size as seen in 
table 2.6. 
The contribution of AH 8 and 
AS 
6 to the total stabilising 
effect may be determined by reference to the work of Napper and 
Netschey (1971) who studied the temperature dependence of AG 6 which 
is given by 
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a(Ec8) /aT--As8 12.221 
From their results it is possible to classify sterically 
stabilised dispersions close to their critical flocculation 
temperature as summarised in table 2.7 (Napper, 1977). Heating 
(autoclaving) p(BCA) nanoparticle supsensions to 121°C at pH 2.2 did 
not induce flocculation but resulted in a small increase in 
nanoparticle diameter from 143 to 202nm with no significant change 
in the polydispersity index. This increase in size is probably due 
to partial hydrolysis of the polymer resulting in swelling of the 
nanoparticle matrix. Cooling also failed to induce flocculation 
unless the supensions were frozen and then thawed, whereupon a 
flocculated system was produced. This flocculation was not 
reversible, however, and therefore does not comply with the 
restraints imposed by equilibrium thermodynamics necessary for the 
application of this theory (Napper and Netschey, 1971). High dextran 
concentrations (> 2.5%w/v) were also found to have a protective 
effect and these suspensions could not be flocculated even after 
several freeze/thaw cycles. Due to this complex behaviour it is not 
possible, therefore, to determine whether the nanoparticle 
suspensions are solely entropically stabilised or whether a combined 
enthalpic-entropic mechanism applies. 
The theory of steric stabilisation also predicts that the 
steric repulsive energy governing particle size, AG 6, 
is dependent 
upon the concentration of stabilising polymer in the adsorbed layer, 
as indicated in equations [2.20] and [2.21) (Sato and Ruch, 1980). 
This concentration is determined by the bulk polymer concentration, 
as shown by the results in table 2.6, and the affinity of the 
TABLE 2.7 Thermodynamic requirements and thermal methods of 
flocculating sterically stabilised dispersions (Napper and Netachey, 
1971). 
AHs sign 1 S5 sign IT A SsI/I L1 Hs) Stabilisation Flocculation 
type method 
++<1 Enthalpic Neat 
+00 Enthalpic Not possible 
>1 Entropic Cool 
0-m Entropic Not possible 
+- >< 1 Enthalpic- Not possible 
entropic 
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stabiliser for the particle surface. Amphiphatic block or graft 
copolymers are found to be the best stabilisers in dispersion 
polymerisation (Walbridge, 1975) since these contain anchoring 
moieties with a high particle surface affinity and stabilising 
moieties soluble in the dispersion medium. These 'dual' properties 
ensure the stabiliser remains firmly attached to the particle 
surface while maintaining an adsorbed layer thickness of sufficient 
magnitude to produce a strong steric repulsive interaction. Dextran, 
however, being a totally hydrophilic polymer does not fit into this 
category and would be expected to have a poor affinity for the 
nanoparticle surface and therefore be a poor stabiliser. Although 
stability by free polymer in solution could be imparted by depletion 
stabilisation, this is only observed at polymer concentrations 
higher than those required to cause the onset of depletion 
flocculation (Napper, 1982) and certainly greater than those 
employed here. Also, nanoparticles may be redispersed readily by 
sonication after removal of the free dextran in solution. These 
'cleaned' nanoparticles were found to be partly composed of dextran 
which could not be removed despite repeated washing. Dextran, 
therefore, appears to copolymerise with the monomer, forming a 
covalently linked surface layer which explains their ability to act 
as efficient stabilisers despite having a low surface affinity. 
These findings are discussed in more detail in chapter 3. 
2.3.3.2. Influence of 13-cyclodextrin 
(3 
-cyclodextrin is a cyclic oligosaccharide, with a molecular 
weight of 1135, consisting of 7 glucopyranose units joined by 
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of-1,4-glycoside linkages forming a torus-like ring (Szejtli, 1982). 
As with dextran, /3 
-cyclodextrin should, in theory, be a poor steric 
stabiliser due to low affinity for the nanoparticle surface. Due to 
the similarities in structure between these two molecules, however, 
copolymerisation of f3 
-cyclodextrin with the monomer is theoretically 
possible. The low molecular weight and cyclic nature of the molecule 
would be expected to produce a relatively thin stabilising layer of 
low repulsive energy, as discussed above, leading to the formation 
of relatively large particles. 
Microscopic analysis of p(BCA) particles prepared using this 
stabiliser revealed the system to consist of individual spherical 
particles approximately 3ym in diameter and loose aggregates of up 
to 30 particles. The aggregates were easily dispersed by addition of 
0.2% w/v poloxamer 188 followed by sonication for 30 minutes. When 
examined by Coulter counting the system was found to have a 
log-normal PSD as shown in figure 2.9. The concentration range 
studied produced only a slight reduction in particle size and no 
significant change in size distribution (table 2.8). This trend is 
similar to that seen for the dextrans over the same range of 
concentrations. 
2.3.3.3. Influence of type and concentration of poloxamer 
The poloxamer non-ionic surfactants are a series of closely 
related polyalkylene oxide block copolymers classified as poly- 
oxypropylene (POP) polyoxyethylene (POE) condensates of the general 
formula 
16 
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Figure 2.9. Typical particle size distribution 
of p(BCA) particles stabilised by ß-cyclodextrin 
(0.75% w/v),. after addition of 0.2% w/v poloxamer 
188 and sonication. 
48 12 16 20 
Particle diameter (pm) determined 
by Coulter counting 
TABLE 2.8 Variation of particle size with f3 -cyclodextrin 
concentration, as determined by Coulter counting. 
Conc. (% w/v) Number average Weight average Polydispersity 
diameter (pm) diameter (pm) ratio * 
0.75 3.45 4.52 1.31 
1.00 3.00 3.58 1.19 
1.50 2.68 3.22 1.20 
1.75 2.70 3.51 1.30 
* ratio of the weight / number average diameter. 
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HO(CH2CH20)a(CHCH20)b(Cii2CH20)cl 
I 
CH3 
where b is at least 15 and a and c are statistically equal. 
The first two digits of the poloxamer number represent, when 
multiplied by 100, the approximate molecular weight of the POP 
moiety; the third digit represents, when multiplied by 10, the 
percentage by weight of the POE portion. 
The influence of poloxamer 188 concentration on nanoparticle 
size and polydispersity index is shown in figure 2.10. The 
polydispersity index is seen to increase with poloxamer 188 
concentration as expected, since the greater rate of poloxamer 
adsorption at higher concentrations leads to a more continuous and 
extended nucleation stage producing a wider PSD (Walbridge, 1975). 
The particle size shows a minimum at a concentration of 1% w/v for 
both dztand dn. The initial decrease in size with increasing 
stabiliser concentration is expected whereas the subsequent increase 
is indicative of a weakly anchored dispersant. This is unlikely for 
poloxamer 188, however, since this surfactant adsorbs strongly to 
the particle surface and is not totally desorbed even after 
extensive dialysis (Ilium, 1984). The increase in average particle 
size with poloxamer 188 concentration may be partly due to a 
measurement artifact caused by the wide particle distribution. PCS 
measurements can be strongly affected by the presence of large 
particles in the sample resulting in the measured particle diameter 
being greater than the true value (Munro and Randle, 1976). This 
effect can be minimised by calculating do from dz and Q values. 
F 
Figure 2.10. Variation of nanoparticle diameter and 
polydispersity index with poloxamer 188 concentration. 
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Consequently, the increase in do is not so great compared with dz 
over the same poloxamer concentration range. 
The influence of the type of poloxamer on nanoparticle size was 
investigated at a concentration of 0.5% w/v as shown in table 2.9. 
The approximate molecular weights of the POP and POE segments in 
each molecule together with the hydrophile-lipophile balance (NLB) 
numbers are also given. When considering the effect of the size of 
the POE groups on nanoparticle diameter, it can be seen that the 
particle size generally decreases with an increase in the average 
molecular weight of the POE segment. This observation may be further 
explained by comparing the results for nanoparticles produced in the 
presence of poloxamers with POP segments of the same molecular 
weight. Poloxamers 237 and 238 have anchoring POP groups of equal 
molecular weight but 238 has larger POE stabilising chains which 
would be expected to impart greater steric stability and so lead to 
smaller nanoparticles, as observed. A similar effect is seen for 
poloxamers 184 and 188. Rationalisation of the particle size results 
in terms of POP molecular weight is much more complex due to the 
size dependent contribution of the water soluble POE moiety to the 
adsorption process and final particle size. Thus, the HLB value is 
of little help in defining particle size effects unless the size of 
the stabilising group remains constant within a given series of 
surfactants. Nevertheless, it is clear that by employing a suitable 
poloxamer at an appropriate concentration it is possible to obtain 
nanoparticles with a controlled average diameter, and low 
polydispersity index, in the range 70 to 2S0nm. 
TABLE 2.9 Variation of p(BCA) nanoparticle size and polydisperaity 
index with poloxamer type at a concentration of 0.5% w/v. 
Average molecular weight 
of each molecular block 
Poloxamer HLB POE POP dz (nm) 0 do (nm) 
338 27 11264 3132 73 0.074 63 
238 28 8536 2262 71 0.085 61 
237 24 5456 2262 118 0.043 108 
188 29 6600 1740 160 0.103 132 
184 15 1144 1740 254 0.066 224 
Also given are the corresponding poloxamer HLB numbers and average 
molecular weights of the POE and POP segments in each molecule 
(manufacturers data). 
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2.3.3.4. Influence of polysorbate type and concentration 
The first report of nanoparticle formation (Couvreur et al, 
1979a) described the use of polysorbate 20 as the stabilising agent 
although, somewhat surprisingly, a variation in surfactant 
concentration was stated to have no effect on particle size. In 
contrast, the results in figure 2.11 show a decrease in nanoparticle 
diameter as polysorbate 20 concentration was increased over the range 
0.3 to 1.0% w/v, although the polydispersity index shows a slight 
decrease contrary to theory (Walbridge, 1975). 
The influence of different polysorbate surfactants on 
nanoparticle size at a fixed concentration of 0.5% w/v was also 
investigated. The affinity of these surfactants for the particle 
surface would be expected to increase in the order polysorbate 
20 < 40 < 60 in relation to the molecular weight increase of the 
hydrophobic anchoring groups. The molecular weight of the water 
soluble (stabilising) moieties in this series remains constant and 
thus a decrease in nanoparticle size should occur as the IBLB number 
decreases as seen in table 2.10. The polydispersity index also follows 
the expected trend of increasing as the affinity of the surfactant for 
the particle surface increases. 
These results show that by using suitable non-ionic surfactants 
at the appropriate concentration it is possible to produce 
nanoparticles of low average size. Other surfactants may also be used, 
such as Brij 96, which at a concentration of 0.5% w/v yields p(BCA) 
nanoparticles with dz - 28nm and Q-0.248. When compared with the 
dextran systems, however, the possible disadvantages of high 
polydispersity values and higher toxicity for these surfactants may 
outweigh any advantages gained in reducing nanoparticle size. 
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TABLE 2.10 Variation of p(BCA) nanoparticle diameter and 
polydispersity index with polysorbate type at a concentration of 
0.5% w/v. 
Polysorbate HLB dz (nm) Q do (nm) 
60 14.9 52 0.169 38 
40 15.6 62 0.154 46 
20 16.7 77 0.150 58 
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CHAPTER THREE: 
NANOPARTICLE COMPOSITION 
3.1. INTRODUCTION 
The need to control the particle size of p(BCA) nanoparticles 
for use in vivo requires their formation under a range of 
polymerisation conditions as described in the previous chapter. Such 
variation in the reaction medium may lead to the formation of 
nanoparticles composed of differing molecular weights, which could 
affect nanoparticle degradation, drug release rates and 
biodistribution of the payload (see sections 1.7.3 and 1.7.5). In 
addition, it would appear that certain polyhydroxyl stabilisers, 
such as dextrans, may copolymerise with the monomer and be 
incorporated into the nanoparticle matrix (section 2.3.3.1). 
The composition of p(BCA) nanoparticles was determined, 
therefore, by examining the molecular weights and molecular weight 
distributions of the cyanoacrylate polymer produced under a series 
of different polymerisation conditions. The incorporation of dextran 
70 into the nanoparticle matrix was also investigated. The data are 
relevant not only to the possible in vivo behaviour of 
nanoparticles, but also the elucidation of the mechanism of 
nanoparticle formation. The systems investigated are those for which 
the greatest variation in particle size was obtained in chapter 2. 
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3.2. EXPERIMENTAL METHODS AND MATERIALS 
3.2.1. Nanoparticle Preparation and Isolation 
Nanoparticles were prepared as described in chapter 2, except 
the preparative scale was increased from 25 to S0ml to provide 
sufficient polymer for extraction. The systems investigated were the 
effects of dextran concentration and molecular weight, polymer- 
isation pH, monomer concentration, poloxamer 188 concentration, and 
polysorbate 20 concentration. 
The nanoparticles were isolated by centrifugation (MSE High 
Speed 25; 20000 rpm for 2 hours) and then repeatedly washed with 
distilled water and centrifuged until no more dextran or surfactant 
could be removed. The samples were then freeze-dried. 
Free dextran in the washings was detected according to the 
method of Corrigan and Stanley (1981). This involved treating 2ml of 
the washings with 4ml of a 0.1% w/v anthrone (Sigma) solution in 
concentrated sulphuric acid. This latter solution was from 4 hours 
to 9 days old. After 15 minutes the sample was cooled to room 
temperature and the absorbance read at 625nm against a suitable 
blank. This method had a sensitivity of approximately 5x10-4X w/v. 
Free surfactants were detected according to the method of 
Baleux (1972). This involved adding 0.1ml of an iodide/iodine 
solution (1g of iodine (resublimed, BDII) and 2g of potassium iodide 
in 100ml of distilled water, not more than 8 days old) to 4m1 of the 
washings and, after 5 minutes, measuring the absorbance at 500nm 
against a suitable blank. This method had a sensitivity of 
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approximately 5x10-5X w/v. Abaorbancea were determined using an LKB 
Ultraspec 4050 (LKB Biochrom 
'UK). 
3.2.2. Polymer Extraction 
Each sample was extracted three times with tetrahydrofuran 
(THF) (Analar, BDH) and any insoluble material removed by low speed 
centrifugation (3000 rpm). The combined THE fractions were 
evaporated under reduced pressure and the resulting oil extracted 
with chloroform (Analar, BDH). This solution was washed three times 
with distilled water and then evaporated under reduced pressure to 
yield an off-white foam. 
The THE insoluble material from the dextran 70 samples was 
isolated and repeatedly washed and centrifuged with TIIF until no 
further cyanoacrylate polymer was removed (as indicated by the 
constancy of the infrared carbonyl stretch of the solid). 
3.2.3. Molecular Weight Analysis 
Although some dextran 70 samples were examined by nuclear 
magnetic resonance (NMR) the majority of the samples were analysed 
by gel permeation chromatography (GPC). This work was performed by 
Dr. S. Holding at the Rubber and Plastics Research Association, 
Shawbury, UK. 
3.2.3.1. Nuclear magnetic resonance 
Approximately 50mg of the polymer sample was dissolved in lml 
of deuterated chloroform (Gold Label, Aldrich, UK) containing 
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tetramethylsilane (NMR grade, Aldrich) as a reference. Spectra were 
recorded using a 90 MHz Varian EM390 spectrometer (Varian 
Associates, USA). The spectra were integrated a total of 5 times and 
the average integral value determined for each signal. 
3.2.3.2. Gel permeation chromatography 
The polymer samples were dissolved in TIIF and analysed using a 
polystyrene calibrated GPC system with THE as the eluant. This 
system consisted of two Du Pont 870 pumps, a Du Pont 834 auto- 
sampler, two Polymer Laboratories columns (1 x 500A and 1x 100A 
columns, 60cm long, filled with 10pm packing material), a Du Pont 
ultraviolet detector, and a Knauer refractive index detector. The 
solvent flow rate was 1.0 ml/minute and an internal marker (toluene) 
was added to allow a flow-rate correction to be made. Data from the 
refractive index detector were collected and analysed using a 
Trivector Scientific, Trojan (level 1) data handling system. Results 
are quoted as the polystyrene equivalent molecular weights for the 
peak molecular weight (Mp) number average molecular weight (Rn) and 
the weight average molecular weight (Mw). The results obtained for 
the high molecular weight polymers (> 20000) are only approximate 
since these values are at the far end of the calibration range for 
the columns. For this reason Mn and 11w values are only quoted for 
the low molecular weight polymers. 
A certain degree of column conditioning was observed for these 
samples so that the first set of data obtained for the effects of 
dextran concentration and molecular weight differ slightly from 
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subsequent results, although data within each set of results may be 
compared directly. 
3.2.4. Infrared Spectroscopy 
Infrared (IR) spectra were recorded on a Perkin-Elmer 257 
grating spectrophotometer (Perkin-Elmer, UK) and the recording wave- 
length checked against a standard polystyrene film. Samples were 
prepared by forming potassium bromide disks containing 2mg of 
polymer. 
3.3. RESULTS AND DISCUSSION 
3.3.1. Dextran Incorporation Into Nanoparticles 
Theoretically, covalent linking of dextran to the cyanoacrylate 
polymer is possible according to the polymerisation mechanism given 
in scheme 2.1. Due to the ease of polarisation of the double bond of 
the monomer caused by the highly electronegative nitrile and 
alkoxycarbonyl groups, polymerisation can be initiated by weak bases 
such as water and alcohol. According to this mechanism the basic 
initiating species is present in the final polymer as an end group 
(Leonard et al, 1966). Normally, under aqueous conditions, OH is 
the attacking nucleophile resulting in a hydroxyl-terminated polymer 
as shown by the IR spectrum of p(BCA) produced under aqueous 
conditions (figure 3.1a). However, when nanoparticles were formed in 
the presence of dextran 70 and the cyanoacrylate polymer removed by 
dissolution in THF, a derivatised dextran molecule was isolated. 
This compound possessed a reduced IR inter- and intra-molecular 
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hydrogen-bonded 011 stretch compared with dextran and a carbonyl 
stretch corresponding to that of the cyanoacrylate polymer (figures 
3.1b and 3.1c). Dextran appears, therefore, to act as an initiator 
for polymerisation and a possible mechanism for this reaction in 
given in scheme 3.1. 
Each dextran molecule could, therefore, contain several 
cyanoacrylate polymer moieties covalently linked via any of the 
available dextran hydroxyl groups. Anchoring of the cyanoacrylate 
groups within the nanoparticle matrix would result in an 
irreversible attachment between the dextran and the nanoparticle, 
possibly by multipoint linkages as depicted in figure 3.2. Although 
most of the dextran would be expected to reside at the particle 
surface, some of the stabiliser could be incorporated into the 
nanoparticle core, producing particles analogous to the 
biodegradable microspheres of polyacryldextran developed by Edman et 
al (1980). 
The degree of dextran incorporation into nanoparticles was 
found to increase with the concentration of dextran added to the 
polymerisation medium as shown in table 3.1. Thus, at a concen- 
tration of 2.5% w/v dextran 70 approximately 20% by weight of the 
nanoparticles are composed of the covalently linked derivatised 
dextran. 
In considering the ability of hydrophilic polymeric alcohols to 
stabilise nanoparticles, the molar fraction of hydroxyl groups 
appears to be important. Dextran and /3-cyclodextrin have a high 
hydroxyl content and act as efficient stabilisers, whereas PEG's 
possess far fewer hydroxyl groups and are ineffective stabilisers in 
Figure 3.1. Infrared Spectra. 
(a) Poly (butyl 2-cyanoacrylate) produced under 
aqueous conditions. A- OH stretch, B =ester 
carbonyl strecth. 
(b) Dextran 70. A =broad OH stretch due to inter- 
and intramolecular hydrogen bonding. 
(c) Derivatised dextran isolated from p(BCA) 
nanoparticles produced in the presence of 
0.5% dextran 70. A= reduced inter- and intra- 
molecular hydrogen bonded OHi strecth, B= ester 
carbonyl stretch corresponding to that of (a). 
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TABLE 3.1 Variation in the amount of derivatised dextran 70 
incorporated into p(BCA) nanoparticles as a function of dextran 70 
concentration. Monomer concentration was 1% v/v and reaction p11 2.25 
Dextran 70 concentration Z incorporation* 
(% w/v) 
0.05 1.0 
0.10 1.8 
0.25 5.4 
0.50 8.7 
1.00 16.0 
2.50 20.5 
results given as the percentage of the total nanoparticle weight 
composed of derivatised dextran 70. 
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nanoparticle formation. Copolymerisation of PEG's with the monomer, 
therefore, occurs at a much lower frequency compared with the 
polysaccharides, resulting in a level of incorporation that is too 
low to impart effective steric stability as shown by the results in 
chapter 2. 
3.3.2. Molecular Weight Analysis by Nuclear Magnetic Resonance 
It is possible to determine an absolute number average 
molecular weight for p(BCA) from the NMR spectrum by comparing the 
ratio of the signal integrals of the repeating butyl ester protons, 
or the backbone methylene protons, with the terminal methylene and 
methine protons. NMR has also been used to study the thermal 
degradation of p(ACA) (Rooney, 1981). 
The NMR spectrum of p(BCA) extracted from nanoparticles 
produced in the presence of 0.5% w/v dextran 70 may be related to 
its chemical structure as follows 
CN CN 
f1e19 HO - CH2 C CH2 -C -H 
dcbaI 
CO2CH2CH2CH2CH3 Co2Bu 
n 
Designation S Signal Number of Integral 
multiplicity protons 
a 1.0 triplet 3H 66 
b, c 1.25-2.0 multiplet 4H 94 
e 2.62 broad singlet 2H 40 
d, f, g 3.8-4.55 multiplet 5H 52 
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Summation of the integrals for the 7 protons of a, b, and c 
gives a value of 160, corresponding to 22.9 for each proton of the 
ester group. The integral value for the d, f, and g protons comprises 
45.8 due to the d protons (2 x 22.9) and, therefore, 6.2 due to the 
f and g protons. This gives an integral value of 2.1 for the 
terminal methine proton. The ratio of the terminal methine proton to 
the repeating protons of the ester group is 10.9 (22.9 / 2.1) so 
that in the general formula above, n-9.9 which gives an 
approximate average molecular weight of 1685. Alternatively, by 
comparing the ratio of the terminal methine with the backbone 
methylene protons, n is found to be 9.5, giving a molecular weight 
of 1625. These values were found to be in reasonable agreement with 
the results obtained by GPC analysis given below. 
Although this technique gives an absolute value for the number 
average molecular weight, it is very insensitive to the presence of 
high molecular weight components and gives no indication of the 
molecular weight distribution. To determine this latter parameter 
GPC must be used. 
3.3.3. Molecular Weight Analysis by Gel Permeation Chromatography 
3.3.3.1. Molecular weights of dextran stabilised nanoparticles 
Dextran molecular weight and concentration had little effect on 
the resulting cyanoacrylate polymer molecular weight as shown in 
table 3.2, although a slight trend in increasing polymer molecular 
weight can be seen with increased stabiliser concentration. A 
typical molecular weight distribution for this type of system 
TABLE 3.2 Effect of dextran type and concentration on the 
molecular weight of p(BCA) produced at a pH of 2.25 and a monomer 
concentration of 1% v/v. 
Conc. Dextran 10 Dextran 40 Dextran 70 
(% w/v) Mp Mn iw Mp Hin Ffw Mp Fin Fiw 
0.05 900 730 970 1050 810 1380 980 700 1090 
0.10 990 880 1150 1020 820 1260 1050 790 1230 
0.25 1110 980 1360 1450 1000 1670 1250 950 1660 
0.50 1340 1180 1600 1020 730 1230 1080 950 1350 
1.00 1820 1430 2340 1340 980 1590 1050 780 1400 
2.50 1700 1190 1950 2180 1340 2460 1420 850 2890 
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(figure 3.3a) shows the presence of two distinct distributions which 
are referred to as distributions 1 (low Mp) and 2 (high Mp). The 
height ratio of the two peaks remained fairly constant. Dextrans 10 
and 70 gave an Mp value of 27000 and dextran 40 an Mp of 29600, with 
these values being unaffected by concentration. 
The bimodal molecular weight distribution obtained with these 
samples indicates the presence of two separate polymerisation 
reactions. The first is assumed to occur in the aqueous phase where 
initiation by hydroxyl ions leads to the formation of growing 
oligomeric chains according to the mechanism in scheme 2.1. 
Polymerisation is terminated rapidly, however, due to the high 
proton, H+, concentration at the low pH, so producing a low 
molecular weight polymer (distribution 1). Aggregation of these 
oligomers produces particle nuclei which grow by capture of further 
oligomers and by sorption of monomer which subsequently polymerises 
within the nanoparticles. In this environment polymerisation 
termination occurs at a much lower frequency, due to the reduced H+ 
concentration, and yields polymers of much higher molecular weight 
(distribution 2). The majority of the polymer, however, has a low 
molecular weight which implies that nanoparticle formation occurs 
via an aggregative mechanism as opposed to self-nucleation which 
would yield polymers of a much higher molecular weight (Barrett and 
Thomas, 1975). 
The results obtained for distribution 1 are similar to those 
found by Van Snick et al (1985) with dextran 40 stabilised systems, 
although these workers did not report the presence of a second high 
molecular weight distribution. Direct numerical comparison of 
Figure 3.3. Molecular weight distributions of the 
cyanoacrylate polymer extracted from p(ICA) 
nanoparticles prepared in the presence of various 
stabilisers. 
(a) 0.5% dextran 70 
(b) 0.5% poloxamer 188 
(c) 0.5% polysorbate 20 
The monomer concentration was 1.0% v/v and the 
polymerisation pit 2.25. 
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results between these two studies is not possible since Van Snick et 
al used polyethylene glycol standards. 
The variation of polymer molecular weight with polymerisation 
pH for a 0.5% w/v dextran 70 system is given in table 3.3 and shows 
the molecular weight values for both distributions to increase with 
increasing pH. These findings are similar to those of other workers 
(El-Egakey et al, 1983; Van Snick et al, 1985). The effect of 
polymerisation pH appears to be complex. Normally, as initiator 
concentration increases (in this case OH ) the resulting polymer 
molecular weight decreases, as seen with other polymerisation 
processes (Goodwin et al, 1973). In the present system, however, the 
pH would also be expected to affect the termination reaction by 
reference to scheme 2.1. This, together with the fact that the 
solvent generates the initiator, may explain the anomalous behaviour 
observed (El-Egakey et al, 1983). 
Increasing the monomer concentration in a 0.5% w/v dextran 70 
stabilised system produced an increase in molecular weight of both 
distributions 1 and 2 as expected (table 3.4). The increase in the 
peak height ratio of distribution 2 would indicate a higher degree 
of polymerisation within the nanoparticles as monomer concentration 
increases. Excess monomer, at the higher concentrations, partitions 
into the growing particles and polymerises whereas at low 
concentrations most of the monomer is consumed forming particle 
nuclei via the aggregative mechanism discussed previously. 
TABLE 3.3 Effect of polymerisation pH on the molecular weight of 
p(BCA). The system was stabilised with 0.5% w/v dextran 70 and the 
monomer concentration was 1% v/v. 
pH Distribution 1 Distribution 2 
Mp Mn Mw Mp 
1.0 1490 1410 1990 
1.5 1700 1610 1990 28000 
2.0 1490 1430 1910 27500 
2.5 1700 1720 2320 29000 
3.0 1820 1680 2300 30500 
3.5 1910 1820 2500 32400 
* no value obtained 
TABLE 3.4 Variation of p(BCA) molecular weight with monomer 
concentration. The polymerisation p11 was 2.25 and dextran 70 
at a concentration of 0.5% w/v used as the stabiliser. 
Monomer conc. Distribution 1 Distribution 2 Peak height 
(% v/v) Mp Mn Mw Mp ratio * 
0.5 1710 1630 2300 27600 0.08 
1.0 1710 1630 2310 27600 0.08 
1.5 1820 1760 2470 31500 0.21 
2.0 1880 1720 2530 32000 0.24 
2.5 1910 1590 2480 33000 0.32 
3.0 2080 1790 2810 32000 0.41 
5.0 1940 1840 2730 34000 0.53 
7.0 2190 2030 2960 33000 0.61 
* this is the peak height ratio of Mp2 / Mpl. 
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3.3.3.2. Molecular weights of poloxamer 188 stabilised 
nanoparticles 
A bimodal molecular weight distribution similar to the dextran 
systems was obtained when poloxamer 188 was used as the stabiliser, 
although each peak was centred at a higher molecular weight (figure 
3.3b). The effect of poloxamer concentration on molecular weight is 
given in table 3.5. The peak height of distribution 2 was seen to 
increase slightly with poloxamer 188 concentration. Similar findings 
have been reported by Couvreur et al (1984) and Van Snick et al 
(1985). 
The formation of polymers with higher molecular weights in 
these poloxamer systems, compared with dextran, may be due to the 
surfactant associating with the growing oligomeric chains and 
particle nuclei, producing a protective layer from the acid 
environment and so reducing the rate of polymerisation termination. 
If this explanation is correct, however, then the molecular weight 
would be expected to show a dependence on the poloxamer 
concentration, which was not seen. This may be due to the 
concentration range investigated being greater than a certain 
critical maximum poloxamer concentration, above which the addition 
of further surfactant to the system had no effect on the molecular 
weight of the polymer. Concentrations of poloxamer less than 
0.1% w/v were not investigated because discrete nanoparticle 
formation does not occur at these low poloxamer concentrations. 
TABLE 3.5 Effect of the concentration of poloxamer 188 on the 
molecular weight of p(BCA). The monomer concentration was 1X v/v and 
polymerisation pH 2.25. 
Conc. Distribution 1 Distribution 2 
(% w/v) Mp Mn Mw Mp 
0.10 3440 2780 4360 41400 
0.25 3940 3140 5030 35200 
0.50 4460 3500 5750 44400 
1.00 3670 3270 4930 36000 
2.50 
* data accidentally erased from floppy disc. 
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3.3.3.3. Molecular weights of polysorbate 20 stabilised 
nanoparticles 
The results obtained with polysorbate stabilised systems did 
not show the distinct high molecular weight distribution seen 
previously (figure 3.3c). These results indicate that sorption of 
monomer and secondary polymerisation within the nanoparticle matrix 
probably does not occur to any great extent. This may help to 
explain why nanoparticles with much smaller diameters of < 70nm are 
obtained with this surfactant compared with approximately 150nm for 
systems stabilised by dextran and poloxamer 188 at a concentration 
of 0.5% w/v. Although a single micellar polymerisation mechanism is 
proposed, a slight shoulder in the molecular weight distribution 
(figure 3.3c) may imply a dual polymerisation process. 
Variation in the concentration of polysorbate 20 had little 
effect on the molecular weight of the resulting polymer (table 3.6), 
probably for the same reasons discussed regarding poloxamer 188. 
These results are similar to those obtained elsewhere (El-Egakey et 
al, 1983). 
3.3.4. Possible Effects of Molecular Weight Differences on 
Nanoparticle Degradation 
Despite the fact that within each system the effects of the 
concentration of the stabiliser on molecular weight are not very 
pronounced, there are marked differences in the molecular weight 
distributions between nanoparticles produced with different 
stabilisers. According to Vezin and Florence (1980) the in vitro 
TABLE 3.6 Effect of the concentration of polysorbate 20 on the 
molecular weight of p(BCA). The monomer concentration was 1% v/v 
and polymerisation pH 2.25. 
Conc. (% w/v) Mp Mn Mw 
0.1 1980 2330 3400 
0.3 2160 2590 4070 
0.5 2280 2780 4340 
1.0 2160 2640 4200 
2.5 2160 2610 4190 
data included although the nanoparticle system was unsuitable due 
to gross flocculation. 
-85- 
degradation rates of p(ACA) appear to be approximately proportional 
to Rn-1 since degradation occurs at chain ends and travels along the 
polymer chain (scheme 3.2). Thus polymers with high fin, as produced 
in the systems stabilised by dextrans and poloxamer 188, would be 
expected to degrade slowly. However, apart from when high monomer 
concentrations were employed, the quantity of the high molecular 
weight component was small compared with the total amount of 
polymer. 
The situation is further complicated by an alternative 
degradation mechanism involving ester hydrolysis (see section 1.7.3) 
which yields, eventually, water soluble poly (2-cyanoacrylic acid) 
and an alkyl alcohol (scheme 3.2). Although there is no evidence to 
indicate that this mechanism is dependent on molecular weight, the 
presence of high molecular weight polymers would be expected to 
retard the dissolution of the nanoparticles due to the binding 
effect of large molecules penetrating throughout the nanoparticle 
matrix. It has been found that the absence of high molecular weight 
components leads to increased water solubility resulting in bulk, 
rather than surface, polymer degradation (Vezin and Florence, 1980). 
The finding that dextran stabilised nanoparticles may be 
composed of up to approximately 20% by weight derivatised dextran 
may have important implications concerning nanoparticle degradation. 
The presence of this hydrophilic polymer in the particles may create 
aqueous channels allowing water to penetrate the matrix to a greater 
extent and increase the rate of cyanoacrylate degradation. 
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CHAPTER FOUR 
CONTROL OF THE ELECTROPHORETIC MOBILITY OF NANOPARTICLES 
4.1. INTRODUCTION 
As already discussed (section 1.3.3), the electrophoretic 
properties of colloidal materials affect both their rate of 
clearance and site of deposition in vivo. These effects are 
complicated, however, by simultaneous changes in other surface 
properties, such as hydrophobicity/hydrophilicity, which can result 
from changes in surface charge. Thus it is probably a concurrent 
effect of the general surface properties of the particles on 
interaction with the RES that determines the fate of colloidal drug 
carriers in the body. 
Previous chapters have shown that polyhydroxyl stabilisers, 
such as dextrans, can copolymerise with ACA's forming covalent 
linkages between the stabiliser and the cyanoacrylate polymer. This 
produces an interfacial layer of the stabiliser which is firmly 
attached to the nanoparticle surface. It should be possible, 
therefore, to alter the surface charge characteristics of 
nanoparticles by the incorporation of dextrans with charged 
functional groups. 
This chapter describes the preparation of p(BCA) nanoparticles 
with high and low negative and positive surface charges using 
dextran 70, dextran sulphate 500, and diethylaminoethyl-dextran 
(DEAE-dextran) as stabilising agents. Subsequent studies in vivo 
with these nanoparticles may show differences in the tissue 
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distribution attributable to the variation in particle charge. 
Hopefully any such effects could be utilised in drug targeting. 
4.2. EXPERIMENTAL METHODS AND MATERIALS 
4.2.1. Nanoparticle Preparation 
The dextran materials, dextran 70, DEAE-dextran and dextran 
sulphate 500, used in preparing the nanoparticles were purchased 
from Sigma. Dextran sulphate is a polyanionic derivative of dextran 
produced by esterification of dextran, molecular weight 500000, with 
chlorosulphonic acid. The sulphur content is approximately 17% which 
corresponds to an average of 2.3 sulphate groups per glucosyl 
residue. The dextran sulphate salt was converted to its free acid 
before use with an ion exchange resin (Amberlite IR-120, BDH). DEAE- 
dextran is a polycationic derivative of dextran containing 
diethylaminoethyl groups coupled to the glucose residues by ether 
linkages. The parent dextran has an average molecular weight of 
500000. The nitrogen content is approximately 3.2% which corresponds 
to one charged group to three glucose units. 
The nanoparticles were prepared by adding 0.25m1 of BCA to 
24.75m1 of a filtered (0.2pm membrane filter, Whatman) stirred 
solution of dextran 70 (0.5% w/v) or DEAE-dextran (1.0% w/v) in 
approximately 0.01N hydrochloric acid, or dextran sulphate 
(1.0% w/v) in distilled water. After the polymerisation was complete 
the suspension was filtered through a sintered glass filter (grade 
4, pore size 11-16ym) and diluted accordingly for particle size or 
electrophoretic mobility measurements. 
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4.2.2. Particle Size Analysis 
Particle size measurements were performed by PCS as outlined in 
chapter 2. Results are quoted as the z-average particle diameter 
(dz) and polydispersity index (0). 
4.2.3. Electrophoretic Mobility Measurements 
The determination of the electrophoretic mobility (EPM) and the 
related zeta potential (ZP) of the nanoparticles was performed using 
the technique of electrophoretic laser doppler anemometry (LDA) 
(Preece and Luckman, 1981). The instrument used was a commercially 
available Malvern Zetasizer (Malvern Instruments) and measurements 
were performed by Malvern Instruments. 
LDA was used to determine the nanoparticle EPM since 
conventional measuring techniques such as microelectrophoresis and 
moving boundary electrophoresis (Shaw, 1969) are not suitable for 
the small particles under investigation here. The technique of LDA 
involves the application of a known electric field across a 
suspension of the sample contained in a cylindrical sample cell. The 
sample is illuminated with a laser light source (15mal helium-neon 
laser) which is split into two beams of equal intensity. The split 
beams are caused to cross at a stationary level (zero electro- 
osmotic flow) in the cell forming an ellipsoid measuring volume. In 
this region a pattern of interference fringes is formed due to the 
coherence of the two laser beams. The spacing of these light and 
dark bands is an exact function of the beam crossing angle and laser 
frequency. Particles moving through the fringe system will scatter 
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light with a frequency different from the incident beam due to the 
Doppler effect. This frequency shift, the Doppler frequency, Fd, is 
correlated with the particle velocity via the equation 
Fd 
-2 sin(A/2) v [4.1] 
where 9 is the detection angle, ). the laser wavelength and v the 
particle velocity. 
To determine the charge and velocity of the particles under 
investigation one of the laser beams is modulated by a frequency of 
250 Hz. This causes the interference fringes to drift in a direction 
parallel to the particle motion. Particles with a net charge of zero 
will remain stationary under the applied electric field but will 
appear to scatter light with a Doppler frequency of 250 Hz due to 
the moving fringe pattern. Charged particles, however, will move 
either with the fringe system, thereby decreasing Fd, or against it, 
thereby increasing Fd, depending on the polarity of the applied 
electric field. Synchronisation of the modulating frequency and the 
field polarity with the particle movement then yields information 
about the sign and magnitude of the particle surface charge. The 
Malvern Zetasizer determines Fd by generating a correlation function 
of the scattered light intensity and converting this to a frequency 
spectrum via a Fourier transform. 
For the electrophoretic measurements, a few drops of the 
nanoparticle suspension were added to 10m1 of a 10-3M potassium 
chloride solution and mixed thoroughly. A total of 1000 measurements 
were performed on each sample at 25°C and the EPM and ZP calculated 
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from the mean result. The DEAE-dextran stabilised nanoparticle 
sample was adjusted to increasing pit values by adding small volumes 
of 0.01N sodium hydroxide and checking with a calibrated p11 meter. 
The electrophoretic measurements were performed immediately after 
each pH value was set. Measurements could not be made above p11 10 
due to rapid degradation of the nanoparticles. 
Calculation of ZP depends upon the magnitude of the Debye- 
Nuckel parameter, k, and the particle radius, r. At large values of 
Kr the Smoluchowski equation can be applied whereas at small values 
of Kr the Nuckel equation is employed (Shaw, 1969). However, for 
values in the range 0.1 <Kr< 100 (James 1980) recourse is made to 
the Henry equation which for non-conducting spherical particles is 
given by 
UE 
- 
ZPe f( Kr) 
6Trn 
[4.2] 
where UE is the electrophoretic mobility, e is the permittivity of 
the medium, n is the solvent viscosity and f( Hr) is a function of 
Kr which varies between 1 (Nuckel equation) and 1.5 (Smoluchowski 
equation). For the systems studied here with particle radii from 
74nm (dextran 70) to 549nm (dextran sulphate) and K of 0.104nm 
1 
(calculated for an ionic strength of 10-3 M), the values of kr are 
7.7 <Rr< 59. The corresponding function f( Kr) may be obtained 
graphically (as in this case) or calculated exactly according to the 
expressions given by Henry (1931). 
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4.3. RESULTS AND DISCUSSION 
4.3.1. Electrophoretic Measurements 
The results for the EPH and ZP of the various nanoparticle 
systems are given in table 4.1. The p(BCA) nanoparticles stabilised 
by dextran 70 were found to bear a small negative charge and have a 
low EPM as reported by other workers (Kreuter, 1983d). This charge 
probably arises from the adsorption of anions from the aqueous 
phase. Cations, which are generally more hydrated than anions, have 
a greater tendency to remain in the bulk aqueous phase compared with 
the larger, more polarising and less hydrated anions which 
consequently are adsorbed more easily (Shaw, 1969). The magnitude of 
the negative charge was significantly increased by preparing 
nanoparticles using the highly charged anionic (SO 3) stabiliser 
dextran sulphate. 
By using DEAE-dextran it was possible to form nanoparticles 
with a positive EPM and ZP due to the cationic tertiary and 
quaternary amino groups present in this polymer. The EPH of these 
particles was found to vary as a function of pH as shown in table 
4.1. This is due to the degree of ionisation of DEAE-dextran being 
dependent upon p11. The ionisation behaviour is complicated by the 
presence of three different ionisable groups each with a different 
PKa as shown below. 
12H5 12H5 12H5 
DEXTRAN-C2H4-N and DEXTRAN-C2H4-N-C2H4-N 
CHCNC 11 252525 
TABLE 4.1 Electrophoretic mobility (EPM), zeta potential (ZP) and 
Kr of p(BCA) nanoparticles produced in the presence of various 
stabilisers. 
Stabiliser pH EPM kr ZP 
(ym. cm. s-l. v'1) (mv) 
Dextran 70 4.8 
-1.72 7.7 -24.2 
Dextran sulphate 3.2 -4.13 59 -49.8 
DEAE-dextran 2.8 +2.93 23 +36.7 
DEAE-dextran 5.0 +2.72 20 +34.5 
DEAE-dextran 10.1 +2.15 9.4 +30.0 
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The tertiary amino group belonging to the simple DEAE substituent 
has a pKa 9.5, the tertiary amino group belonging to the 'tandem' 
DEAE-DEAE substituent has a pK 
a 
5.7 and the quaternary amino group 
belonging to the DEAE-DEAE substituent has a pKa ~ 14 (Cubensek and 
Lapanje, 1968). Thus, the higher the pH the less the polymer is 
ionised and hence a lower EPM and ZP of the nanoparticles are 
obtained. Due to the presence of the charged quaternary amino group 
it is not possible to obtain a polymer with a neutral charge, so at 
pH 10 the nanoparticles still have a positive EPM. 
4.3.2. Particle Size Analysis 
Turbidometric analysis of DEAE-dextran stabilised nanoparticles 
indicated the system to have an average particle diameter of less 
than 100nm. Analysis by PCS of the suspension diluted with distilled 
water (final pH - 4), however, gave an average diameter of 484nm. It 
was also found that the nanoparticle diameter given by PCS was 
highly dependent upon the ionic strength of the analysis medium 
(table 4.2 and figure 4.1). As the concentration of added sodium 
chloride was increased up to 0.5M the measured particle size 
decreased from 484 to 181nm. The most marked variation in size with 
sodium chloride concentration occurred from zero to approximately 
0.35M. The polydispersity index however, remained fairly constant 
indicating the PSD of the system was unaltered. These results may be 
explained by considering the nature of the particle surface and the 
fact that PCS generates a hydrodynamic diameter (Pusey, 1982) which 
comprises the particle core plus any firmly bound surface layer that 
diffuses with the core as a kinetic unit. 
TABLE 4.2 Variation of the PCS measured particle diameter (dz) and 
polydispersity index (Q) with added sodium chloride concentration at 
pH 4, for DEAE-dextran stabilised p(BCA) nanoparticles. 
Added sodium chloride dz ad p ad 
concentration (nm) 
(mole dm 3) 
0.0 484 7.6 0.192 0.015 
0.002 340 14.0 0.179 0.020 
0.010 279 4.1 0.189 0.021 
0.020 251 5.0 0.190 0.018 
0.100 214 4.3 0.190 0.012 
0.200 196 4.4 0.179 0.013 
0.350 183 4.3 0.166 0.019 
0.500 181 4.6 0.171 0.024 
ad - standard deviation 
Figure 4.1. The variation in size of DEAE-dextran 
stabilised nanoparticles as a function of ionic strength, 
expressed as the negative logarithm of the added sodium 
chloride concentration (a), and as a function of the 
pH of the dispersion medium at an ionic strength 
of 10-4M (o). 
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Nanoparticles produced in the presence of DEAE-dextran were 
found to be composed of approximately 25% by weight of DEAE-dextran 
which was firmly bound to the nanoparticle matrix and could not be 
desorbed by repeated washing and centrifugation. At pH 4 and low 
ionic strength the amino groups of DEAE-dextran will be virtually 
totally ionised resulting in the polymer chains, residing in the 
aqueous phase, adopting an extended conformation due to electro- 
static repulsion of the charged groups. This has the effect of 
providing a relatively large hydrodynamic diameter for the nano- 
particles as measured by PCS. However, by increasing the ionic 
strength of the aqueous medium, charge shielding of the cationic 
groups reduces the electrostatic interaction allowing the polymer 
chains to adopt a more compact configuration as depicted in figure 
4.2. A limiting size of about 180nm at pH 4 is indicated (table 4.2) 
A similar effect was seen by altering the pH of the dispersion 
medium while the ionic strength was kept constant at 10-4M as 
expressed in table 4.3 and figure 4.1. As already discussed, by 
increasing the pH the degree of ionisation of the polymer decreases. 
This will lead to a reduction in the inter- and intra-chain 
electrostatic repulsion, thereby reducing the hydrodynamic diameter 
of the nanoparticles. A limiting size of about 180nm is indicated at 
pH 10 and ionic strength of 10-4 M. However, when both the ionic 
strength and pH were increased to 0.5M and 10 respectively, the PCS 
diameter decreased to 158nm correspdding to the maximum collapse of 
the surface polymer. Similar effects have been reported for other 
polymer latices with strongly bound layers of water soluble polymers 
(Goossens and Zembrod, 1979 and 1981). 
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TABLE 4.3 Variation of PCS measured particle diameter (dz) and 
polydispersity index (Q) with p11 for DEAE-dextran stabilised 
nanoparticles at a constant ionic strength of 10-4M. 
pH dz 
(nm) 
ad Q ad 
4.0 472 11.6 0.183 0.020 
5.0 431 7.3 0.204 0.021 
6.0 372 14.0 0.184 0.023 
7.0 321 12.4 0.176 0.019 
8.0 276 6.2 0.203 0.011 
9.0 199 7.9 0.193 0.021 
10.0 179 8.5 0.194 0.014 
sd - standard deviation 
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The shape of the DEAE-dextran molecule is known to be affected 
by changes in the ionic strength of the medium, approximating more 
closely to that of a random coil as the ionic strength is raised. 
Even when the ionic strength is very low, however, a rigid 
cylindrical model for the polyfon is inadequate to account for some 
of its properties and a certain amount of folding of the molecule 
must be assumed. Similar changes in shape may be expected to occur 
during titration of the charged groups (Gubensek and Lapanje, 1967 
and 1968). 
The consideration of nanoparticle hydrodynamic diameter may be 
important with respect to possible extravasation of the carrier. On 
the basis of the PCS results obtained at low p11 and ionic strength 
there is little chance of these particles passing through fenestrae 
(approximate diameter 100nm) to reach target sites outside the 
circulation. However, only the particle core would possess a rigid 
structure whereas the surface polymer would be able to adapt its 
conformation to allow passage through pores much smaller than the 
hydrodynamic diameter of the nanoparticles. In addition, the high pit 
and ionic strength of the blood stream would result in the surface 
polymer adopting a collapsed configuration in vivo. 
The particle diameter of dextran sulphate stabilised 
nanoparticles was found to be 1098nm with a polydispersity index of 
0.240, as determined by PCS. This would indicate that this polymer 
is a poor stabiliser despite its high molecular weight which should 
produce a high degree of steric stabilisation. In addition, the 
charged nature of the polyfon would be expected to impart an 
additional electro- static repulsive effect which could reduce 
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particle size still further. One explanation for the low level of 
stabilisation may be the high degree of substitution of sulphate 
groups in the glucose residues of the parent dextran; approximately 
75% of the available hydroxyl groups are substituted. This would 
greatly reduce the ability of dextran sulphate to copolymerise with 
the monomer and form a firmly attached surface layer of polymer that 
is essential for an effective steric barrier as discussed in chapter 
3. The use of a dextran with a much lower degree of sustitution 
would hopefully overcome this problem. 
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CHAPTER FIVE 
COVALENT ATTACHMENT OF AMINES TO NANOPARTICLES 
5.1. INTRODUCTION 
The potential benefits of using MCA's to achieve site specific 
targeting have already been illustrated in section 1.4.3.3. 
Utilisation of the antigen specific 'homing' action of a MCA in 
association with the high payload capacity and versatility of 
particulate carriers makes such a combination a highly attractive 
targeting modality for use in cancer chemotherapy. 
This approach has been investigated with p(ACA) nanoparticles 
by Ilium et al (1983 and 1984) (see section 1.7.7.3). Although these 
studies showed tumour-specific targeting of nanoparticles to occur 
in vitro this was not observed in vivo. There are several possible 
explanations for the lack of targeting in vivo such as RES capture, 
failure to extravasate and antibody displacement from the particle 
surface by serum proteins. This latter problem was also found to 
occur in vitro (Ilium et al, 1983) and could be a major limiting 
factor to the use of MCA-nanoparticle combinations where the 
antibody is bound by physical adsorption. Some method is needed, 
therefore, of linking the MCA to the nanoparticles via an 
irreversible bond. 
There are several ways of attaining a higher degree of 
association between microspheres and antibodies and these are 
summarised in table 5.1 (Ilium and Jones, 1985). Non-covalent 
attachment can be enhanced by the use of ligands which interact 
TABLE 5.1 Methods of attachment of monoclonal antibodies to microspheres. Reactive 
groups and reactions involved (Mum and Jones, 1985). 
Functional group Mechanism of attac}ment Exanpies 
on microsphere and convents 
surface 
"[3octie" 1. Direct adsorption. Possible p(tCA) nanoparticles 
canpetitive displacement by (1,2). 
blood proteins. 11b chemical 
reagents. Sinple procedure. 
Hydrophobic surface required. 
2. Indirect adsorption via protein p(ACA) nanoparticles(3). 
A. Simple efficient method. Ab lim=n seem albumin 
chemical reagents. nicrospheres(4). 
3. Indirect adsorption via avidin- Methyl methacrylate 
biotin. Requires covalent corn inicrospheres(5). 
jugation of avidin to particles 
and biotin to ILCA. 
Aldehyde 1. Direct coupling. Sinple and 
(U efficient method. 
Carbaxylic 1. Coupling via carbodiimide. 
acid Simple and efficient but 
COOR crosslirking of the anti- 
body can occur. 
Fölyacrolein microsptieres 
(6), polyaldehyde micro- 
spheres(7) and albumin 
tnicrospheres(8). 
Methyl methacrylate 
microsphers(9). 
2. Coupling via Woodwards Pblyacrylyl polymer- 
reagent K. Degree of bindirg etizyme(10). 
easy to control. 
HydrQCyl 1. Coupling via cyanogen Methyl methacrylate 
OH bromide. Not very efficient, microspheresill). 
highyl p1 dependent and 
toxic material. 
TASTE 5.1 continued. 
Amino 1. Couplir via glutaraldehyde. Ethylenedianine 
M Efficient but derivatisation derivatised t th - 
of the carrier often needed. acrylate microepheres 
(5). 
2. Coupling via SPDP*. Uposomes(12). 
Efficient but lengthy 
couplicated procedure. 
Dextran 1. Introduction of aldehyde groups 
by periodate oxidation and imine 
formation with amino groups. 
For 
2. Coupling of amines via cyanogen examples 
bromide. see 
text. 
3. Introduction of a bifunctional 
amine using cyanogen bromide and 
subsequent linking via 
glutaraldehyde. 
* N-succinimidyl 3-(2-pyridylthio) propionate. 
References. (1,2) Ilium et al, 1983 and 1984; (3) Couvreur, 1984; 
(4) Kandzia et al, 1981; (5) Kaplan et al, 1983; (6) Margel et al, 
1982; (7) Margel et al, 1979; (8) Longo et al, 1982; (9) Molday et 
al, 1975; (10) Patel et al, 1967; (11) Yen et al, 1976; (12) 
Weinstein and Leserman, 1984. 
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specifically with the intact or modified antibody. Staphylococcus 
aureus protein A (molecular weight 42000) has the capacity to bind 
with high affinity the Fc portion of the majority of the sub-classes 
of IgG (Langone, 1982), and this has been exploited for the coupling 
of antibodies to microspheres (Kandzia et al, 1981; Couvreur, 1984). 
Alternatively, the antibody may be conjugated with biotin and this 
specifically adsorbed onto microspheres bearing a covalently linked 
surface layer of avidin (Kaplan et al, 1983). The avidin then forms 
essentially an irreversible complex with the biotinylated protein. 
Functional groups on the particle surface may be utilised for 
the covalent coupling of MCA's to microspheres and examples of these 
are given in table 5.1. Many of these techniques, however, are not 
applicable to p(ACA) nanoparticles. The cyanoacrylate polymer itself 
may be regarded as relatively unreactive with respect to 
derivatisation once the particles are formed. Fortunately, the 
surface layer of covalently linked dextran present in nanoparticles 
formed using dextran as a stabiliser (see chapter 3) provides an 
alternative means of covalent attachment. 
Dextran has been widely investigated as a carrier molecule and 
has been coupled with a diverse range of substances such as amino 
acids (Barker et al, 1972), enzymes (Foster, 1975), drugs (Nuten and 
Schilling, 1975; Harding, 1971) and MCA-drug conjugates (Rowland, 
1977; Latif et al, 1980; Bernstein et al, 1978; Manabe et al, 1984). 
Molecules containing amino groups may be coupled by first activating 
the dextran hydroxyl groups with cyanogen bromide (Rowland, 1977; 
Latif et al, 1980) or by oxidising the dextran with periodate to 
introduce aldehyde functions which may then be condensed with amines 
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(Bernstein et al, 1978; Arnon and Sela, 1982). Alternatively, the 
dextran can be derivatised with a bifunctional amine (e. g. 
1,6-diaminohexane) and this coupled to an amino containing ligand 
using glutaraldehyde (Rowland, 1977). Of these techniques, the 
periodate oxidation method is the most suitable for use with 
nanoparticles, being relatively simple compared with the 
derivatisation method and not requiring the high pH of the cyanogen 
bromide procedure which would cause nanoparticle degradation. The 
mechanism of periodate oxidation and imine formation is outlined in 
scheme 5.1. 
This chapter describes the preliminary investigations for the 
application of this technique using the simple amine, aniline, as a 
model compound. 
5.2. EXPERIMENTAL METHODS AND MATERIALS 
The nanoparticles in these experiments were used in a 
flocculated state as obtained after lyophilisation. This allowed 
rapid centrifugation at low speed (3000 rpm) which was essential for 
the release measurements and beneficial in the other studies. All 
reactions were carried out in triplicate and the mean result 
calculated. 
5.2.1. Nanoparticle Preparation and Isolation 
The nanoparticles were prepared according to the standard 
formulation given in chapter 2, except 1% w/v dextran 70 was used as 
the stabiliser. 
ýaHZc 
0 
H 
HO 
OH 
0-H2? 
?. Na 104 
O 
OHC + HCO2H 
OHC 
RNH 2 
ý-- 
aH2c 
0 
HOHZC 
R-HNH2C 
4- O-H2C 
0 
NaCNBH3 OHC 
R-N=HC 
Scheme 5.1. Mechanism of periodate oxidation of 
dextran to introduce aldehyde groups which may 
then be condensed with an amine to give the 
corresponding imine. The imine may be reduced with 
borohydride to. give a stable secondary amine. 
When R=phenyl (aniline) the intermediate imine 
is relatively stable and does not require final 
borohydride reduction. 
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Free dextran was removed by repeated washing and centrifugation 
as described in chapter 3. The 'clean' nanoparticles were isolated 
by lyophilisation. 
5.2.2. Optimum Periodate Concentration for Dextran Oxidation 
Clean nanoparticles (20mg) were suspended in various 
concentrations (1 to 10 mg/ml) of sodium periodate (BDH) in 
distilled water (2m1). These suspensions were agitated in the dark 
for 3 hours and then unreacted periodate removed by centrifugation 
and washing with distilled water 5 times. The nanoparticles were 
then suspended in 2m1 of a3x 10-2M solution of aniline 
(redistilled, Analar, BDH) in O. 1M Mcllvaines buffer (pH 4) and 
agitated in the dark for 16 hours. After this time each supsension 
was centrifuged and the concentration of aniline remaining in 
solution determined spectrophotometrically by measuring the 
ultraviolet (UV) absorbance at 283nm against a suitable blank. 
Absorbance readings were carried out at alkaline pH by diluting the 
samples with 0.01N sodium hydroxide. This ensured the amino group 
was unprotonated and free to act as an auxochrome. 
5.2.3. Optimum Coupling pH 
Clean nanoparticles (20mg) were suspended in 2m1 of a sodium 
periodate solution (4 mg/ml) and agitated for 3 hours in the dark. 
Unreacted periodate was removed by centrifugation and washing with 
distilled water 5 times and the nanoparticles then resuspended in 
2m1 of 3x 10-2M aniline solution in Mcllvaines buffer at various 
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pH's (pH 3 to 7). After agitation in the dark for 16 hours the 
aniline uptake was determined as before. 
This was repeated except periodate was not added during the 
initial oxidation stage. The uptake at each pH due to covalent 
linking was then determined by subtracting the uptake onto 
non-oxidised nanoparticles from the uptake onto periodate treated 
(oxidised) nanoparticles. 
5.2.4. Adsorption of Aniline onto Oxidised and Non-oxidised 
Nanoparticles at pH 4 and 7 
Clean nanoparticles (20mg) in 2m1 of a sodium periodate 
solution (4 mg/ml) were agitated in the dark for 3 hours and then 
free periodate removed as before. The oxidised particles were then 
resuspended in various concentrations of aniline (5 to 100 x 10-3M) 
in Mcllvaines buffer at pH 4 or 7. After agitating for 16 hours in 
the dark at 20°C the degree of aniline uptake was determined as 
above. 
To determine the uptake onto non-oxidised nanoparticles the 
procedure above was repeated except periodate was not added at the 
initial oxidation stage. 
5.2.5. Release of Aniline from Oxidised and Non-oxidised 
Nanoparticles 
Oxidised or non-oxidised nanoparticles were loaded with aniline 
to give an uptake of approximately 5x 10-5 mole/100mg of 
nanoparticles and isolated from free aniline in solution by 
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centrifugation. These particles were then suspended in 200m1 of O. 1M 
phosphate buffered saline (PBS) (pH 7.4), and stirred at room 
temperature for 24 hours. The release medium was not heated at 37°C 
due to the volatile nature of aniline. During this time 5m1 samples 
were withdrawn periodically and rapidly centrifuged. The level of 
aniline in the aqueous phase was determined as before and the 
release expressed as a percentage of the total quantity of aniline 
added in nanoparticle form to the dissolution medium. 
The release of aniline from nanoparticles into PBS containing 
1% w/v bovine serum albumin (BSA) (Sigma) was also determined as 
above. The protein interfered with the UV assay, however, and had to 
be precipitated by the addition of 3ml of acetonitrile (HPLC grade, 
Romil Chemicals, UK) to 2m1 of the centrifuged release sample. The 
protein was precipitated as an oil which was easily separated by 
centrifugation. The absorbance at 235nm was then recorded against a 
blank prepared from 2ml of 1% w/v BSA in PBS mixed with 3m1 of 
acetonitrile and treated in the same way. The aniline concentration 
was calculated from a calibration curve prepared using the same 
method but with known concentrations of aniline. 
5.2.6. Analysis of Polyaldehyde Dextran by NHR 
Dextran 70 (80mg) was dissolved in 2.5ml of deuterium oxide 
(spectroscopy grade, Aldrich) containing 120mg of sodium periodate 
and 0.75m1 of this transferred to an NMR sample tube. The NMR 
spectrum was recorded periodically for 6 hours and the signal 
observed at 6 8.2 was integrated. After this time a trace amount of 
trifluoroacetic acid (Aldrich) was added to the sample and the 
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spectrum again recorded. Details of the spectrometer are given in 
chapter 3. 
5.3. RESULTS AND DISCUSSION 
5.3.1. Effect of Periodate Concentration on Aniline Uptake 
The variation of aniline uptake with the concentration of 
sodium periodate used during the oxidation stage is given in table 
5.2. This shows the level of aniline uptake to steadily increase 
with periodate concentration up to approximately 4 mg/ml of 
periodate. Addition of further oxidising agent to the system above 
this concentration failed to enhance aniline uptake. There is no 
advantage to be gained, therefore, in using sodium periodate 
concentrations above 4 mg/ml since possible over-oxidation of the 
dextran (Dyer, 1956) could reduce the binding efficiency, although 
this was not seen over the concentration range studied here. 
At a concentration of 4 mg/ml the molar ratio of sodium 
periodate to the repeating anhydroglucopyranose units of dextran 70 
is approximately 1.9 (calculated assuming 100mg of nanoparticles 
contains 16mg of dextran 70 as found in chapter 3). On first 
inspection this figure is in good agreement with the mechanism 
proposed in scheme 5.1 where complete oxidation requires 2 moles of 
periodate. However, no increase in aniline uptake due to covalent 
linking would be expected to occur after the consumption of one 
molar equivalent of periodate, since the second mole of oxidising 
agent is involved in formaldehyde production and does not introduce 
further aldehyde groups. According to this theory, uptake should 
a 
TABLE 5.2 Variation of aniline uptake onto p(BCA) nanoparticles with 
the concentration of sodium periodate used for oxidation. 
Periodate conc. Equilibrium conc. % uptake Loading* 
(mg/ml) (mole dm -3 x 102) (mole x 105) 
1 2.78 7.4 2.21 
2 2.57 14.3 4.29 
4 2.39 20.4 6.12 
7 2.36 21.3 6.39 
10 2.39 20.4 6.12 
* loading expressed as moles of aniline per 100mg of nanoparticles. 
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plateau at a periodate concentration of approximately 2 mg/ml- 
oxidations are seldom performed using one molar equivalent of 
periodate, however, and this reagent is always used in excess of 
that required for primary oxidation (Dyer, 1956; Rankin and Jeanes, 
1954). This would agree with the finding that a periodate 
concentration greater than 2 mg/ml is required for optimum aniline 
uptake. The situation is complicated due to a number of the dextran 
glucose units being involved in covalent linking with the 
cyanoacrylate polymer, and the possible incorporation of dextran 
into the nanoparticle matrix. Rationalisation of the nanoparticle 
dextran content in terms of periodate oxidation and subsequent imine 
formation is, therefore, not possible. 
5.3.2. Effect of Coupling pH on Aniline Uptake 
The variation of aniline uptake onto oxidised and non-oxidised 
nanoparticles with coupling pH is given in figure 5.1. Uptake 
increased for both types of particles as the pH increased due to 
decreasing ionisation of the aniline, which has a higher affinity 
for the nanoparticles in its unionised form (see section 1.7.4). The 
uptake was higher, however, at all pH's with the oxidised 
nanoparticles which are capable of covalent binding. Assuming the 
only difference between the two types of nanoparticles is the 
presence or absence of aldehyde moieties in the stabilising layer of 
surface dextran, then the enhanced uptake must be due to covalent 
linking of the amine. Subtraction of the two curves generates a pH 
profile for aniline uptake due to covalent linking alone which 
showed a maximum at approximately pH 4. This behaviour is typical 
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Figure 5.1. Variation of aniline uptake onto oxidised (0) 
and non-oxidised (A) nanoparticles as a function of pH. 
Subtraction of these two curves gives the uptake due 
to covalent linking alone (o). 
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for imine formation (Roberts and Caserio, 1977) and may be explained 
by reference to the rates of equilibria involving aniline and the 
aldehyde, as well as the rate of dehydration, given by the reaction 
mechanisms below where Dx denotes dextran and Ph is phenyl. 
Ph-NH 2+ H+ Ph-NH 3+ (5.1] 
Dx-CH-O + Ph-NH2 DX-CH-NH-Ph (5.2) 
1 
0111 
Dx-CH-NH-Ph 
-HH 
Dx-CH=N-Ph + H2O [5.3] 
1 
OH 
Clearly, if the unshared electron pair on the nitrogen of 
aniline is combined with a proton, equation [5.1), it cannot attack 
the carbonyl carbon to give the aminoalkanol as in equation (5.2]. 
At low pH the rate of equilibrium for the overall reaction is 
unfavourable but as pH rises the rate increases because there is 
more free Ph-NH2 in solution. Dehydration of the aminoalkanol [5.3) 
is acid catalysed and this reaction is normally fast at pit values 
smaller than 3 to 4. At higher pH values it eventually becomes too 
slow to give a useful overall rate of reaction. This sequence of 
changes in rate and equilibria has been shown to account precisely 
for rate-pH profiles for imine formation (Roberts and Caserio, 1977) 
and is reflected in figure 5.1. 
The optimum pH value for the coupling reaction with aniline 
appears, therefore, to be approximately pit 4. This would have to be 
determined separately for each amine coupled in this way since the 
protonation step (equation [5.1)) is dependent on the pKa of the 
amine, which for aniline is 4.58. This value is much lower than the 
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PKa values of aliphatic amines (typically -10) due to sharing of the 
nitrogen lone pair of electrons in aniline with the aromatic ring. 
5.3.3. Aniline Uptake onto Oxidised and Non-oxidised Nanoparticles 
The uptake of aniline onto oxidised and non-oxidised nano- 
particles was determined over a range of aniline concentrations at 
pH 4 and 7. The resulting adsorption isotherms are given in figure 
5.2. At pH 4 the adsorption of aniline onto non-oxidised nano- 
particles was minimal due to the partial ionisation of the amino 
function. With the oxidised system, however, uptake was much higher 
due to covalent linking. An increased uptake was also observed at 
pH 7 with the oxidised nanoparticles compared with the non-oxidised 
system. Uptake for both types of particles was much greater at pH 7 
than at pH 4 due to the increase in non-specific adsorption of 
unionised aniline. 
From the results obtained at phl 4 the maximum uptake due to 
covalent linking was approximately 5x 10-5 mole/100mg found by 
subtracting the adsorption values of non-oxidised and oxidised 
nanoparticles. This compares with a maximum theoretical uptake of 
2x 10-4 mole/100mg calculated assuming 100mg of nanoparticles 
contains 16mg of dextran (see chapter 3) and each anhydrogluco- 
pyranose unit can bind two molecules of aniline. Approximately 25% 
of the total theoretical covalent binding capacity, therefore, is 
utilised by this method. This figure may be regarded as a reasonable 
level of incorporation since not all of the dextran would be 
available for reaction, as discussed earlier, and it is unlikely 
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that every aldehyde group could accommodate an aniline molecule due 
to steric hindrance. 
5.3.4. Release of Aniline From Oxidised and Non-oxidised 
Nanoparticles 
The release-time profiles of aniline from oxidised and 
non-oxidised nanoparticles into PBS (pH 7.4) with or without BSA are 
shown in figure 5.3. The release from oxidised nanoparticles was 
much less than the corresponding release from the non-oxidised 
system. For both types of particles there was a rapid 'burst effect' 
which has been observed for other types of microspheres (Tomlinson 
et al, 1984; Yapel, 1979). This initial rapid release phase was 
followed by a much slower rate of release over the next 24 hours. 
With the oxidised system approximately 16% of the total aniline 
content was rapidly lost. At a loading of 5x 10-5 mole/100mg, 14% 
of the payload is held by non-specific adsorption, so the initial 
rapid release of aniline is assumed to be due to desorption of this 
component. With non-oxidised nanoparticles, over 40% of the payload 
was released initially before an adsorption/desorption equilibrium 
became established according to the mechanism proposed by 
(El-Samaligy and Rohdewald, 1982). Subsequent release of aniline in 
both systems occured slowly as the polymer degrades and, in the case 
of covalently linked aniline, as the imine broke down. 
In the presence of 1% w/v BSA the release rate was enhanced 
with the non-oxidised nanoparticles to a much greater extent 
compared with the oxidised system. This indicates that covalently 
attached aniline is relatively unaffected by the protein interacting 
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Figure 5.3. The release of aniline from oxidised (o) 
and non-oxidised (A) nanoparticles into phosphate 
buffered saline (pH 7.4) and from oxidised (. ) and 
non-oxidised (A) nanoparticles into phosphate 
buffered saline containing 1% w/v bovine serum 
albumin (pH 7.4). 
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with the nanoparticle surface, whereas adsorbed aniline can be 
displaced to some degree by the albumin. 
5.3.5. Covalent Linking of Proteins to Nanoparticles 
The initial studies with aniline demonstrated the feasibility 
of linking simple amines to the nanoparticle surface via a covalent 
bond. Application of this technique to the binding of antibodies 
should, theoretically, result in a stable linkage between the 
particles and the macromolecule. However, initial investigations 
could not differentiate between covalently attached and physically 
adsorbed proteins due to the high affinity of proteinaceous material 
for the hydrophobic nanoparticle surface. 
One approach to solving this problem could be the use of NMR to 
follow the fate of the signal due to the aldehyde proton. This 
should undergo a shift in the NMR spectrum upon reaction with an 
amine to give a new signal due to the imine proton. The fate of this 
signal could also be followed during borohydride reduction as the 
secondary amine is formed. However, when the NMR spectrum during the 
formation of polyaldehyde dextran was recorded, no aldehyde signal 
was observed, although a peak at d 8.2 due to the formation of 
formic acid was seen. The integral value for this proton steadily 
decreased with time as the formic acid was oxidised to carbon 
dioxide and water. 
The absence of the aldehyde signal could be due to the proton 
exchanging with deuterium from the solvent, but this is unlikely 
since aldehydes are normally unaffected by the addition of D20. 
Alternatively, the aldehyde groups could react with free hydroxyls 
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present in dextran to form a hemi-acetal or acetal according to the 
following reaction mechanism where Dx and Dx' denote dextran 
aldehyde and hydroxyl moieties respectively. 
+Dx' OH +H+ 
Dx-CIF'O Dx-CH-OH - Dx-CH-0+11 
-Dx'OH ! 
+ 
-l1 
2 I 
ODx' ODx' 
'hemi-acetal' 
+11 20 -1120 
-11 +Dx' 0H 
Dx-CH-ODx' Dx-CH-0 + (H)Dx' + DX-C 11-ODx' 
I +H I 
-Dx'OH 
ODx' ODx' 
'acetal' [5.4] 
Normally the hemi-acetal is not isolated and the reaction 
proceeds to acetal formation. The proton in either of these systems 
could not be resolved since it occurs at a point where it is masked 
by other signals from the molecule. The reaction given in [5.4) is 
normally reversed by the addition of acid. However, when 
trifluoroacetic acid was added to the NMR sample the aldehyde signal 
failed to appear, indicating the acetal is particularly stable. 
This reaction is known to occur with polyaldehyde dextran 
(Ishak and Painter, 1978) and may explain the behaviour observed in 
the NMR spectrum. Similarly, Sloan et al (1954) found polyaldehyde 
dextran to give only a weak IR carbonyl absorption and no UV 
aldehyde absorption, although these workers proposed a hydration 
effect to explain the anomalous spectra. 
NMR does not, therefore, appear to be a suitable method for 
following the coupling reaction with proteins. Although a more 
powerful spectrometer could possibly resolve the remainder of the 
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spectrum, it is doubtful if the resolution would be high enough to 
achieve this on the nanoparticle surface and in the presence of 
interference from the protein. 
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CHAPTER SIX 
RADIOLABELLINC OF NANOPARTICLES 
6.1. INTRODUCTION 
In order to determine the in vivo distribution of parenterally 
administered nanoparticles, the colloidal system must be 
radiolabelled with a suitable radionuclide. This may be achieved 
using a beta-emitter such as carbon-14 which has been used with 
p(ACA) nanoparticles (Grislain et al, 1983; Lenaerts et al, 1984b) 
and various other colloidal systems such as poly methyl methacrylate 
particles (Leu et al, 1984). The use of 
14C 
as a radiolabel for 
p(ACA) nanoparticles, however, has several problems. Initial 
prepration of the 
14C labelled monomer is a highly specialised 
procedure and this compound, when isolated, is prone to spontaneous 
polymerisation and yields systems with a wide particle size 
distribution (Kreuter, 1984). The in vivo studies require the 
sequential sacrifice of a large number of animals, normally rats or 
mice, and subsequent time consuming liquid scintillation counting of 
the activity in individual organs. Interference from the degradation 
products of labelled particles is hard to detect and eliminate since 
the biodistribution of these components cannot readily be 
determined. 
Alternatively, the nanoparticles could be radiolabelled with a 
gamma-emitting radionuclide and the biodistribution followed by 
gamma scintigraphy. This approach has several advantages over beta 
counting, requiring fewer animals and yet providing much more data 
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on kinetics concerning the dynamics of the distribution pattern. It 
cannot, however, resolve fine distribution detail (e. g. it is often 
not possible to distinguish the liver and spleen separately) nor 
provide information on cellular distribution within a given organ. 
Despite this, gamma scintigraphy has found many applications for 
radionuclide imaging in drug research (Wilson et al, 1982) and has 
been used to determine the fate of colloidal systems such as 
liposomes (Pro fitt et al, 1983), polystyrene latices (Kanke et al, 
1980; Ilium and Davis, 1984a and b) and emulsions (Davis and 
Hansrani, 1982) in a range of animals (rats, mice, rabbits, dogs). 
Before in vivo studies can be performed it is necessary to 
develop a technique for radiolabelling nanoparticles with a suitable 
gamma-emitter. The choice of radionuclide will be governed by 
several factors: the gamma ray energy should be in the range 70 to 
400 keV with an ideal energy of about 150 keV (McAfee and 
Subramanian, 1969) and the half life of the nuclide should be 
sufficiently long to enable imaging over a period of at least a day. 
Taking into account these factors, together with the practical 
aspects of cost and availability, there are a limited number of 
suitable radionuclides available (table 6.1). These may be divided 
into those which can be covalently bonded and the metal-ion nuclides 
which are mostly used in a complexed form. Of the 'covalent labels' 
iodine-131 is the most widely used but has the disadvantage of 
beta-emission, making handling hazardous. Although iodine-123 is 
ideal for gamma camera imaging its short half life affects 
availability and cost. 
TABLE 6.1 Radionuclides which may be suitable for labelling 
nanoparticles (data taken from Kelly, 1982). 
Radionuclide T1/2 Principle photons, keV, 
with abundances 
'Covalent' labels 
75 Se 
123 
1251 
1311 
197 Hg 
Metal-ion nuclides 
67 Ca 
99MTc 
lllIn 
113min 
201T1 
118.5 days 136 (54%), 265 (57%) 
13 hours 159 (97%) 
60 days 27 (138%) 
8.05 days 360 (79%) 
2.7 days 77 (20%), 69 (75%) 
78 hours 93 (40%), 184 (24%), 296 (22%) 
6 hours 140 (90%) 
2.8 days 171 (91%), 245 (94%) 
1.7 hours 393 (65%) 
73 hours 69-83 (98%) 
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There are several techniques available for radioiodinating 
substrates (Kelly, 1982) such as exchange iodination (Hupf et nl, 
1978), direct iodination (Bolton, 1977), indirect iodination (Bolton 
and Hunter, 1973) and direct chemical synthesis (Kabalka et al, 
1981). Polystyrene particles have been radiolabelled by irradiating 
suspensions of polystyrene latex containing 
1311 
with a cobalt-60 
source at radiation doses up to 5x 1020 eV ml-1 (Huh et al, 1974). 
Labelling was proposed to occur by the reaction of hydroxyl 
radicals, produced by the ionising radiation, with 
1311 
to form 
stable carbon-iodine-131 bonds. This technique has been used by 
Ilium and Davis (1984a and b) when radiolabelling polystyrene 
particles for use in vivo. 
Of the metal-ion nuclides, technetium-99m is widely used due to 
its chemical versatility, ideal decay energy, optimum half life and 
relatively low cost (Kelly, 1982). Technetium-99m is readily 
obtained from a generator system (Stang and Richards, 1964) in which 
99Mo decays to 
99mTc 
and is eluted from the generator column as 
99mTCO4. In this oxidation state (+7) 99mTc will not bind to 
chelating agents nor to particles. Consequently it is reduced to one 
of its lower oxidation states usually with stannous ion. The 
radiochemistry of 
99mTc has been extensively studied (Eckelman and 
Levenson, 1978) together with its applications for labelling 
radiopharmaceuticals (Eckelman and Levenson, 1977). of the other 
metal-ion nuclides, indium-111 is highly versatile and has attracted 
much attention (Thakur, 1977). 
Although a vast literature exists on radiolabelling techniques, 
the application of this technology to p(ACA) nanoparticles poses 
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many problems. Ideally the radiolabel should remain associated with 
the colloid over a sufficient period of time to allow the 
biodistribution to be accurately determined. If the label does 
dissociate in vivo then spurious results will be obtained. Much of 
the work presented in this chapter, therefore, is concerned not only 
with developing a simple and efficient radiolabelling technique but 
also with its validation for use in vivo. In addition, the label 
itself should not adversely affect such factors as nanoparticle 
size, stability, degradation or surface characteristics. 
6.2. EXPERIMENTAL METHODS AND MATERIALS 
6.2.1. Labelling of Nanoparticles Using Rose Bengal and Rose Bengal 
Benzyl Ester 
Rose bengal was investigated as a possible radiolabel for 
nanoparticles since this compound read 
radioiodination (Hupf et al, 1978) and 
high affinity for p(BCA) nanoparticles 
nature. In addition, this organic acid 
yield less polar esters which would be 
affinity for the nanoparticles. 
ily undergoes exchange 
would be expected to have 
due to its hydrophobic 
may be readily derivatised to 
expected to show an enhanced 
6.2.1.1 Synthesis of rose bengal benzyl ester 
The benzyl ester of rose bengal was prepared according to a 
modified method of Lamberts and Neckers (1983). This is outlined in 
scheme 6.1. 
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To 500mg of rose bengal (BDII) in 10m1 of dimethylformamide was 
added 62mg of benzyl chloride (Aldrich) and this heated at 100°C for 
3 hours. After cooling, ethyl acetate (30ml) and distilled water 
(30m1) were added and the organic phase separated after gentle 
agitation. The aqueous layer was then extracted with ethyl acetate 
(3 x 30m1) and the combined extracts washed with distilled water 
(2 x 50m1). The ethyl acetate was removed under reduced pressure and 
dichloromethane (50m1) together with IN hydrochloric acid (20ml) 
added to the residue. After vigorous shaking the organic phase was 
washed with water (2 x 30m1) followed by saturated sodium 
bicarbonate solution (1 x 30m1), distilled water (3 x 30m1), IN 
hydrochloric acid (1 x 30m1), distilled water (2 x 30ml), and 
saturated sodium chloride solution (1 x 30ml). After drying over 
dried magnesium sulphate the solvent was removed under reduced 
pressure. The resulting solid was washed with ether (3 x 30ml) and 
then dried in vacuo to give a dark red solid. Yield - 57%. 
1H NMR, 90MHz (CDC13, Me4Si) 6: 5.00 (2H, s, CHH2Ph), 6.70-7.40 (711, 
m, aromatics and xanthene 2H). UV max., in water containing 1% w/v 
poloxamer 338 (E1%): 572 (635), 532 (128). IR max., wavenumber 
(cm 1): 3420,2920,1735,1610,1560,1505,1250,960. 
6.2.1.2. Adsorption isotherms of rose bengal and its benzyl ester 
Clean flocculated dextran 70 stabilised nanoparticles were 
prepared as described in chapter S. The particles (30mg) were 
suspended in 3m1 of various concentrations of rose bengal in PBS 
(pH 7) and gently agitated at 20°C for 3 hours. After this time the 
samples were centrifuged (3000 rpm) and the equilibrium 
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concentration remaining in solution determined by UV analysis at 
547nm against a suitable blank. From this, the equilibrium uptake 
was calculated and an adsorption isotherm constructed. 
This was repeated using nanoparticles stabilised with DgAE- 
dextran, prepared as described in chapter 4. These particles were 
cleaned by repeated washing and centrifugation and used in a 
flocculated state as obtained after lyophilisation. 
The adsorption of rose bengal benzyl ester onto dextran 70 
stabilised nanoparticles was determined as described above using a 
wavelength of 572nm for UV analysis. Due to the low water solubility 
of this compound, solutions had to be prepared using PBS (pH 7) 
containing 1% w/v poloxamer 338. To enable comparison between the 
uptake of rose bengal and its benzyl ester an additional adsorption 
isotherm was constructed for rose bengal using solutions prepared in 
PBS (pH 7) containing 1% w/v poloxamer 338. 
6.2.1.3. Release of rose bengal and its benzyl ester from 
nanoparticles 
Dextran 70 stabilised nanoparticles (100mg) were loaded with 
approximately 2x 10-6 mole of rose bengal or its benzyl ester and 
isolated by centrifugation. The particles were then suspended in 
200m1 of PBS (pH 7.4) or in PBS (pH 7.4) containing 1% w/v BSA. 
These suspensions were stirred at 37°C for 24 hours and Sml samples 
withdrawn periodically. The samples were rapidly centrifuged and the 
concentration of label in solution determined by UV analysis against 
a suitable blank. The release was then calculated and expressed as a 
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percentage of the total amount of rose bengal or its ester added to 
the dissolution medium. 
This was repeated with DEAE-dextran nanoparticles loaded with a 
similar quantity of rose bengal. 
6.2.2. Radiolabelling of the Nanoparticle Cyanoacrylate Polyher 
With Iodide-131 
The polymerisation mechanism of ACA given in scheme 2.1 
indicates the initiating nucleophile is present in the final polymer 
as an end group. This has been shown to occur during nanoparticle 
formation (chapter 3) and during ACA polymerisation by other workers 
(Leonard et al, 1966). The ability of a nucleophile to initiate 
polymerisation will be related to its degree of nucleophilicity 
which is defined as the ability to form bonds with carbon atoms 
(Finar, 1973). The order of nucleophilicity is dependent upon the 
nature of the solvent but generally may be given as 
PhS > CN >I> Et0 > OH > Br > Ph0 > Cl 
This indicates that iodide is a more powerful nucleophile than 
hydroxyl which is normally the initiating species. Addition of 
1311 
to the polymerisation medium could result in this nucleophile being 
incorporated into the polymer chain, thereby providing a simple 
method for radiolabelling nanoparticles. 
To the standard nanoparticle reaction formulation at pH 1 or 2, 
given in chapter 2, was added O. Olml of sodium iodide-131 solution 
(Amersham, UK) containing a total activity of 1 mega-Becquerel 
(MBq). After addition of the monomer the mixture was stirred for 2 
hours. The nanoparticles were then flocculated by a freeze/thaw 
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cycle and centrifuged. The activity in the solid was determined by 
gamma counting (IN Intertechnique CG4000 Automatic Gamma Well 
Counter, Intertechnique, France) and expressed as a percentage of 
the total added activity. 
6.2.3. Radiolabelling of Nanoparticles With Iodine-131 
Molecular iodine, I2, is poorly soluble in water (0.33g dm 
3 
at 
250C) but partitions readily into non-polar solvents such as carbon 
tetrachloride (Cotton and Wilkinson, 1968). This species would be 
expected, therefore, to partition into the hydrophobic nanoparticle 
matrix in preference to the aqueous phase. 
6.2.3.1. Incorporation of molecular iodine-131 into nanoparticles 
To a solution of dextran 70 (125mg) and sodium iodide (17.3mg) 
in distilled water (24.4m1) was added O. lml of a sodium iodide-131 
solution (total activity 1MBq). This was followed by 25mg of 
chloramine T (Sigma) and 0.31ml of IN hydrochloric acid to adjust 
the pH to 2. BCA (0.25m1) was rapidly added and the mixture stirred 
at room temperature until polymerisation was complete (2 hours). The 
nanoparticles were then flocculated and centrifuged. The percentage 
of the total added activity incorporated into the nanoparticles was 
then determined by gamma counting. 
The optimum chloramine T/sodium iodide ratio was determined by 
keeping the chloramine T concentration constant at 1 mg/ml and 
varying the sodium iodide concentration in the formulation given 
above. 
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6.2.3.2. Release of incorporated molecular iodine-131 from 
nanoparticles 
Nanoparticles radiolabelled with 
13112 
were prepared as 
described above. This suspension was flocculated by a freeze/thaw 
cycle and a 10ml sample centrifuged. The solid was resuspended in 
200m1 of PBS (pH 7.4) or PBS (pH 7.4) containing 1% w/v BSA and 
stirred at 20°C for 24 hours, during which time 5ml samples were 
withdrawn at regular intervals and centrifuged. The activity 
released into solution was then determined for each sample by gamma 
counting and expressed as a percentage of the total activity added 
to the dissolution medium. 
6.2.4. Radiolabelling of Nanoparticles With IndiurIII-Oxine 
Oxine (8-hydroxyquinoline) forms a saturated (3: 1) complex with 
indium (Thakur, 1977). This neutral, lipid soluble complex would be 
expected to partition into nanoparticles with high affinity and 
thereby provide a simple radiolabelling procedure. 
6.2.4.1. Adsorption of indium-111-oxinc onto nanoparticles 
Clean, flocculated dextran 70 stabilised nanoparticles were 
prepared as described in chapter 5. To 2.5m1 of a 1% w/v nano- 
particle suspension in distilled water at pH 7 (adjusted by the 
addition of 0.01N sodium hydroxide) was added O. lml of an indium-111 
oxine complex (Amersham) with a total activity of 1MBq. After 1 hour 
this mixture was centrifuged and the uptake onto the nanoparticles 
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determined by gamma counting and expressed as a percentage of the 
total added activity. 
This was repeated over a range of pH's (3 to 7) with the p11 
being adjusted by the addition of MIN hydrochloric acid or sodium 
hydroxide and checking with a calibrated pit meter. Uptake was also 
determined using PBS (pH 7) as the suspending medium. 
6.2.4.2. Release of the indium-111-oxine complex from nanoparticles 
Nanoparticles were labelled with the indium-111-oxine complex 
as described above by adding 0.2ml of the complex (2MBq) to 5m1 of a 
1% w/v nanoparticle suspension and then isolating the solid by 
centrifugation. These particles (50mg) were then resuspended in 
100ml of PBS (pH 7.4) or distilled water. The pHI of the latter 
system was maintained at 7.4 by the addition of 0.1N sodium 
hydroxide. This was repeated with the release media containing 
1% w/v BSA. The release of the complex into solution was determined 
at 37°C over a period of 24 hours as described for 
13112 labelled 
nanoparticles. 
6.2.5. Radiolabelling of Nanoparticles Using a Technetium-99m- 
Dextran Complex 
Technetium-99m is capable of forming a complex with dextran 
after reduction of pertechnetate with stannous ion according to the 
following mechanism (Henze et all 1982a) 
Tc04 + 2[C61110051 + Sn2+ + 1120 
-º 
[Tc0(C6it805)2) + 41+ + [Sn02(011)212 
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in which two anhydroglucopyranose units of the dextran chains form 
bidentate chelates with the reduced 
99mTC. Two adjacent hydroxyl 
groups per anhydroglucopyranose unit are assumed to be involved in 
forming the two five membered chelate rings. The resulting complex 
is stable in vitro and in vivo and has been used for angio- 
cardiography (Henze et al, 1982a) and lymphoscintigraphy (Henze t 
al, 1982b). 
It has already been shown (chapter 3) that dextran can 
copolymerise with the monomer during nanoparticle formation and 
become incorporated into the nanoparticle matrix. It should be 
possible, therefore, to radiolabel nanoparticles using a 
99mTc-dextran 
complex. 
6.2.5.1. Incorporation of a technetium-99m-dextran complex into 
nanoparticles 
Technetium-99m was attached to dextran 10 (molecular weight 
9000, Sigma) after reduction with stannous ion by a modified method 
of Henze et al (1982a). This involved adding, with vigorous mixing, 
10ml of a 10% w/v dextran 10 solution in deoxygenated distilled 
water to 0.05m1 of a solution of stannous chloride (Sigma) in 
concentrated hydrochloric acid (6 mg/ml). 2.2m1 of this solution was 
filtered (0.2ym membrane filter) and mixed with lml of the eluate 
from a 
99mTc 
generator (Amersham) containing 1 MBq of activity. 
After 10 minutes this was diluted to llml with deoxygenated 
distilled water and 9.8ml filtered (0.2pm membrane filter) into a 
McCartney vial fitted with a glass covered magnetic stirrer bar. To 
this was added BCA (0.2ml) and the mixture rapidly stirred for 1.75 
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hours. After this time lml of 0.5M phosphate buffer (p11 7) was added 
and stirring continued for a further 15 minutes. 2.5m1 of the 
suspension was then passed through a1x 20cm Sepharose CL 4B column 
(Pharmacia, Sweden) which had been pre-conditioned with 2m1 of a 
'cold' nanoparticle suspension flushed through with 30m1 of PBS (pH 
7). The labelled nanoparticles were eluted with PBS (pi 7) and the 
activity in each lml fraction was determined by gamma counting and 
expressed as a percentage of the total activity added to the column. 
The total nanoparticle elution volume was found to be 2.5ml which 
had a solids content of 33mg. 
Thin layer chromatography was performed on the 
99mTc-dextran 
solution prior to addition of the monomer and on the nanoparticle 
solutions before and after gel filtration. Silica gel impregnated 
glass fibre sheets (1 TLC-SG, Gelman Instruments, USA) were used 
with 0.9% w/v sodium chloride as the solvent. The chromatograms were 
scanned by a radiochromatogram scanner (Medical Physics Department, 
Queens Medical Centre, Nottingham). 
6.2.5.2 Release of activity from 
99mTc-dextran labelled 
nanoparticles 
The labelling procedure was repeated as above and the column 
fractions containing a total of 50mg of labelled nanoparticles 
combined and flocculated (obtained from two separate column 
elutions). These particles were resuspended in 100ml of PBS (pi1 7.4) 
or PBS (pH 7.4) containing 1% w/v BSA. The suspensions were stirred 
at 37°C for 24 hours and the release of activity determined as 
described previously. 
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6.3. RESULTS AND DISCUSSION 
6.3.1. Labelling With Rose Bengal and its Benzyl Hater 
The high affinity of rose bengal for p(BCA) nanoparticles is 
shown by the adsorption isotherm for rose bengal onto dextran 70 
stabilised nanoparticles given in figure 6.1. The data give a good 
linear relationship (correlation coefficient 0.9991) when analysed 
in accordance with the linear form of the Langmuir adsorption 
isotherm equation (Giles et al, 1974) which may be written as 
c/(x/m) - 1/sb + c/s [6.11 
where x is the amount of solute adsorbed by weight, m, of adsorbant, 
c is the equilibrium concentration, b is a constant related to the 
enthalpy of adsorption, and s, which is related to the surface area 
of the solid, is a measure of the adsorptive capacity of adsorbent 
for the adsorbate. 
The Langmuir constants in this case were found to be 
s-5.37 x 10-3 mole g-1 and b-1.06 x 102 dm-3 mole-1 
The adsorption of rose bengal was greatly enhanced (10 fold) by 
using nanoparticles stabilised with DEAE-dextran as shown by the 
adsorption isotherm in figure 6.2. The cationic groups of this 
surface polymer located at the nanoparticle surface are capable of 
ion-pairing with anionic rose bengal molecules giving a high binding 
capacity. The isotherm shows complete (high affinity) adsorption of 
rose bengal from solution up to a particle loading of approximately 
3.5 x 10-4 mole solute/g of nanoparticles. This corresponds well 
with the theoretical maximum uptake attributable to the DEAE-dextran 
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Figure 6.1. Adsorption isotherm of rose bengal onto 
dextran 70 stabilised nanoparticles at 200C. 
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Figure 6.2. Adsorption isotherm of rose bengal onto 
DEAE-dextran stabilised nanoparticles at 20°C. 
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content, calculated assuming each cationic group will bind one 
molecule of rose bengal. Thus, 1g of nanoparticles containing 0.25g 
of DEAF-dextran with a nitrogen content of 3.2% gives a binding 
capacity of 5.7 x 10-4 mole. However, this assumes all amino groups 
will be charged, but at pH 7 the tertiary amino group of the 
'tandem' DEAE-DEAE substituent (pKa 5.7) will be mainly unionised 
(-r 3% as N) giving a maximum theoretical binding capacity of 
approximately 3.8 x 10-4 mole/g nanoparticles. The sharp inflection 
point in the isotherm which occurs at this loading implies, 
therefore, that most or all of the DEAE-dextran is situated on the 
nanoparticle surface. 
Once the readily available surface polymer is saturated with 
rose bengal, a second adsorption phase is seen to occur, probably 
due to microporous adsorption. In this process, the solute begins to 
penetrate the particle pores in such a way as to provide access for 
following solute molecules (Giles et al, 1974). The surface 
available for adsorption therefore expands proportionally with 
solute concentration giving a linear region to the adsorption 
isotherm. Figure 6.2 therefore implies that DEAE-dextran stabilised 
nanoparticles have a high degree of porosity. 
Adsorption was also enhanced by preparing the benzyl ester of 
rose bengal. This is shown by the adsorption isotherms of this 
compound and rose bengal onto dextran 70 stabilised nanoparticles 
suspended in PBS (pH 7) containing 1% w/v poloxamer 338 (figure 
6.3). The increased uptake, compared with rose bengal, is due to the 
decreased ionic character and increased hydrophobicity caused by 
esterification of the carboxylic acid group of the parent compound. 
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Figure 6.3. Adsorption isotherm of rose bengal (0) 
and rose bengal benzyl ester (0) onto dextran 70 
stabilised nanoparticles in the presence of 1% w/v 
poloxamer 338 at 20°C. 
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The adsorption data, however, were obtained in the presence of 
1% w/v poloxamer 338 which was needed to increase the water 
solubility of the ester. This surfactant causes a decrease in the 
uptake of the solutes by adsorbing to the nanoparticle surface, 
thereby displacing adsorbed solute and decreasing the effective 
surface hydrophobicity. This can be seen by comparing the uptake of 
rose bengal in figure 6.1 (maximum loading 50 pmole/g) with the 
diminished uptake due to the presence of the poloxamer in figure 6.3 
(maximum loading 14 )lmole/g). The true adsorption of the rose bengal 
benzyl ester in the absence of any surfactants would be, therefore, 
much greater than indicated here. 
Despite the high affinity of rose bengal for the nanoparticle 
surface, the release rate from dextran 70 stabilised nanoparticles 
was found to be quite rapid, with a time for 50% release of 
approximately 30 minutes (figure 6.4). In addition, a 'burst effect' 
was observed in which 35% of the payload was released within 5 
minutes. The release of rose bengal from DEAE-dextran nanoparticlea 
and rose bengal benzyl ester from dextran 70 nanoparticles was, 
however, much slower (figure 6.4). After 24 hours, only 
approximately 10% of the label was found free in solution for these 
systems and indicates a much higher affinity of the adsorbate for 
the adsorbant which corresponds with the adsorption data. 
When the same release studies were repeated in the presence of 
BSA, however, totally different release profiles were obtained 
(figure 6.5). In all three systems the label was rapidly released 
with over 80% being found in solution after only 1 hour. Despite 
this, differences can be seen between each system in the initial 
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Figure 6.4. Release of rose bengal from nanoparticles 
stabilised with dextran 70 (A) or DEAF-dextran (0), 
and rose bengal benzyl ester from dextran 70 stabilised 
nanoparticles (0), at 37°C in phosphate buffered 
saline (pH 7.4). 
2468 10 
Time (hrs) 
A 
. ý---- A 
aJ 
f0 
L 
a) 
Q' 
rD 
-1-- 
N 
v 
L 
a I 
-141 
10 22 24 
Figure 6.5. Release of rose bengal from nanoparticles 
stabilised with dextran 70 (") or DEAE-dextran (0), 
and rose bengal benzyl ester from dextran 70 stabilised 
nanoparticles (A), at 37°C in phosphate buffered 
saline (pH 7.4) containing 1% w/v bovine serum albumin. 
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release phase of up to 30 minutes with the release rate decreasing 
in the order rose bengal-dextran 70 > rose bengal-DEAE-dextran 
rose bengal benzyl ester-dextran 70. The enhanced release in the 
presence of BSA is due to the protein displacing the adsorbed label 
from the nanoparticle surface or exchanging with rose bengal in the 
ion-pair complex in the DEAE-dextran system. This is followed by 
subsequent binding of rose bengal or its ester by albumin in 
solution. These findings correlate with the known interaction of 
serum proteins with nanoparticles (Kreuter, 1983d) and with rose 
bengal (Coulson and Yonetani, 1972). 
In vivo the release rates would be expected to be at least as 
fast as those found in vitro. Since any free label would be rapidly 
cleared by liver hepatocytes (Bowman and Rand, 1980) it would be 
difficult to distinguish between liver accumulation of the labelled 
nanoparticles and hepatic uptake of free label. Thus radiolabelling 
with 
131I-rose bengal or its benzyl ester is not considered a 
suitable method for following the biofate of nanoparticles by gamma 
scintigraphy. 
6.3.2. Radiolabelling With Iodide-131 
When nanoparticle formation was carried out in the 
presence of 
1311 
at pH 1 or 2, only low levels of activity 
(approximately 2%) were found associated with the nanoparticles. 
This low degree of incorporation can be accounted for by the 
non-specific iodide adsorption and implies that initiation by 
1311 
is occuring only at a very low frequency, if at all. The vast excess 
of hydroxyl ions in comparison with the trace amounts of 
131 1 
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effectively prevents initiation by iodide. Unfortunately, this 
method is unsuitable as a radiolabelling procedure due to the low 
incorporation efficiency. 
6.3.3. Radiolabelling With Iodine-131 
Iodine-131 may be readily formed by the oxidation of 
iodide-131 and carrier iodide using chloramine T (Millar and 
Springall, 1966). When this reaction was carried out in situ during 
nanoparticle formation, up to 90% of the added activity was 
incorporated into the nanoparticles as shown in table 6.2. This 
table shows the effect of various iodide/chloramine T ratios on the 
level of incorporation. The optimum molar ratio was found to be 
1: 1.3 (chloramine T: sodium iodide). This is in contrast to the 
theoretical optimum ratio of 1: 2 for the formation of 
13112 
given by 
the following equations 
CH3C6H4SO2N Cl Na+ + HC1 CH3C6H4SO2NHC1 + NaC1 
CH3C6H4S02NHC1 + H2O CH3C6H4S02Nti2 + HOC1 
HOC1 + HC1 
- 
1120 + C12 
C12 + 2NaI 
__ 
12 + 2NaC1 
Over-oxidation with excess chloramine T would yield iodate 
according to 
12 + 5HOC1 + 1120 
-o- 2103 + 711+ + 5C1 
TABLE 6.2 Variation of iodine-131 incorporation into nanoparticles 
with the molar ratio of sodium iodide to chloramine T. The 
concentration of chloramine T was kept constant at 1 mg/ml. 
Concentration 
of NaI (mg/ml) 
Molar ratio of 
NaI/chloramine T 
% of total added 
activity incorporated 
0.052 0.10 14 
0.133 0.25 16 
0.267 0.50 54 
0.532 1.00 88 
0.692 1.30 92 
0.852 1.60 86 
1.064 2.00 76 
2.128 4.00 60 
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and under-oxidation would leave unreacted iodide. Both of these ions 
would have low affinity for the nanoparticles and would therefore 
reduce labelling efficiency. In addition, free iodide in solution 
would increase the aqueous solubility of the iodine, thereby 
reducing nanoparticle uptake still further. The need to use a higher 
molar ratio of oxidising agent than theoretically required may be 
due to the complex nature of the reaction conditions in which strict 
stoichiometry may not apply. 
The release of activity from 
131 I2 labelled nanoparticles is 
shown in figure 6.6. In contrast to the rose bengal systems, 
addition of BSA to the release medium retarded release of the label 
slightly, indicating that the label would be unaffected by the 
presence of serum proteins. Release, however, is still fairly rapid 
with 50% of the label being lost in approximately 3 hours. This 
moderately fast release rate together with possible toxicity 
problems of any residual chloramine T makes this method unsuitable 
as a radiolabelling technique for nanoparticles. 
6.3.4. Radiolabelling With Indium-111-Oaine Complex 
The uptake of 
111 In-oxine onto nanoparticles was found to be 
highly dependent upon pH. At below pH 4 the level of uptake fell 
sharply from 83% (pH 4) to 20% (pH 3) due to protonation of the 
basic nitrogen in oxine (pK 
a 
5.02) which in this form is no longer 
able to form a complex. Due to this effect it is not possible to 
incorporate the complex into nanoparticles during the polymerisation 
stage because of the low reaction pH. Despite this, the labelling 
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Figure 6.6. Release of radioactivity from 
13112 
labelled nanoparticles in phosphate buffered 
saline (p11 7.4) (0), and in phosphate buffered 
saline (pH 7.4) containing 1% w/v bovine serum 
albumin (O) at 20°C. 
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efficiency in water at plis' greater than 5 was found to be high 
giving an uptake of 88% at p11 7. Phosphate ions were also found to 
interfere with the labelling efficiency. When adsorption of 
111In-oxine 
was carried out in PBS (pH 7) none of the activity was 
found associated with the nanoparticles. It is known that terminal 
phosphate groups on lipid molecules can complex with indium (11wang, 
1978) and a similar process probably occurs in PBS resulting in the 
formation of a water soluble 
"In-phosphate 
complex. 
The indium complexing behaviour of phosphate ions can also be 
observed in the release profiles of 
IIIln-oxine labelled 
nanoparticles given in figures 6.7 and 6.8. When release studies 
were performed in PBS (figure 6.7) a much greater rate of release 
was observed compared with release into water (figure 6.8). The 
addition of BSA to the release media also enhanced release in both 
systems. This may be attributed to the ability of indium to form a 
complex with albumin (Hagan et al, 1978) and displacement of the 
oxine complex from the nanoparticle surface due to adsorption of 
albumin. 
Despite the simple and efficient nanoparticle labelling 
procedure with 
111In-oxine 
this technique is not suitable for use in 
vivo due to rapid release of the label. Although an indium-tropolone 
complex would be expected to yield better results due to higher 
stability and lipophilicity (Dewanjee et al, 1981) this complex has 
been found to be taken up poorly by p(BCA) nanoparticles 
(Fitzgerald, 1985). 
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Figure 6.7. Release of radioactivity from 
111In-oxine 
labelled nanoparticles in phosphate buffered saline 
(pH 7.4) (o), and in phosphate buffered saline (pH7.4) 
containing 1% bovine serum albumin (0) at 37°C. 
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Figure 6.8. Release of radioactivity from In 
_oxine 
labelled nanoparticles in distilled water (pit 7.4) (d), 
and in distilled water containing it w/v bovine serum 
albumin (pH 7.4) (e) at 370C. 
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6.3.5. Radiolabelling With Technetium-99 
-Dextran Complex 
The technetium-99m-dextran 10 complex was relatively simple to 
prepare and could be used directly in place of ordinary dextran for 
nanoparticle formation. The resulting particle size and 
polydispersity index were unaffected (dz - 126nm, Q"0.130). 
Labelled nanoparticles were readily separated from free radiolabel 
by gel filtration chromatography. On passing through a Sepharose CL 
4B column, the small dextran molecules were retained to a much 
greater extent than the relatively large nanoparticles which were 
eluted in the column void volume. By using dextran 10 as opposed to 
higher molecular weight dextrans the separation was enhanced 
allowing the use of relatively short columns which was necessary to 
keep dilution of the nanoparticle fraction to a minimum. The 
elution-activity profile for this system is given in figure 6.9. The 
combined nanoparticle fractions were found to contain approximately 
21% of the activity added to the column. Centrifugation (20000 rpm) 
of these particles indicated that 88% of this activity was firmly 
bound to the nanoparticles, which gives a labelling efficiency of 
18.5%. 
Thin layer chromatography of the 99mTc-dextran complex showed 
most of the activity to move at the solvent front (figure 6.10a) and 
indicates that 
99mTc labelled tin colloid, which would remain at the 
origin, was not formed. Similar chromatographic analysis of the 
nanoparticle suspension prior to gel filtration (figure 6.10b) 
showed approximately 18% of the activity to remain at the origin due 
to incorporation into nanoparticles. This figure is in good 
agreement with the results obtained after centrifugation. After the 
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nanoparticles were isolated from the column, most of the activity 
was found at the origin and no distinct band of activity due to the 
free complex could be detected at the solvent front (figure 6.10c). 
When these radiolabelled nanoparticles were suspended in PBS or 
Was obtained 
PBS containing BSA, a low but steady release Aover a period of 
24 
hours which was relatively unaffected by the presence of protein as 
shown (figure 6.11). Since the technetium-99m-dextran complex is 
known to be highly stable (Henze et al, 1982a and b) the release of 
activity was probably due to nanoparticle degradation. 
Despite the low incorporation efficiency, this technique is 
regarded as a suitable method for radiolabelling dextran stabilised 
nanoparticles. Although the slow release of activity observed in 
vitro could cause interference when determining the fate of the 
colloid in vivo, rapid filtration by the kidneys of the free label 
would be expected to minimise any adverse effects. 
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Figure 6.11. Release of radioactivity from 
99'rc-dextran labelled nanoparticles in phosphate 
buffered saline (p11 7.4) (0) 
, 
and in phosphate 
buffered saline containing It w/v bovine serum 
albumin (pit 7.4) (a) at 37°C. 
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CHAPTER SEVEN 
IN VIVO STUDIES 
7.1. INTRODUCTION 
A major limiting factor to the systemic use of particulate drug 
delivery systems is the rapid clearance of the carrier from the 
circulation by the RES (Poste, 1985). This problem has already been 
discussed together with the possible solutions in chapter 1. Of 
these, the coating of particles with non-ionic surfactants has been 
shown to be highly effective in altering the pattern of RES capture 
(Davis et al, 1985). Although coating polystyrene particles with 
poloxamer 338 greatly reduced liver and spleen uptake, this system 
was rapidly cleared by RES cells of the bone marrow (Ilium and 
Davis, 1984a). This may be prevented, however, by employing Tetronic 
908 as the coating agent. This non-ionic surfactant has similar 
properties to the poloxamers (Schmolka, 1967) and can suppress RES 
capture throughout the body leading to prolonged circulation times 
(Davis et al, 1985). This approach may be applicable to p(ACA) 
nanoparticles which are normally deposited mainly in the liver and 
spleen (Crislain et al, 1983). 
The previous chapter has shown that it is possible to 
radiolabel p(BCA) nanoparticles with the gamma-emitting radionuclide 
technetium-99m. This will enable the biodistribution of these 
labelled nanoparticles to be followed by the technique of gamma 
scintigraphy. This involves determining the radiation pattern due to 
the injected label using a scintillation detector known as a gamma 
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camera. Only a brief outline of the function of this system will be 
given here since comprehensive coverage of the subject in available 
by Fernando et al (1978) together with applications in drug research 
by Wilson et al, (1982). 
A gamma camera system is depicted dingramrnaticaly in figure 
7.1. The scintillation detector consists of a single large thallium- 
activated sodium iodide crystal about 50cm in diameter and 1.2cm 
thick, with one face optically coupled via a clear plastic 'light 
pipe' to a hexagonal array of 37 photomultiplier (PH) tubes. A 
parallel hole collimator fitted to the other side only allows 
passage of gammma rays travelling in an approximately perpendicular 
direction. The gamma rays penetrating the collimator strike the 
scintillation crystal yielding photons of an energy proportional to 
the amount of energy dissipated within the crystal. Each 
scintillation event is detected by the PH array and analysed by the 
positioning circuitory which converts the signal into a two 
dimensional image. This is shown on the display unit as a brief spot 
of light in a position which is related to the position of the 
radiation source. Summation of these events over a period of time 
yields an image indicating the areas of more, or less radioactivity 
in the object of interest. If this time period is sufficiently short 
(a few seconds) and images recorded sequentially, then dynamic views 
of the distribution of the radionuclide with time are produced. 
Alternatively, static views can be collected at suitable time 
intervals which may be minutes, days or weeks. 
Most gamma cameras are interfaced with a computer-controlled 
data acquisition, storage and analysis system. The data are 
pulses of signals to/from 
electrical emrgy tontrd console I ýteador 
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Figure 7.1. Diagram of the gamma camera detector 
head. Signals from the detector are passed to a 
control console and then to a computer system 
for data storage and manipulation. 
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digitalised into a maximum of 16384 (128 x 128) elements, with the 
number of gamma rays in each element denoted by up to 16 different 
shades of grey or colours. These data may be presented as a hard 
copy or scintigram, which shows the qualitative and quantitative 
distribution of activity. The computer allows the activity within 
various parts of the image to be calculated by defining a region of 
interest (ROI). For example, by constructing a ROI around the liver 
it is possible to determine the uptake of activity within this 
organ. R0I's may be defined for other areas allowing background 
correction and calculation of the total body activity. 
There are, however, various errors associated with gamma 
scintigraphy. The relationship between the detected radiation and 
the quantity of radionuclide is constant only if the source-to- 
detector distance is kept constant, together with the thickness of 
any absorbing media in between. The positioning of the animal 
should, therefore, be reproducible. Since a two dimensional image is 
obtained, possible interference from superimposed organs must be 
taken into account. In addition, the error associated with the 
operator definition of the ROI is difficult to eliminate. Finally, 
the intrinsic variation in the gamma camera response, as n result of 
variations in the sensitivity across the field of view and from 
spatial non-linearality can lead to errors of about 6% in day-today 
measurements (Pitt and Sharp, 1981). 
This chapter describes the use of gamma, scintigraphy in 
determining the biodistribution of 
99mTc-dextran labelled p(BCA) 
nanoparticles. The effects of coating these particles with poloxamer 
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338 and Tetronic 908 have also been inventignted in an attempt to 
alter the biodistribution pattern. 
7.2. EXPERIMENTAL METHODS AND MATERIALS 
7.2.1. Adsorption of Poloxamer 338 and Tetronic 908 onto 
Nanoparticlcs 
Nanoparticles were prepared according to the standard 
polymerisation formulation in chapter 2, except dextran 10 at a 
concentration of 2% w/v was used as the stabiliser and a monomer 
concentration of 2% v/v was employed. After polymerisation, the 
nanoparticle suspension was flocculated by freezing and the free 
dextran removed by repeated centrifugation (3000 rpm) and washing 
with distilled water as described in chapter 3. The nanoparticles 
were isolated by lyophilisation and fully resuspended by sonication 
in distilled water to give a solids content of 15 mg/ml. A series of 
dilutions of this suspension were prepared giving a final 
nanoparticle concentration of 1 mg/mi and a poloxamer 338 or 
Tetronic 908 (Pechiney Ugine Kuhlmann) concentration over the range 
1 to 50 x 10-3% w/v. These samples were gently agitated for 2 hours 
at 20°C and then centrifuged (20000 rpm). The supernatant from each 
sample was analysed according to the method of Baleux (1972) given 
in chapter 5 and the equilibrium concentration determined. From 
these results adsorption isotherms were constructed. 
The rates of uptake of the surfactants onto nanoparticles were 
determined by suspending flocculated nanoparticles (10 mg/ml) in 
1x 10-3X w/v solutions of each surfactant and periodically 
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centrifuging samples of these suspensions. The degree of uptake of 
the eurfactant was then determined an described above and expressed 
an a percentage of the amount of surfactant added to the system. 
7.2.2. Preparation of Radiolabelled Nanoparticlea 
The nanoparticles were radiolabelled with a 
99mTc-dextran 10 
complex according to the method given in chapter 6. Aseptic 
technique was used throughout the preparation procedure. All 
glassware was sterilised by autoclaving (121°C for 15 minutes), 
solutions prepared using sterile apyrogenic water and filtrations 
carried out using sterile 0.2pm membrane filters (Millipore, USA). 
The sepharose gel filtration material was sterilised by autoclaving 
according to the manufacturer's instructions (15 minutes at 121°C). 
The column was pre-conditioned as before with a sterile nanoparticle 
suspension and flushed through with sterile PBS (p11 7). 
To produce a final nanoparticle suspension of sufficient 
specific activity for use with the gamma camera, 400MBq of 
99mTe04 
in 2ml of eluate from the technetium generator was used. This was 
added to the 10% w/v dextran 10 solution in place of the 1MBq of 
activity previously used in chapter 6. 
The nanoparticle fraction from the sepharose CL 4B column 
(2.5ml) was diluted to 3.3m1 with 0.9% w/v sodium chloride, or 
0.9% w/v sodium chloride containing 4.13% w/v poloxamer 338 or 
Tetronic 908. This gave a final activity of approximately 4 MBq/ml 
(Isotope assay calibrator 238. Pitman, UK), a nanoparticle 
concentration of 10 mg/ml and a surfactant concentration (if added) 
of 1% w/v. The supensions were left to equilibrate for 15 minutes 
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prior to injection. Adding eurfactnnt to the nnnopnrticlc aunpension 
did not affect the labelling efficiency. 
7.2.3. Preparation of Free Technetiua--99w-dextrnn 10 
Dextran 10 (0.5g) was dissolved in deoxygenated water (5ml) and 
this added to 0.025m1 of a solution of stannous chloride (30mg) in 
concentrated sulphuric acid (Smi). 0.4ml of this was filtered (0.2j, m 
sterile membrane filter) into a sterile vial and 0.2m1 of eluate 
from a 
99mTc 
generator added to this (total activity 10MBq). After 
10 minutes, 3.4m1 of sterile PBS (p11 7) aas added to give a 1% W/V 
solution of 
99mTc-dextran 10 with an activity of 4 MBq/ml. This 
solution was filtered through a sterile 0.2, um membrane filter prior 
to injection. 
7.2.4. Animal 1xpcrimentn 
Male New Zealand White rabbits (NZW) (Animal House, Medical 
School, Nottingham University) 2.5kg in weight were randomly divided 
into four groups of three. Each experimental group was injected with 
uncoated, poloxamer 338 coated or Tetronic 908 coated nanoparticles, 
with each rabbit receiving iml of suspension via the right marginal 
ear vein. The control group of three animals were each injected with 
lml of the 
99mTc-dextran 10 solution. Injections were flushed 
through with Iml of sterile 0.9% w/v sodium chloride solution. The 
animals were positioned on the gamma camera (Maxi Camera It, General 
Electrics, USA) and data acquisition commenced immediately. Dynamic 
images (45 x 20 seconds) were recorded during the first 15 minutes 
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and static images (60 seconds) taken at 1,2,4 and 8 hours post 
injection. The data were stored and processed by a dedicated 
computer system (Micas 2020 Medical Computer System, Nodecrest, UK). 
7.2.5. Data Processing 
ROI's were created around the liver/spleen, lung/heart, lower 
kidney and bladder, and the activity within each region calculated. 
The data for each ROI were normalised by subtracting the background 
count for an equivalent sized ROI taken from an image recorded 
without an animal on the camera. For the dynamic data, a decay 
correction was applied to account for the radioactive decay of 
99m'Pc 
during the dynamic phase. Results for each ROI during the dynamic 
phase are expressed as a percentage of the total activity in the 
whole animal. For the static images, the total body activity at 1 
hour post injection was used to calculate the total activity at 2,4 
and 8 hours, after allowing for radioactive decay. The activity in 
each ROI was then expressed as a percentage of this value. 
Due to the image of the upper kidney (situated on the right of 
the image) being superimposed on the liver image, the activity in 
the lower, well resolved kidney was subtracted from the liver 
activity to give values due to liver uptake alone. In calculating 
the total kidney and bladder activities, the value from the lower 
kidney was doubled and added to that of the bladder. All activities 
are quoted as the mean of the three animals within each group 
together with the standard deviations. 
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7.3. RESULTS AND DISCUSSION 
7.3.1. Adsorption of Poloxa, cr 338 and Tetronic 908 onto 
Nanoparticlce 
The adsorption of poloxamer 338 and Tetronic 908 onto p(BCA) 
nanoparticles was found to be rapid, with equilibrium being 
established in a few minutes (table 7.1). It was necessary to 
determine the rate of uptake for the in vivo work because the 
nanoparticles needed to be prepared and used on the some day due to 
the relatively short half life (6 hours) of 
99mTc. For this reason, 
extensive incubation times could not be employed and it was 
essential to establish the minimum time needed to reach equilibrium 
for the uptake of the surfactants. 
The adsorption isotherms given in figure 7.2 show a maximum 
uptake of approximately 85 mg/g of nanoparticles for poloxamer 338 
and 60 mg/g for Tetronic 908. At a nanoparticle concentration of 
10 mg/ml the minimum concentrations of surfactants needed to ensure 
full surface coverage would be approximately 0.29% w/v for poloxamer 
338 and 0.36% w/v for Tetronic 908. 
On the basis of these findings the nanoparticles were coated 
with surfactant by incubating the suspensions for 15 minutes in 
1% w/v solutions of poloxamer 338 or Tetronic 908. 
7.3.2. Biodistribution of Uncoated and Surfactant Coated 
Nanoparticlca in Rabbits 
Following injection into NZW rabbits via the marginal car vein, 
approximately 50% of the uncoated nanoparticles were found to 
TABLE 7.1 Rate of uptake of poloxamer 338 and Tetronic 908 onto 
nanoparticlea. 
Time % taken up from solution 
(mina) Poloxamer 338 Tetronic 908 
5 88.4 83.1 
15 94.5 81.3 
30 96.1 84.1 
60 96.3 79.2 
90 97.1 
- 
120 98.0 80.5 
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Figure 7.2. Adsorption isotherms of poloxemer 338 (ý) 
and Tetronic 908 (0) onto nanoparticles at 20 °C. 
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localise in the liver/spleen region within 2 minutes (figure 7.3). 
Coating with poloxamer 338 or Tetronic 908 caused a slight delay in 
liver/spleen clearance with maximum uptake occurring after 4 minutes 
(figure 7.3). There was no significant difference, however, in the 
final liver/spleen uptake between the coated and uncoated systems. 
The loss of activity from this region after 3 to 4 minutes is due to 
nanoparticle degradation resulting in the release of the water 
soluble 
99mTc-dextran 
radiolabel. In contrast, non-biodegradable 
polystyrene particles give a constant liver/spleen activity profile 
over the some time period (Ilium and Davis, 1984x). 
As the liver/spleen activity decreased, the activity found in 
the kidneys and bladder steadily increased as the radiolabel was 
filtered by the kidneys and accumulated in the bladder (figure 7.4). 
The kidney activity maintained a constant level of approximately 14% 
as the label was filtered and discharged to the bladder, in which 
activity steadily increased with time. After 4 hours, between 50 and 
60% of the total injected activity was found in the kidneys and 
bladder. This value fell sharply during the next 4 hours when the 
animals urinated, giving activities of approximately 25% at 8 hours 
post injection. No significant difference was found between the 
activity-time profiles for the coated and uncoated nanoparticles 
given in figure 7.4. The initial rapid filtration by the kidneys of 
about 15% of the total injected activity was due to the presence of 
free radiolabel which constituted 12% of the injected dose. 
The activity-time profiles for the lung/heart region are given 
in figure 7.5. Following injection into the marginal ear vein, the 
suspension is delivered to the heart and then the lungs before 
Figure 7.3. Activity-time profile for the liver/spleen 
region of interest following injection of uncoated (0), 
poloxamer 338 coated (0) and Tetronic 908 coated (o) 
nanoparticles labelled with 
99mTc-dextran 10. 
Results are the mean for 3 rabbits together with the 
standard deviation (bar). 
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Figure 7.4. Activity-time profiles for the kidney and 
bladder regions of interest-following injection of 
uncoated (0), poloxamer 338 coated (") and Tetronic 908 
coated (o) nanoparticles labelled with 99mTc-dextran 10. 
Results are the mean for 3 rabbits together with the 
standard deviation (bar). 
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Figure 7.5. Activity-time profiles for the lung/heart 
region of interest following injection of uncoated (0), 
poloxamer 338 coated (0) and Tetronic 908 coated (A) 
nanoparticles labelled with 
99mTc-dextran 10. 
Results are the mean for 3 rabbits together with the 
standard deviation (bar). 
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returning to the heart and entering the general circulation. Hence a 
relatively high activity was observed initially in this region 
before the nanoparticles and free label were cleared by the RES and 
kidneys. A similar profile is observed for polystyrene particles 
(Ilium and Davis, 1984a). Although there was a small difference 
between the profiles for the uncoated and Tetronic 908 coated 
nanoparticles, this was not significant (Mann-Whitney U test, U 
statistic - 200). 
The distribution pattern can be observed clearly in the 
scintiscans given in figure 7.6 for a rabbit injected with uncoated 
nanoparticles. At 1 minute post injection, the localised activity in 
the lung/heart region could be seen. After 2 minutes, the liver was 
well defined and the outline of the two kidneys could be 
distingushed (normally the right kidney was obscured by the liver 
image). At 6 minutes, the bladder could be seen and by the end of 
the dynamic phase (15 minutes) most of the activity was in the 
liver, kidneys and bladder. In all these scintigrams the outline of 
the rabbit was well defined indicating a relatively high level of 
circulating activity. After 1 hour, the bladder was seen to contain 
most of the activity and this distribution was maintained until 4 
hours post injection. The apparent increase in liver and kidney 
activity at 8 hours is due to the data analysis system automatically 
increasing the sensitivity due to loss of most of the activity in 
the urine. Liver activity at this stage was only about 30% of the 
total injected dose after allowing for radioactive decay. 
Figure 7.7 gives the activity-time profiles for the control 
animals injected with free 
99mTc-dextran 10. This compound was 
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Figure 7.6. Scintiscans of a rabbit injected with 
uncoated nanoparticles labelled with 
99mTc-dextran 10 
at various times after injection. 
The regions of interest are shown in the 3rd frame. 
Normally the kidney seen on the right was obscured 
by the liver/spleen image (R0I designation: 1= lung/ 
heart, 2= liver/spleen, 3= kidneys and 4= bladder). 
Time after injection- (a) 1 minute 
(b) 2 minutes 
(c) 4 minutes 
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Figure 7.6. continued. Scintiscans of a rabbit injected 
with uncoated nanoparticles labelled with 
99mTc-dextran 
10 at various times after injection. 
(e) 8 minutes 
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Figure 7.6. continued. Scintiscans of a rabbit injected 
with uncoated nanoparticles labelled with 
99mTc-dextran 
10 at various times after injection. 
(i) 1 hour 
(j) 2 hours 
(k) 4 hours 
(1) 8 hours 
Figure 7.7. Activity-time profiles for the control 
animals injected with free 99mTc-dextran 10. 
(A) liver/spleen region 
(o) lung/heart region 
(") kidneys and bladder regions 
Results are the mean for 3 rabbits together with 
the standard deviation (bar). 
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rapidly cleared by the kidneys and accumulated in the bladder. The 
kidney and bladder activities in these animals were much higher 
compared with the experimental groups, since all of the radiolabel 
is essentially free in the circulation and capable of being filtered 
by the kidneys. The low levels of activity found in the liver/spleen 
region are further evidence for the lack of 
99mTc-tin-colloid 
formation during the radiolabelling procedure. Due to the very rapid 
clearance of the label from the circulation, data are only given for 
the dynamic phase. Any liver uptake of colloidal contaminants would 
have been observed in these first 15 minutes following injection. 
Taking into account the level of free radiolabel in the 
uncoated nanoparticle injection (about 12%) the maximum liver/spleen 
uptake was of the order 60%. This figure is much lower compared with 
other colloidal systems (Ilium and Davis, 1984a; Leu et al, 1984) 
and approximately 20% lower than the findings of Grislain at al 
(1983) for 14C labelled p(iBCA) nanoparticles injected into rats. 
Obviously direct comparison of results between various studies is 
not possible due to the large number of variables which include the 
nature of the particles (size, surface charge, composition, 
hydrophobicity), radiolabelling procedures, animal species, 
radiation detection techniques and dosage levels. The results 
obtained here, however, imply that p(BCA) nanoparticles stabilised 
by dextran 10 are mostly cleared by the liver and/or spleen and are 
rapidly degraded. The coating of nanoparticles with surfactants did 
not significantly alter the liver/spleen uptake in contrast to other 
systems (Illum and Davis, 1984a; Leu et al, 1984). It has been 
proposed (Davis et al, 1985) that the interfacial coating of 
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surfactants decreases capture by macrophages of the RES due to 
enhanced steric stabilisation preventing close approach and 
particle/cell interactions. Since the nanoparticle system under 
investigation here already possesses a strong steric barrier 
provided by the surface layer of covalently linked dextran, the 
addition of further stabiliser to the system may fail to 
significantly increase the existing repulsive steric potential 
energy. This is reflected in the liver/spleen activity-time profiles 
(figure 7.3). Other factors such as particle-surfactant affinity and 
particle polydispersity also may be important. Clearly further work 
needs to be done in this area to resolve the possible mechanisms of 
macrophage capture in relation to particle-cell surface 
interactions. 
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CHAPTER EICHT 
GENERAL DISCUSSION 
8.1. GENERAL DISCUSSION AND CONCLUSIONS 
The work presented in this thesis has involved a systematic 
study of the characteristics of p(BCA) nanoparticles in relation to 
their potential use as drug carriers for site specific drug 
targeting. The results have yielded valuable information concerning 
nanoparticle formation, composition, surface properties and 
behaviour in vivo. Much of these data were unpublished at the outset 
of this project which was surprising considering the importance of 
such physico-chemical properties on the behaviour of particulate 
drug carriers. Of these, the effects of particle size are 
particularly well understood. The initial investigations, therefore, 
dealt with the control of nanoparticle size. 
By varying the nature and concentration of polymeric 
stabilisers added to the polymerisation medium used in nanoparticle 
preparation, it was possible to vary particle size over a wide 
range. Dextrans were found to be the most versatile stabilisers and 
by altering the molecular weight and concentration of this 
polysaccharide, it was possible to prepare nanoparticles with 
diameters in the range of approximately 100 to 800nm. The upper size 
limit could be extended to about 3ym by using an oligosaccharide, 
i3 
-cyclodextrin, in place of the dextran. The lower size limit was 
extended to approximately 20nm by using non-ionic surfactants such 
as polysorbate 20. Variation in other polymerisation factors such as 
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pH, ionic strength, temperature and monomer concentration, although 
producing small changes in nanoparticle diameter, did not affect 
particle size greatly. These results, in combination, imply that 
nanoparticles are stabilised by steric forces and that electrostatic 
stabilisation is not important in maintaining colloidal stability. 
This is in contrast to many other colloidal systems which are formed 
by a free radical polymerisation mechanism which results in the 
incorporation of charged initiators into the particle matrix. 
The formation of very small nanoparticles (<100nm diameter) may 
be important with respect to the possible extravasation of the 
carrier in vivo, which was discussed in detail in the general 
introduction. In addition to the importance of average particle size 
is the consideration of particle size polydispersity. This factor is 
often ignored when determining the potential of particulate carriers 
to reach extravascular sites. The importance of polydispersity may 
be illustrated by considering the nanoparticles used in the in vivo 
work described in chapter 7 as a theoretical example of a carrier 
system loaded with drug. This system had an average diameter of 
126nm and a polydispersity index of 0.13 as measured by PCS, which 
gives the theoretical particle size distribution in terms of 
particle number shown in figure 8.1. If 100nm is taken as an 
arbitrary diameter below which particles could escape the vascular 
circulation, then integration of this curve indicates that only 44% 
of the carrier could extravasate despite the average size (number 
average diameter - 98.6nm) being approximately 100nm. In terms of 
drug delivery, even less of the drug would be expected to reach the 
target site, since the payload capacity of these nanoparticles is 
Figure 8.1. Theoretical particle size distributions 
for a nanoparticle supsension calculated from PCS 
measurements (dz= 126nm, Q= 0.130) according to 
equation 2.13. 
(") distribution given in terms of particle number. 
(0) distribution given in terms of particle surface 
area. 
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mainly dependent on surface sorption of the drug. Thus, if the 
distribution is plotted in terms of particle surface area and 
integrated, only 21% of the total therapeutic payload has the 
possibility of extravasation (figure 8.1). For carrier systems where 
drug loading is a function of particle volume, such as liposomes, an 
even smaller percentage of the total payload would be contained in 
carriers with diameters less than 100nm. 
With nanoparticle systems a compromise has to be reached 
concerning the requirements for low particle size and 
polydispersity. Although the polysorbate stabilised nanoparticles 
had a very low average diameter this was associated with a wide 
particle size distribution. The narrowest size distributions were 
obtained with dextran stabilised systems, but the particle size of 
these carriers was generally greater than 100nm. Certain poloxamer 
stabilised nanoparticles, however, gave reasonably low sizes 
together with low polydispersity values. The situation is further 
complicated by the need to maximise the therapeutic payload, which 
can be drastically reduced in the presence of surfactants as shown 
in chapter 6 with rose bengal. Overall, nanoparticles stabilised 
with dextran 10 appear to offer the best compromise with respect to 
size, polydispersity and possible drug loading. 
The choice of steric stabiliser was also found to affect 
markedly the molecular weight of the cyanoacrylate polymer which 
comprised the nanoparticle matrix. Although the molecular weight of 
this polymer theoretically may affect the rate of nanoparticle 
degradation and possibly drug release, this has yet to be 
ascertained. The copolymerisation of dextran with the monomer also 
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has important implications regarding degradation and release of the 
payload. These results, in conjunction with those obtained in 
controlling particle size, imply that nanoparticles are formed 
initially by an aggregative mechanism involving aggregation of many 
relatively small oligomeric polymer chains. 
The great importance of the interfacial region of nanoparticles 
was demonstrated throughout the course of the work. In particular, 
the finding that dextran could be incorporated via covalent linkages 
and resided at the nanoparticle surface was extensively exploited to 
manipulate various properties. 
By employing dextrans with charged functional groups, such as 
DEAF or sulphate, it was possible to control to a certain degree the 
electrophoretic behaviour of nanoparticles. In theory, it should be 
possible to produce nanoparticles with a range of particle charges 
by varying the concentration of charged stabiliser added to the 
polymerisation medium. However, the formation of small particles 
bearing a highly negative potential was not possible with the 
materials available. This section of work (chapter 4) demonstrated 
the versatility of PCS in determining particle size. PCS was used 
throughout the project and was invaluable for routine size analysis 
or the more detailed studies performed in chapters 2 and 4. 
The interfacial layer of dextran was exploited still further in 
chapter 5 for the covalent attachment of ligands to the particle 
surface. Although this section of work did not realise the initial 
objectives, it did demonstrate the feasibility of attaching 
antibodies to the nanoparticle surface via dextran 'bridges'. This 
approach may also be used for increasing drug loading and 
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controlling the release of amino containing drugs. Theoretically, 
several cytotoxic agents such as methotrexate, daunorubicin, 
azaserine or mitomycin C could be linked to nanoparticles in this 
way. 
Radiolabelling the nanoparticles for use in vivo proved to be a 
highly difficult task. Conventional adsorption or incorporation of 
radiolabels such as rose bengal, molecular iodine or indium-oxine, 
although giving good loading efficiencies, produced rapid release 
rates that were unsuitable for use with gamma scintigraphy. These 
findings also have relevance to the release of drugs from 
nanoparticles and imply that in many instances drug release could be 
very rapid in vivo. This was well demonstrated in the case of rose 
bengal. Although the release of this compound in buffer solution was 
steady over a period of 24 hours, in the presence of protein release 
was virtually complete in a matter of minutes. Despite the 
ion-pairing effect of DEAE-dextran stabilised nanoparticles or the 
use of a water insoluble ester, both of which substantially retarded 
release rates into buffer, the presence of albumin in the release 
medium lead to a rapid release in both instances. Further detailed 
studies are needed with a wide range of drugs before a single 
release mechanism, if one exists, can be proposed. 
Eventually, radiolabelling was achieved by utilising the 
covalent attachment of dextran to the nanoparticle matrix. By 
preforming a technetium-99m-dextran complex and adding this to the 
polymerisation medium, it was possible to incorporate sufficient 
activity to allow imaging by a gamma camera following injection into 
rabbits. It may be possible to improve the labelling method by using 
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a higher molecular weight dextran in place of dextran 10. This would 
be expected to give a slower rate of release of the radiolabel due 
to the higher degree of association between each dextran molecule 
and the nanoparticle matrix. 
The in vivo data given in chapter 7 represent preliminary 
studies into the biofate of nanoparticles. As expected, most of the 
carrier was found to be taken up into the liver and/or spleen, 
although the level of uptake was found to be lower than with many 
other colloidal systems. Coating the particles with surfactants 
which are known to reduce the uptake of other colloidal materials 
failed to reduce the liver accumulation of nanoparticles. This 
effect needs to be investigated further. 
In summary, p(BCA) nanoparticles have been shown to be a highly 
versatile colloidal drug delivery system. This project has attempted 
to emphasise the possibilities and problems associated with their 
potential use in drug targeting, mainly from a physico-chemical 
perspective. Despite studies such as this, the main problems in 
achieving site specific drug delivery to tumour sites have yet to be 
addressed fully. Many of these concern processes which occur at a 
cellular level and are obviously outside the scope of this project. 
Although a detailed knowledge of the carrier system can help in 
resolving these problems, this type of approach in the field of drug 
targeting is regarded by certain workers, possibly with some 
justification, as merely "rearranging the deckchairs on the 
Titanic". It is hoped that the rearrangements presented in this 
thesis may eventually help 'the sinking ship'. 
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APPENDIX I 
Listing of the computer program designed to calculate the 
theoretical particle size distribution from PCS data according 
to equation 2.13. The program is written for use with an Apple 
Ile microprocessor (Apple Computers, USA). 
]LIST 
50 PRE 3 
100 01 
-0 
200 G4- 0 
300 INPUT "INPUT SAMPLE NUMBER "1A$ 
350 PRINT "' 
400 INPUT 'INPUT PCS DIAMETER(NM) '; D 
450 PRINT "" 
500 INPUT "INPUT PCS POLYDISPERSITY INDEX "iQ 
550 PRINT '" 
600 INPUT 'PRINT SIZE DISTRIBUTION? Y OR N 'IB$ 
700 PRE I 
800 PRINT "SAMPLE NUMBER "A$ 
850 PRINT "" 
900 PRINT 'PCS DIAMETER(NM)-'D' POLYDISPERSITY INDEX-'0 
910 PRINT i PRINT 
1000 IF B$ 
- 
"N' 00T0 2800 
1200 PRINT 'LN(DIAM) DIAMETER(NM) NUMBER V. CUM. % UNDERSIZE' 
1300 FOR I-1.5 TO 500 STEP 0.15 
1400 A-- ((1 / (2 * LOG (1 + Q))) * (CI 
-C LOG CD / ((1 + 0) * 2.5))) )) ' 2) 
1500 B-1/( SOR (2 * 3.14159265 *( LOG (1 + 0)))) 
1600 0- INT ((( EXP (A) +º B) +ý 10800) + 0.5) 
1700 IF 01 
-0 COTO 1900 
1800 IF 0<1 COTO 2300 
1900 IF 0<1 G0T0 2200 
2000 IF 2-1 GOTO 10000 
2100 01 
-0+ 01 
2200 NEXT I 
2300 02 
- 
100 / 01 
2400 2-1 
2500 01 
-0 
2680 GOTO 1300 
2700 PRINT 
2800 D1 
- 
INT (((D / ((1 + 0) 2.5)) * 10) + 0.5) / 10 
2900 S- INT C( EXP C SOR ( LOG (1 + 0))) * 1000) + 0.5) / 1000 
3000 D2 
- 
INT ((( EXP ( LOG (D1) + (0.5 * LOG 0+ Q)))) * 10) " 0.5) / 
10 
3100 M- INT ((C EXP C LOG (D1) 
- 
LOG (1 + 0))) * 10) + 0.5) / 10 
3200 C- INT ((C SOR (0) * 100) +º 10) + 0.5) / 10 
3400 PRINT "GEOMETRIC MEAN DIAMETER- "D1"NM" 
3500 PRINT 'GEOMETRIC STANDARD DEVIATION- "S 
3600 PRINT "LENGTH NUMBER MEAN DIAMETER- 'D2"NM" 
3708 PRINT "NUMBER MODAL DIAMETER- "M'NM" 
3800 PRINT "COEFFICIENT OF VARIATION- "C"%" 
3900 PRINT i PRINT i PRINT i PRINT 
4000 PRE 0 
4200 COTO 50 
10000 03 
" INT ((0 * 02 * 100) + 0.5) / 180 
10100 04 
- 
03 + 04 
10200 IF 03 C 0.009 GOTO 10700 
10300 11 
- 
INT ((I * 100) + 0.5) / 100 
10400 E- INT C( EXP (I) * 10) + 0.5) / 10 
10500 PRINT III TAB( 12)IEI TAB( 28); 031 TAB( 39)104 
10600 GOTO 2200 
10700 IF 04 > 50 0010 2700 
10800 GOTO 2200 
20000 END 
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Example of a typical print out of results obtained from the 
computer program given on the previous page. The program 
automatically adjusts the upper and lower limits of the size 
range for each set of data. 
SAMPLE NUMBER EXAMPLE 
PCS DIAMETER(NM)=200 POLYDISPERSITY INDEX=. 15 
LN(DIAM) DIAMETER(NM) NUMBER % CUM. /. UNDERSIZE 
3.6 36.6 
. 
02 
. 
02 
3.75 42.5 
. 
09 
. 
11 
3.9 49.4 
. 
31 
. 
42 
4.05 57.4 
. 
89 1.31 
4.2 66.7 2.15 3.46 
4.35 77.5 4.44 7.9 
4.5 90 7.78 15.68 
4.65 104.6 11.63 27.31 
4.8 121.5 14.79 42.1 
4.95 141.2 16.01 58.11 
5.1 164 14.75 72.86 
5.25 190.6 11.57 84.43 
5.4 221.4 7.73 92.16 
5.55 257.2 4.4 96.56 
5.7 298.9 2.13 98.69 
5.85 347.2 
. 
88 99.57 
6 403.4 
. 
31 99.88 
6.15 468.7 
. 
09 99.97 
6.3 544.6 
. 
02 99.99 
GEOMETRIC MEAN DIAMETER= 141NM 
GEOMETRIC STANDARD DEVIATION= 1.453 
LENGTH NUMBER MEAN DIAMETER= 151.2NM 
NUMBER MODAL DIAMETER= 122.6NM 
COEFFICIENT OF VARIATION= 38.7Y. 
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